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Chapter 1 
Introduction 
Chapter 1 
INTRODUCTION 
Respiratory distress syndrome (RDS) is an important cause of morbidity and mortality in the 
preterm infant despite the introduction of prenatal glucocorticosteroids, postnatal surfactant 
treatment, and improved perinatal care. The important factor causing the development of 
RDS is primary surfactant deficiency. Pulmonary surfactant is necessary to maintain alveolar 
patency by reducing the surface tension at the air-liquid interface in the alveoli. 
Surfactant is a complex mixture of lipids and surfactant specific proteins. Of the surfactant 
lipids, phosphatidylcholine is the most abundant and main surface tension lowering compo-
nent. Surfactant is synthesized in the alveolar type II pneumocyte and secreted to the alveo-
lar space to form a surface active monolayer. Surfactant components can be recycled by the 
type II cell or catabolized and cleared from the lung. Knowledge about surfactant production 
and catabolism is important to understand the pathophysiology of RDS and to improve treat-
ment. 
Administration of large amounts of exogenous surfactant to the preterm infant with RDS is 
now standard treatment. Some in vitro and animal studies suggest the presence of a feed-
back mechanism to regulate endogenous surfactant synthesis. It is unknown whether exoge-
nous surfactant interferes with endogenous surfactant synthesis in preterm infants. 
In vitro studies show that corticosteroids stimulate surfactant synthesis but studies in ani-
mals give conflicting results. Preterm infants that received corticosteroids prenatally have a 
decreased incidence and severity of RDS. Whether this is due to increased surfactant synthe-
sis is unknown. 
In animals surfactant metabolism is studied with radioactive isotopes, however, this ap-
proach is not acceptable in human subjects, especially not in human preterm infants. The 
ionizing radiation may cause injury to the molecular structure of the cell, leading to chromo-
some aberrations or cell death. Surfactant metabolism has been studied in many experiments 
in different animals, at different developmental stages, under different conditions, with hor-
monal and surfactant treatments. Surfactant analyses of sequential tracheal aspirates of hu-
man infants have been performed and provide data on the quality and concentration of sur-
factant in the epithelial lining fluid. However, the data are difficult to interpret as the total 
volume of the epithelial lining fluid is unknown and the surfactant tissue pools have not been 
measured, and therefore, do not give direct information on the processes of synthesis and 
catabolism. In addition, the study of endogenous surfactant metabolism with the current 
methods is complicated by the administration of large doses of exogenous surfactant as 
therapy for severe RDS. 
To study metabolic pathways and turnover in humans, stable isotopes have been applied 
for the last 60 years. Stable isotopes have the obvious advantage of being nonradioactive and 
thus can be used safely in preterm infants. The use of stable isotopes is a potential method 
to study surfactant metabolism in humans. There are different stable isotopes, like 2H (deute-
rium), 16N, and 13C. In the studies presented in this thesis, we used the tracers [U-
13C1glucose, [U-13C]palmitic acid, and [U_13C]linoleic acid, all containing the stable isotope 13C. 
The stable isotope 13C has a natural occurrence (enrichment) of ..... 1.11 % of the total carbon 
atoms in the human body. Small differences are present between individuals, mainly due to 
differences in diet. To account for this natural enrichment, baseline samples are taken prior to 
isotope administration. In the samples, the ratio of 13C/12C are measured directly, so sampling 
techniques and sample amount are of little influence. The stable isotopes are administered to 
the infants and are incorporated into the fatty acids in surfactant phosphatidylcholine by en-
dogenous synthesis of phosphatidylcholine. The rate of incorporation is a measure for synthe-
sis of surfactant phosphatidylcholine. The disappearance of the stable isotope from phospha-
tidylcholine is a reflection clearance of surfactant phosphatidylcholine. 
10 
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AIM OF THE STUDIES 
1. To develop and use a novel method to study surfactant metabolism in preterm and older 
infants. 
(chapters 3 and 4). 
2. To study endogenous surfactant synthesis in relation to prenatal glucocorticosteroids. 
(chapters 5 and 6). 
3. To study the influence of surfactant therapy on endogenous surfactant metabolism. 
(chapters 7 and 8). 
4. To study surfactant composition and concentration after surfactant therapy. 
(chapter 8). 
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Summary 
Pulmonary surfactant phosphatidylcholine (PC) is synthesized and stored as lamellar bodies in 
the alveolar type II pneumocyte. In respiratory distress syndrome (RDS), surfactant alveolar 
pool sizes are low (5 to 10 mg PC/kg) and the composition is immature with less disaturated 
PC. The process of synthesis and secretion to the alveolus is a slow process in vivo, as 
shown by studies with labeled precursors in animals and human infants. The slow incorpora-
tion of labeled precursors into surfactant PC over days corresponds to slow increases in PC 
concentrations in alveolar fluid and total lung pool sizes after preterm birth. The synthesis of 
endogenous surfactant is stimulated by administration of prenatal corticosteroids in preterm 
animals and human preterm infants. Because the synthesis of surfactant PC is low, the ac-
cumulation of sufficient amounts in the alveolus for adequate ventilation requires several 
days. 
Surfactant is cleared from the alveoli mainly by uptake by the type " pneumocyte and is 
recycled to a large extent (-90% in the premature anima/). The apparent half-life of exoge-
nously administered surfactant PC ranges from 30 to 110 h in preterm infants with RDS. 
Therefore, the concentration of surfactant in the alveoli remains elevated for several days 
after exogenous surfactant therapy for RDS. There are data that show that exogenous sur-
factant does not suppress endogenous surfactant synthesis in preterm infants. 
Submitted 
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INTRODUCTION 
After premature delivery, neonatal respiratory distress syndrome (RDS) is an important cause 
of morbidity and mortality.1 Avery and Mead showed in 1959 that pulmonary surfactant defj~ 
ciency is a major factor in the pathophysiology of RDS.2 In 1980, for the first time, exoge~ 
nous surfactant was administered endotracheally to preterm infants to treat ROS successfully 
by Fujiwara et al. 3 Later, multicenter trials demonstrated decreased death rates and complica~ 
tions of RDS after surfactant administration.4-6 Although most infants respond favorably to 
surfactant treatment, some infants have no or little response and some complications of ROS 
like bronchopulmonary dysplasia, intraventricular and pulmonary hemorrhage have not de~ 
creased significantly by the introduction of surfactant therapy. Surfactant deficiency in RDS 
is characterized by small surfactant pools, immature surfactant composition and functional 
inhibition by plasma proteins. Because the intracellular and alveolar surfactant reserves are 
small, they are tightly regulated by synthesis, secretion, and recyclingJ In the present review, 
surfactant phospholipid metabolism in the human preterm infant will be discussed and in vitro 
and animal studies will be used to put the data from human studies into perspective or when 
little information from humans is available. Other reviews have focused mainly on surfactant 
metabolism in vitro and in animals.S-14 
Liggins et al. showed in 1972 that one course of prenatal corticosteroids decreased the in~ 
cidence and severity of RDS in preterm infants.15 Multiple courses can decrease birth weight 
and increase mortality. 16 Enhancing lung maturation by administration of prenatal corticoste~ 
roids seems more effective than surfactant therapy in reducing RDS and its complica~ 
tions. 17,18 The combined use of prenatal corticosteroids and postnatal surfactant is more 
beneficial than either treatment alone. 19 The effects of prenatal corticosteroid therapy and 
postnatal surfactant administration on surfactant PC metabolism will be discussed. A better 
understanding of surfactant metabolism could help to fine~tune the treatment of the preterm 
infant with surfactant deficiency. 
SURFACTANT FUNCTION, COMPOSITION, AND POOL SIZE IN THE PRETERM NEONATE 
Adequate amounts of pulmonary surfactant decrease the surface tension at the air~liquid in~ 
terface in the alveoli and distal bronchioli which promotes lung expansion during inspiration 
and prevents alveolar collapse at expiration. Insufficient amounts of surfactant lead to de-
creased pulmonary compliance, decreased functional residual capacity, atelectasis, and en-
largement of the functional right-to-Ieft shune decreased gas exchange, respiratory acidosis, 
and pulmonary edema with further inactivation of surfactant by plasma constituents. 
Surfactant is a complex mixture of lipids ( ..... 90%) and proteins ( ..... 10%) and its composition 
is similar across species including the human.2o-22 Surfactant is synthesized and stored in the 
alveolar type II pneumocyte and secreted to the alveolus. Of the surfactant lipids, 80 to 90% 
are phospholipids, and the other lipids, in decreasing order, are cholesterol, triacylglycerol, 
and free fatty acids.23 Phosphatidylcholine (PC) is the major phospholipid (70 to 80% of the 
phospholipids) and is the main surface tension lowering component of surfactant. The PC 
molecule comprises a glycerol backbone, two fatty acids, phosphate, and a choline moiety. 
Approximately 50 to 60% of the PC is disaturated (Sat PC, DSPC) of which ..... 75 % is the 
dipalmitoyl (16:0/16:0) species (DPPC).20,24,25 Other surfactant phospholipids are phosphati-
dylglycerol, phosphatidylethanolamine, phosphatidylinositol, phosphatidylserine, Iysophospha-
tidylcholine, and sphingomyelin.22 
The surfactant proteins are either hydrophilic (SP-A and SP-O) or hydrophobic {SP-B and 
SP_C).26 The surfactant proteins are either exclusively lung-associated or predominantly found 
in the lung. SP-A reduces the secretion of PC and stimulates the formation of tubular myelin 
14 
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from secreted lamellar bodies.27 SP~B and possibly SP~C are required for the formation of tu~ 
bular myelin and both proteins are necessary for rapid spreading of surfactant onto the air~ 
liquid interface.28-32 Surfactant protein A and 0 playa role in the first line defense against 
inhaled pathogens33 The present review will not deal extensively with the surfactant proteins, 
and the reader is referred to other reviews.22,26,34,35 
The composition and concentration of surfactant phospholipids in amniotic fluid reflect 
lung maturation and the risk of developing RDS. Several measures to estimate lung maturity 
or risk of developing RDS have been described such as the lecithin:sphingomyelin ratio (LIS 
ratio),36,37 Sat PC concentration in amniotic fluid,38 the palmitic acid:stearic acid (PIS) ratio of 
PC,39AO and the presence or absence of phosphatidylglycerol.36,41 Such measurements, how~ 
ever, are rarely made in clinical practice and should be interpreted with caution as reviewed 
by Gluck et al. 42,43 After birth, lung maturation continues as reflected by alveolar surfactant 
measurements.44-46 Hunt et al. found in human fetal lung tissue that PC became more disatu~ 
rated during gestation with predominantly PC (16:0/16:0) and PC (14:0/16:0}.2o Surfactant 
PC from preterm infants at birth with RDS contains a lower percentage palmitic acid than 
infants that do not develop RDS, and the percentage palmitic acid increases during the first 
weeks of Iife.47.48 
Jackson et al. measured an alveolar pool size of Sat PC of .... 5 mg/kg by lavage in preterm 
monkeys with RDS at birth.49 Preterm sheep and young pigs have alveolar pool sizes of PC of 
.... 10 mg/kg.50-52 The pool size estimates are remarkably constant across animal species and 
humans. The first pool size studies of phospholipids in humans were performed by Adams et 
al. using autopsy material from premature infants.44 The total lung and alveolar phospholipid 
and PC pool sizes remained constant up to 24 weeks and increased afterwards.44A5 Hallman 
et al. administered exogenous surfactant containing PG and measured the dilution by endoge~ 
nous alveolar surfactant, as endogenous surfactant in infants with RDS does not contain 
PG53 Hallman found an alveolar pool size of 8 to 10 mg PC/kg.46 Using the same method 
with either sphingomyelin or PG as markers, Griese et al. found an alveolar pool size of .... 20 
mg phospholipid/kg. 54 Torresin et al. administered exogenous surfactant labeled with [U~ 
13C]DPPC, to preterm infants with RDS and calculated the alveolar pool size to be .... 8 mg 
PC/kg.55 These methods using dilution of an exogenous marker to calculate pool size have to 
be considered with some caution. After surfactant administration approximately 50% of the 
introduced surfactant becomes directly lung tissue associated and cannot be retrieved by la~ 
vage, which would lead to an overestimation of the dilutional effect by endogenous alveolar 
surfactant, resulting theoretically in a 50% overestimation of the alveolar endogenous pool 
size. 12 Furthermore, the exogenous label probably equilibrates with surfactant in the type II 
cell and lung tissue phospholipids. It is not clear to which extent the extra~alveolar surfactant 
phospholipid pool is included in these calculations. However, the remarkable similarity with 
the autopsy and animal data is reassuring. 
SURFACTANT SYNTHESIS AND SECRETION 
Surfactant PC is synthesized in the endoplasmatic reticulum (proteins) and/or Golgi apparatus 
(lipids) (fig. 1 ).56 Precursors (glucose, ketone bodies, acetate) and components (fatty acids, 
choline, phosphorus, glycerol) are used for surfactant PC synthesis.57-6o 
The CDP~choline pathway is the principle pathway involved in the de novo synthesis of 
surfactant PC.14,24.25,61,62 The formation of glycerol~3-phosphate is the principle starting 
point for the synthesis of diacylglycerolipids. The glycerol~3-phosphate is mainly formed by 
reduction of dihydroxyacethone phosphate. Cholinephosphotransferase catalyses the forma-
tion of PC from diacylglycerols and CDP~choline. The required CDP~choline is made by CTP-
phospho choline cytidylyltransferase from phospho choline, which in turn is formed from 
15 
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Figure 1. Illustration of surfactant phosphatidylcholine metabolism. The precursors for surfactant PC 
are taken up by tl1e type" pneumocyte from blood. The secreted surfactant forms a surface tension 
lowering monolayer. The surfactant is degraded after some cycles of compression and expansion and 
mainly recycled. TB "" tubular myelin, MV8 = multi vesicular body, LysoPC =lysophosphatidylcllOline. 
choline by choline kinase. There is ample evidence that the enzyme CTP-phosphocholine cyti-
dylyltransferase plays an important regulatory role in the de novo synthesis of PC.63-66 In the 
type II cell of the fetal lung, intracellular glycogen stores appear to be a major source of the 
gly-cerol backbone of PC,57 and in the adult lung glucose from the blood stream is a major 
substrate for glycerol. The choline is mainly derived from the diet.G8 The fatty acids required 
for the surfactant phospholipids are derived from blood supply and from de novo fatty acid 
synthesis. There is evidence that the lipogenesis of fatty acids from glucose and lactate 
among other substrates, is of particular importance to supply fatty acids for phospholipid syn-
thesis in the prenatal lung.69-71 In more mature lungs, the fatty acids of surfactant PC are 
derived mainly from uptake of fatty acids from plasma. 52 The composition of the newly 
formed PC is modified to achieve high levels of DPPC, by acyl remodeling, mainly involving 
sequential actions of phospholipase and acyltransferase enzymes,72-74 
Intracellular surfactant is stored as lamellar bodies which are condensed, highly structured 
lipoprotein packages (fig. 1 J. Lamellar bodies can be detected in human type II cells from ap-
proximately 20 weeks gestation75 and are secreted thereafter, as reflected by increasing PC 
concentrations in amniotic fluid. 38 Secretion of lamellar bodies is stimulated by mechanical 
stretch of the alveolus during inspiration76.81 Various agents, including agonists for fJ-
adrenergic-, purino-, and vasopressin-receptors increase cytosolic Ca+, cellular c-AMP, or ac-
tivate protein kinases which can stimulate secretion of lamellar bodies.9,76,80,82-85 At secre-
tion, the lamellar bodies lose their limiting membrane86 and enter the hypophase (epithelial 
lining fluid, ELFJ. The lamellar bodies unravel to form loose membranous arrays and lattice-like 
structures, called tubular myelin (fig. 1 ).87-89 In cultured hUman fetal type" cells at 16 to 21 
week of gestation SP-A is already being synthesized and mainly secreted apart from the 
16 
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lamellar bodies.90 SP-A deficient mice do not have tubular myelin in the alveolar surfactant 
fraction. This lack has no effects on overall metabolism of Sat PC or SP-B in mice.91 ,92 At 
alveolar surface expansion during inspiration, surfactant components insert from the hypo-
phase into the monolayer. At expiration the alveolar surface reduces and the monolayer is 
compressed, thereby squeezing out some surfactant proteins, unsaturated PC, and other lip-
ids. By this mechanism, the monolayer comprises mainly the most surface tension lowering 
component DPPC during compression.93,94 
The time required for de novo PC synthesis, secretion, and significant alveolar accumula-
tion has been studied in animals using radioactive labeled substrates. In the newborn rabbit 
and sheep, following the intravascular injection of radiolabeled palmitic acid, recovery of la-
beled alveolar PC reaches its peak at 35 to 45 h, as shown in figure 2, which suggests a 
slow de novo surfactant PC synthesis in these animals.a,95-97 In preterm ventilated lambs, by 
24 h, only 0.5% of the endogenously synthesized PC had been secreted to the alveolus, indi-
cating slow movement of the PC from the synthetic sites to the alveolus.5o 
Preterm infants « 34 wk) that do not develop RDS have higher surfactant PC con centra-
tions48,98,99 and percentages of DPPC in tracheal aspirates and alveolar lavages 100 implying a 
more developed surfactant production compared to infants that develop RDS. In preterm in-
fants with RDS, surfactant concentration increased slowly on day one and two of life, and 
then remained constant at values similar to infants that were treated with surfactant for RDS 
or that did not have RDS.48,98 Others report in preterm infants ventilated for RDS that alveo-
lar concentrations of Sat PC and SP-A are very low at birth, with concentrations still signifi-
cantly lower three days after birth than in preterm ventilated infants without RDS.99 These 
slow increases in PC and SP-A concentration could imply a slow endogenous surfactant syn-
thesis and corresponds to the usual clinical improvement several days after birth in infants 
with RDS. In preterm infants with RDS that received the stable isotope {U-13Clglucose, the 
palmitic acid in surfactant PC became labeled after approximately 18 h and was maximally 
labeled after about 70 h (fig. 3).101 In ventilated critically ill infants surfactant PC became 
labeled after about 10 h after infusion of [U-13CJpalmitic acid or [U-13CJlinoleic acid and was 
labeling maximal after -65 h.102 
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Figure 2. Kinetics of secretion of de novo synthesized phosphatidylcholine fPC}. The curves show the 
accumulation of labeled PC in the airspaces fol/owing the intravascular injection of the radiolabeled 
precursor palmitic acid. This precursor is incorporated into lung PC within minutes of intravascular in-
jection. The curves were normalized such that the maximal specific activities for each curve expressed 
as CPM/ mol PC were given a value of 1.0. The curves show slower accumulation in the newborn than 
in the adult. Data are derived from several sources as reviewed by Jobe. 8 
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In preterm infants with RDS, the first incorporation of linoleic acid from intravenous feeding 
into surfactant PC had a delay of ..... 3 d.48 The patterns of l3C-incorporation in infants are in 
line with results in preterm ventilated lambs and baboons (fig. 2)8,95,96,103 and the slow in-
crease in surfactant PC concentrations after birth measured by Hallman et al. 98 Cogo et al. 
used plasma IU-13C]palmitic acid and plasma [U-13C]linoleic acid as tracers for surfactant PC 
metabolism in critically ill ventilated infants {with a mean age of 50 d).102 It was estimated 
that 34 and 50% of the total surfactant PC pool was synthesized per day, when calculated 
with palmitic and linoleic acid, respectively.l02 Absolute synthesis rates have been estimated 
in vivo in RDS and range from minimally 5 mg/kg/d in preterm infants to ..... 12 mg/kg/d in pre-
term monkeys.49,101 
In summary, the endogenous synthesis and secretion of surfactant PC in the preterm infant 
is a slow process. The lung of the preterm infant seems not to be able to adapt rapidly to 
extra-uterine life which requires a significant alveolar surfactant pool and therefore exogenous 
surfactant administration is necessary to rapidly augment surfactant pools in RDS. 
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SURFACTANT CLEARANCE 
Due to the cyclic surface changes during respiration the surfactant monolayer is degraded to 
small aggregates representing "used surfactant". By differential centrifugation of alveolar 
fluid, these "small aggregates" (= inactive surfactant) can be separated from the lamellar 
bodies and tubular myelin, the "large aggregates" (= active surfactant).104-106 
The major route for clearance of alveolar surfactant is through uptake of the small aggre-
gates by the type" cell,107 which is stimulated by SP-A in vitro. 10B The PC molecule is not 
degraded by phospholipase prior to reuptake. 109 The PC molecule is probably reutilzed mainly 
intact directly110,111 via lamellar bodies or becomes degraded in Iysosomes to degradation 
products which can be used for surfactant synthesis or lost from the type " cell. 112 In the 
newborn, only small amounts of alveolar surfactant ( ..... 10%) are lost via uptake by macro-
phages and other lung celis, via the airways, and lost to the blood. After instillation of radio~ 
labeled surfactant, radioactivity can be measured in liver, brain, kidney, and serum indicating 
loss of surfactant components from the lung. 113 In the term newborn rabbit and in preterm 
lambs, the turnover time (the time to fill the pool if it were empty) for alveolar Sat PC has 
been estimated to be about 10 and 13 h, respectively.l11.114 This is a short period relative to 
the slow de novo surfactant PC synthesis due to a high degree of alveol,ar recycling. The sur-
factant PC recycling was calculated to be > 90% in the newborn rabbit and 50% in adult 
rabbits 115 and 90% in young pigs.52 
18 
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The half~life of a surfactant component is often described as "apparent" because surfactant 
components are lost from the total lung much slower than from the alveolus due to recycling. 
Alveolar and total lung half~life are difficult to separate in in vivo studies. Measurement of 
half~life of alveolar surfactant is complicated and findings are different between studies be~ 
cause of many difficulties with the models. When a labeled precursor is injected intrave~ 
nously, the alveolar pool of surfactant PC is not pulse labeled.97.116 This factor along with 
reutilization tends to prolong the apparent half~life. After an intravenous tracer, the half~life 
probably represents the disappearance of label from the total lung surfactant pool. When la~ 
beled preparations of exogenous surfactant are administered endotracheally, the alveolar pool 
PC becomes pulse labeled and therefore only the reutilization would be involved in prolonging 
the apparent half~life. labeled components of surfactant PC can be used for lung tissue syn~ 
thesis. Degradation of lung tissue can then again release labeled substrates for surfactant PC 
synthesis, which prolongs the measured surfactant PC half~life.117 The continued entrance of 
labeled PC precursors from other body pools (e. g. liver or adipose tissue) long after the initial 
label administration could in theory also prolong a measured half~life. 
It is not clear how surfactant pools change after birth and after surfactant administration in 
the human preterm infant. In 3~day-old rabbits, total lung surfactant pool sizes remained con-
stant for 3 d after increasing the pool three~ to five-fold by exogenous surfactant. 118 Half~ 
lives calculated in animal studies differ depending on gestational and postnatal age, the la-
beled substrate used and the surfactant pool studied. The difference between species is small 
when similar methods are applied. 119 The half~life of alveolar surfactant PC in newborn rab~ 
bits after intravenous palmitic acid ranged from 97 to 136 h, and after intravenous choline 
the half-life of PC was> 200 h.120 In lung parenchyma, the half-lives of PC-palmitate ranged 
from 50 to 94 h and for PC~choline it was > 100 h.120 In term newborn lambs, CH]palmitate 
labeled PC in alveolar samples had a half-life of approximately 50 h, after intravenous admini~ 
stration of CH]palmitate.95 These values indicate a very slow catabolism and/or considerable 
reutilization of endogenous surfactant PC in the newborn. After endotracheal injection of 
CHJPC in the newborn lamb, the half~life of alveolar PC were 12 and 6 d for alveolar and lung 
tissue PC, respectively.l17 These values are different from half~lives of alveolar rl4CIDPPC in 
the very premature baboon of ..... 30 h after intratracheal administration,121 possibly due to 
more recycling in premature animals, and species difference. Although ..... 80% of the labeled 
surfactant had disappeared from the total baboon lung on day six, the lung tissue contained 
increased Sat PC pools with low amounts in the alveolus, indicating extensive synthesis of PC 
but little secretion. 121 
Studies on surfactant catabolism have been performed mainly in premature infants treated 
with surfactant for RDS. In preterm infants who received human amniotic fluid~derjved sur~ 
factant containing phosphat idyl glycerol (PG), the half-life of PG calculated from tracheal aspi-
rates was ..... 30 h.46 This value is similar to the half~life of PG ..... 35 h, calculated in preterm 
lambs with the same method. 50 In preterm infants treated with Survanta®, alveolar PG and 
sphingomyelin had half~lives of -105 and ..... 97 h, respectively, but in infants treated with AI-
veofact®, alveolar PG had a half~life of ..... 43 h.54 Differences in the lipid composition or the 
higher content of SP-8 in Alveofact® could playa role in the different half~lives of PG between 
the preparations. The similar half~lives of PG and sphingomyelin in the Survanta® treated in~ 
fants indicate that these two phospholipids may be metabolized similarly. Hallman et a/. 
treated three preterm infants with human surfactant with [2H]DPPC and unlabeled PG .122 In 
these neonates, the PG concentration had a shorter half-life than the 2H~enrichment of DPPC 
(-33 versus .... 50 h), which could reflect a difference in the metabolism between these phos~ 
pholipids. l22 The apparent half-life of PG in natural human surfactant containing SP~A was 
significantly shorter compared to the half~life of PG in Alveofact@ without SP~A. This could be 
related to the presence of SP~A which enhanced lipid uptake by the type" ceJl.123·125 How~ 
ever, SP~A did not promote lipid uptake in SP~A knock-out mice. 126 
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Indirect evidence for a slow clearance of surfactant is reflected in several studies about al-
veolar surfactant concentration and composition after surfactant administration. In preterm 
infants the concentration of PC did not decrease significantly for many days - even up to four 
weeks - after therapy. 98,99 Ashton et al showed that the percentage DPPC of total lipids in 
tracheal aspirates increased due to surfactant (containing a high percentage of DPPC) and 
returned to baseline by d 6 after administration. 100 Bunt et al. showed that the administration 
of Survanta® containing 85% palmitic acid in PC, increased the PC palmitate percentage in 
tracheal aspirates directly, with a subsequent half-life of ...... 34 h after one dose and ..... 53 h 
after two doses of surfactant.48 
T orresin et al. treated pre term infants with RDS with Curosurf® with [U-13C]palmitic acid-
labeled DPPC and calculated the half-life to be -36 h" Using labeled DPPC has the advantage 
that it is the major component while PG and sphingomyelin are minor components of surfac-
tant.ln preterm infants the half-life of 13C-labeled PC-palmitate measured in tracheal aspirates 
was ...... 99 h (71 to 144) after an intravenous infusion of {U_13C]glucose.101,127 Half-lives were 
similar after one, two, or three doses of surfactant, but tended to be lower ( .... 70 h) when the 
infants had received no exogenous surfactant. 127 
In infants with acute respiratory distress syndrome that did not receive exogenous surfac-
tant, the half-life of "C-Iabeled PC-palmitate ranged from 17 to 178 h and the half-life of "C-
labeled PC-linolate ranged from 24 to 144 h after a [U-13C]palmitic acid and [U-13ClIinoleic 
acid infusion. 102 This variability between individual patients could be related to differences in 
lung diseases and could possibly affect the clinical course of the respiratory failure. 102 
In infants with severe RDS, the first dose of surfactant (100 mg/kg) is sufficient to in-
crease the surfactant pool size immediately, and when more doses are necessary, this is 
probably required to overcome inhibition,128 as the lungs of neonates with RDS are abnor-
mally permeable to small solutes and proteins. 129 
In term rabbits, the clearance of labeled exogenous surfactant from the total lung was a 
fixed (16%) percentage of the dose per day and showed that the lung can adapt to large 
amounts of exogenous surfactant and that clearance mechanisms were not saturated. 130 In 
the human preterm infant, some studies reported that half-lives were unrelated to the number 
of doses.46,48 Others showed longer half-lives in relation to more doses exogenous surfac-
tant. lOO,127 However, the number of patients were small in each study, with large inter indi-
vidual variability, and therefore the effect of exogenous surfactant on surfactant clearance in 
preterm infants should be studied further. 
In summary, compared to animal studies, there exist only few studies on surfactant me-
tabolism in the human infants and there are no data on recycling of surfactant. The preterm 
and newborn lung is characterized by a slow turnover of PC with very efficient recycling, and 
little clearance. 
EFFECTS OF SURFACTANT THERAPY ON SURFACTANT SYNTHESIS 
Although the administration of exogenous surfactant has become routine treatment of RDS in 
the preterm infant, there is very little information regarding effects of exogenous surfactant 
on endogenous surfactant metabolism. In healthy adult rabbits in vivo, administration of sur-
factant to the left lung only, resulted in increased incorporation of palmitic acid from plasma 
into surfactant PC in the left lung but not in the right lung 131 suggesting stimulation of en-
dogenous synthesis. In preterm ventilated lambs, surfactant treatment stimulated [3H]palmitic 
acid incorporation into surfactant PC after correction for the increased surfactant pool.5o In 3-
day-old rabbits, the administration of surfactant did, however, not influence the incorporation 
of labeled precursor in the total lung surfactant pool. 118 
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In preterm infants with ROS, the half-life of phosphatidyJglycerol was independent of the dose 
of exogenous surfactant (60 versus 120 mg/kg).46 This indicates that the absolute turnover 
had doubled after a two doses of surfactant compared to one dose. In preterm infants, the 
concentration of SP-A increased after exogenous surfactant while this preparation did not 
contain any SP-A, which suggests that endogenous SP-A secretion was stimulated and not 
suppressed. 132,133 In preterm infants the incorporation of 13C from intravenous {U_13C}glucose 
into alveolar surfactant PC palmitate increased after exogenous surfactant treatment. 127 
In summary, there is little information from animal and human studies about effects of ex-
ogenous surfactant on surfactant metabolism. Exogenous surfactant treatment in the prema-
ture with ROS, seems not to suppress endogenous surfactant synthesis. 
PRENATAL CORTICOSTEROIDS 
The role of corticosteroids on surfactant PC synthesis and structural lung development has 
been described mainly in in vitro and animal studies. 134,135 In many in vitro studies cortico-
steroids increase the activity of the enzymes involved in surfactant PC synthesis64,136-139 and 
increase surfactant protein synthesis. 137,140-142 The rate limiting enzyme CTP:phosphocholine 
cytidylyltransferase (CT) in the surfactant PC synthetic pathway, is enhanced by corticoste-
roids probably in the following way: corticosteroids stimulate the synthesis of the fibroblast 
pneumocyte factor (FPF) in the lung fibroblast. The FPF stimulates the formation of CT di-
rectly in the type II cell, and FPF induces via fatty acid synthetase the synthesis of fatty acids 
that can stimulate the activity of CT139,143,144 and stimulates surfactant phospholipid synthe-
sis by the type II cell. 145 Corticosteroids can probably also stimulate PC synthesis in the ab-
sence of fibroblasts. 64 Corticosteroids stimulate glycogen storage in the type II cell during 
early gestation 146, 147 and stimulate glycogenolysis in the type" cell to supply acetate for 
fatty acids and the glycerol for PC synthesis later in gestation during the period of surfactant 
synthesis.148-150 
In in vitro experiments with lung slices and isolated type " cells, corticosteroids increase 
the incorporation of radiolabeled precursors into surfactant PC, reflecting increased PC syn-
thesis. 136,139,144,15l-156 Corticosteroids at low concentrations in vitro seem to increase SP-A 
and SP-B synthesis and at high concentration inhibit their synthesis.157-l59 The in vivo prena-
tal corticosteroid treatment of preterm lambs increases surfactant proteins mRNA's rapidly 
and surfactant protein amounts in lung tissue. 160 In a study by Kessler et al. in premature 
baboons, a 72-h treatment with prenatal dexamethasone did not increase radioactive palmi-
tate incorporation in lung lipids, but it increased total lung phospholipid and alveolar lavage 
OPPC in lung lavage fluid at birth. 16l In preterm baboons, the synthesis rate of surfactant PC 
from plasma glucose was doubled after a 48 h treatment with prenatal corticosteroids. 162 
Data on pool size measurements as an indication of surfactant synthesis in vivo are con-
flicting. In some studies with newborn rabbits, preterm monkeys, and lambs chronically 
catheterized in utero, corticosteroid treatment 2 to 3 d before delivery increased surfactant 
PC pool sizes in alveolar lavage and lung tissue significantly after birth. 136,161,163,164 In con-
trast, other studies in large animals show no prenatal steroid induced increase of the alveo-
lar165-169 or total lung Sat PC pool size after birth.165-16B Ballard et al. and Ikegami et al. did 
not find an increase in total lung Sat PC pool size at birth in preterm lambs when corticoste-
roids were administered 2 to 4 d before preterm delivery.166,170 However, when corticoste-
roids were administered one week before delivery T the total lung Sat PC pool sizes at birth 
increased significantly. 166, 170 
Obladen et al. found increased concentrations of both PC and PG in tracheal and pharyn-
geal aspirates in preterm infants after stressed pregnancies. 171 In preterm infants that had 
received prenatal corticosteroids, the alveolar surfactant showed improved function in vitro 
21 
Chapter 2 
during the first days of life although PC concentrations in tracheal aspirates were not ele-
vated, which would imply qualitative rather than quantitative changes. l72 Arias et al. found 
increased LIS ratios in amniotic fluid from mothers who had been treated with dexametha-
sone. 173 We recently found in preterm infants that two doses of prenatal corticosteroids 
doubled the endogenous surfactant synthesis from the precursor plasma glucose. 174 
In summary, prenatal corticosteroids enhance surfactant PC synthesis in vivo, but the de 
novo synthesis rates remain low, and alveolar pool sizes are not increased within 48 h. In 
preterm animals with RDS, prenatal corticosteroids improve pulmonary compliance within 15 
h168 accompanied by stimulated structural development.175-180 Therefore, it could well be 
that the improved outcome of preterm infants after a relative short period of exposure to pre-
natal corticosteroids is more the result of non-surfactant phospholipid mechanisms by which 
pulmonary function is improved. 
CONCLUSIONS 
Pulmonary surfactant deficiency in the preterm infant is a major factor in the pathophysiology 
of RDS. The incidence and severity of RDS has decreased by the use of prenatal corticoste-
roid therapy and surfactant therapy. A clear understanding of surfactant metabolism will help 
to gain more insight in the pathophysiology and treatment of RDS and other neonatal lung 
diseases. The information about surfactant phosphatidylcholine metabolism in the newborn 
animal is extensive, but there are few studies in human infants. Studies in newborn animals 
suggest a slow de novo synthesis and clearance of surfactant and a rapid recycling in order 
to "reactivate" used surfactant. Surfactant PC concentrations are low in RDS and increase 
slowly in several days. Several studies in the human preterm infant indicate a slow synthesis 
and clearance from the lung. Surfactant treatments do not seem to interfere with endogenous 
metabolic pathways for surfactant synthesis and secretion. Data suggest that prenatal corti-
costeroids increase surfactant synthesis in the preterm infant. To which extent this stimula-
tion contributes to improved neonatal outcome after a relative short period of exposure to 
prenatal corticosteroids remains unclear. 
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Summary 
We studied surfactant synthesis and turnover in vivo in preterm infants using the stable 
isotope [U_13C]glucose, as a precursor for the synthesis of palmitic acid in surfactant ph os-
phatidylcholine (PC). Six preterm infants (birth weight, 916 ± 244 g; gestational age, 
27.7 ± 1.7 wk) received a 24-h IU- 13C}glucose infusion on the first day of life. The 13C_ 
enrichment of palmitic acid in surfactant PC, obtained from tracheal aspirates, was measured 
by gas chromatography-combustion interface-isotope ratio mass spectrometry. 
We observed a significant incorporation of carbon-1 3 from glucose into surfactant PC 
palmitate. PC palmitate became enriched after 19.4 ± 2.3 (16.5 to 22.3) h and reached 
maximum enrichment at 70 ± 18 (48 to 96) h after the start of the label infusion. The 
fractional synthesis rate (FSR) of surfactant PC palmitate from glucose was 2.7 ± 1.3%/d. We 
calculated the absolute production rate of surfactant PC to be 4.2 mg/kg/d, and the half-life 
10 be 113±25 (8710144) h. 
Data on endogenous surfactant production and turnover were obtained for the first time in 
human infants with the use of stable isotopes. This novel and safe method could be applied 
to address many important issues concerning surfactant metabolism in pre term infants, 
children, and adults. 
Am. J. Respir. Crit. Care Med. 1998; 157: 810-814 
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INTRODUCTION 
pulmonary surfactant deficiency is the main cause of respiratory distress syndrome (RDS) in 
the preterm infant. 1 Prenatal administration of corticosteroids and postnatal treatment with 
exogenous surfactant have greatly reduced morbidity and mortality caused by RDS.2,3 
However, some infants respond poorly or only temporarily to surfactant therapy. Different 
clinical responses to exogenous surfactant could reflect differences in surfactant metabolism 
between individuals. 
To date, surfactant analysis of sequential tracheal aspirates is the only available method 
for the evaluation of surfactant production in humans.4•6 Although this method provides data 
on the quality and concentration of surfactant, it does not give information on the endoge-
nous production and catabolism. In animals surfactant synthesis and catabolism are measured 
with radioactive tracers.6-9 This approach is not acceptable in humans, and especially not in 
infants. We studied endogenous surfactant production and turnover in preterm infants with 
RDS, using a novel and safe method. We used the stable isotope [U_13C]glucose as a precur-
sor for the fatty acid synthesis of lung phosphatidylcholine (PC). We measured carbon-13 
incorporation into the fatty acids of surfactant PC obtained from tracheal aspirates of preterm 
infants with RDS. 
METHODS 
Subjects and study design 
Six premature infants requiring mechanical ventilation were studied (birth weight, 916 ± 244 
g; gestational age, 27.7 ± 1. 7 wk) (table 1), starting directly after birth. Inclusion criteria 
were: gestational age <31 wk, prenatal corticosteroid therapy, severe RDS on chest 
radiograph (Giedeon grade III-IV), and written parental informed consent. Exclusion criteria 
were: congenital infection, maternal diabetes, and chromosomal abnormality. Patients 
received a constant intravenous infusion of [U- 13CJglucose {Campro Scientific, Veenendaal, 
The Netherlands} for 24 h at 0.170 mg/kg/min. The start of the study It~O} was defined by 
the start of the infusion of the labeled glucose. This was 4.2 ± 1.1 h after birth. The labeled 
glucose was infused by a high precision pump (M22, Harvard Apparatus Co. Inc., South 
Natick, MA). The total glucose intake was 5.7 mg/kg/min, including nonlabeled glucose. 
Before and during the glucose infusion, 1 ml arterial blood was drawn every 6 h for determi-
nation of glucose enrichment. Exogenous surfactant (Survanta®; Abbott Laboratories, North 
Chicago, IL) was administered endotracheally at t=O, at a dose of 100 mglkg phospholipids, 
if the mean airway pressure exceeded 7.5 em of water, or if the inspiratory oxygen fraction 
(FJoz) was higher than 0.40. Infants received a second dose 6 h later if the criteria were still 
met. Tracheal aspirates were obtained every 6 h during the time that the infant was intu-
bated. The tracheal suctioning procedure was performed during routine patient care and did 
not deviate from the normal clinical protocol. Twenty seconds after 0.5 ml normal saline was 
injected into the tracheal tube, suction was done beyond the tip of the endotracheal tube. 
The suction catheter was flushed with normal saline. Tracheal aspirates were immediately 
placed at -20°C, until further processing. No tracheal suction was done within 6 h after 
surfactant administration. Total parenteral nutrition including lipids was started at t=48 h. 
The study was approved by the local medical ethics committee. 
Analytical procedure 
Tracheal aspirates. After thawing, normal saline was added to the aspirate. This was 
vortexed and centrifuged at 450 x g for 10 min at 40C,10 lipids were extracted from the 
supernatant. 11 Surfactant PC was isolated from the lipid extract by thin layer chromatography 
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(TLC) 12 using Kieselgel 60 TLC plates (Merck, Darmstadt, Germany) and a Camag Linomat IV 
(Merck, Darmstadt, Germany). The PC was derivatized,13 and the fatty acid methyl esters 
were extracted with hexane and stored at -20°C. Tracheal aspirates containing visible blood 
were not analyzed. 
Blood samples. Blood was collected from the patient in lithium-heparin-containing vacutai-
ners and directly centrifuged to separate plasma and cells. The plasma was stored at -70°C 
until further processing. Plasma· was deli pi dated with chloroform and methanol.14 The water 
fraction was passed over a column with anion-exchange resin (AG-1X8 [acetate], 100-200 
mesh; BioRad Laboratories, Richmond, CAl and cation-exchange resin {AG-50W X8 [Hydro-
gen], 200·400 mesh; BioRad}. The elute containing the glucose was evaporated to dryness at 
aooc and derivatized to an aldonitril pentacetate derivative. 15 
Determination of enrichment 
The enrichment of selected fatty acids, components of surfactant PC, and of plasma glucose 
was measured by gas chromatography-combustion interface-isotope ratio mass spectrometry 
(GC-CI-IRMS) (VG Isotech, Middlewich, Cheshire, UK) as described.'6 For fatty acid analysis, 
1pl was injected on column (30 m Omegawax column; Supelco, Zwijndrecht, The Nether-
lands). The injection and oven temperature was 45°C for 2 min and raised at 150C/min to 
175°C, held for 15 min at 175°C, and subsequently ramped with 2°C/min to 240°C. 
For glucose, lpl was injected on a 25 m x 0.25 mm, 0.11 pm HT-5 capillary column (Sci· 
entific Glass Engineering, Victoria, Australia), with a split ratio of 30:1. The oven temperature 
was isothermal at 220°C. The enrichment was expressed in atom per cent excess (APE), 
which represents the increase in the percentage of carbon-13 atoms in total carbon dioxide 
from the combusted compounds above baseline enrichment (before infusion). Enrichments 
were corrected for the contribution of unlabeled carbon atoms added during derivatization. 
Calculations 
Tissue bound and alveolar surfactant were regarded as one pool, since studies in newborn 
rabbits showed that recycling is ""'16 times faster than de novo synthesis and clearanceJ-9 As 
palmitic acid is by far the most abundant fatty acid in surfactant PC, calculations were 
performed for palmitic acid only. 
Secretion time was defined as the time lag between the start of the [U- 13C]glucose infu-
sion and the appearance of enriched fatty acids in surfactant PC. The time of appearance of 
the enrichment in PC palmitate was calculated by plotting the regression line for the linear-
increasing part of the enrichment versus time curve, and extrapolating it to baseline enrich-
ment.17 
Fractional synthesis rate (FSR) of palmitic acid is expressed as the percentage of the total 
surfactant PC palmitate pool synthesized from glucose per day. it is calculated by dividing the 
slope of the linear increase of enrichment of PC palmitate by the steady state enrichment of 
plasma glucose.18 
Half-life of PC palmitate was calculated by exponential curve-fitting at the final, monoex-
ponential part of the downslope of the enrichment versus time curve. 
Data are presented as mean ± standard deviation (range). 
RESULTS 
The patients' characteristics are shown in table 1. Patients received two doses of exogenous 
surfactant, except for patient 2 who received one dose and was extubated on the second day 
of life. Exogenous surfactant therapy decreased of the Ffo2 from 0.53 ± 0.18 to 0.25 ± 0.06. 
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Table 1. Patients' characteristics 
Patient number 2 3 4 5 6 Mean SO 
Gestational age (wk) 27.1 27.7 29.1 26.1 30.3 25.6 27.7 1.7 
Birth weight (g) 1140 840 770 900 1225 590 916 244 
RDS-grade IV IV IV III IV III 
Doses of surfactant 2 1 2 2 2 2 
Apgar at 5 min 9 7 8 8 6 6 7.3 1.2 
Umbilical pH 7.30 7.30 7.17 7.30 6.95 7.21 0.16 
F102 at t=24 0.26 0.21 0.26 0.35 0.40 0.40 0.31 0.08 
F102 at t=36 0.25 0.21 0.35 0.34 0.37 0.44 0.33 0.08 
F102 at t=48 0.23 0.21 0.30 0.34 0.35 0.35 0.30 0.06 
Days of intubation 15 2 22 12.6 5.5 31 14.5 11 
In patient 6, the F102 decreased after the first dose of surfactant, from 0.50 to 0.25, but it 
increased again to 0.40, and a second dose did not result in a decrease in oxygen need. 
The 13C-enrichment of plasma glucose reached a steady state of 2.63 ± 0.45 APE in all 
patients between t=6 and t=24 h (data not shown). This was concluded because the slope 
of the enrichment versus time curve per patient did not deviate significantly from zero in this 
period. 
The 13C-enrichments of selected fatty acids of PC in patient 3 are shown in figure 1. The 
enrichment versus time curves of the nonessential fatty acids showed the same pattern. As 
expected, the essential fatty acids were not enriched (only linoleic acid is depicted). 
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Figure 1. 13C-enrichment of 
selected fatty acids of 
surfactant phosphatidyl-
choline (PC) in patient 3 
with ROS. At birth a 24-h 
[U-13C/glucose infusion was 
administered. Tracheal as-
pirates were obtained. The 
13C-enrichment of surfac-
tant PC was measured and 
expressed in atom percent 
excess. 
The increasing enrichment of PC palmitate, for all patients is shown in figure 2. The regres-
sion line of the linear part was used for calculating the secretion time, which was 19.4 ± 2.3 
(16.5 to 22.3) h (table 2), and for calculating the fractional synthesis rate. The FSR of PC 
palmitate from glucose was 2.7 ± 1.3 (1.06 to 4.25) % per day. Maximal enrichment was 
reached at 70 ± 18 (48 to 96) h. Decreasing enrichment of palmitic acid of PC in each 
individual patient is shown in figure 3. The closed marks represent the mono exponential part 
used for half-life calculations, in one patient only. The half-life of endogenous synthesized 
surfactant PC palmitate was. 113 ± 25 (87 to 144) h. 
32 
SUrf(lctant turnover in preterm infants 
Figure 2. Unear increase in 13C_ 
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DISCUSSION 
This study measures for the first time endogenous surfactant production and turnover in 
humans, We infused the stable isotope [U_ 13Clglucose in preterm infants and measured the 
13C-enrichment of selected fatty acids in surfactant PC. The incorporation of the carbon-13 
into surfactant PC palmitate began at 19.4±2.3 (16.5 to 22.3) h after the start of the 
isotope infusion (fig. 2), which likely corresponds to the time required for palmitic acid 
synthesis from glucose, processing of surfactant PC in the alveolar type" cell, and secretion 
into the alveolar spaces. In preterm ventilated lambs that received an intravenous injection of 
[3H]palmitic acid, radioactivity was already detected in surfactant after 5 h.9 This suggests 
that incorporation of plasma palmitate into surfactant PC is a faster process than palmitic 
acid synthesis from glucose with subsequent incorporation into surfactant PC. In our study, 
the PC palmitate enrichment was maximal 70 ± 18 (48 to 96) h after the start of the isotope 
infusion. This time to peak enrichment is dependent on the duration of the isotope infusion 
(24 h) among other factors. The maximal enrichment was found at 46 ± 18 h after the finish 
of the isotope infusion (fig. 1), which is comparable to the 35 to 60 h found in newborn 
rabbits and lambs after a single intravenous bolus of radio-labeled palmitic acid.9 ,19,20 
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Table 2. Kinetics of palmitic acid in surfactant phosphatidylcholine 
Secretion time FSR Time of maximal Half-life 
Patient (hi (%/d) enrichment (h) (hi 
1 16.5 4.25 48 144 
2 20.0 4.07 
3 21.6 2.28 60 97.6 
4 22.3 1.40 73 86.6 
5 18.9 3.14 74 105 
6 17.4 1.06 96 133 
Mean 19.4 2.70 70 113 
SD 2.3 1.34 18 24.5 
Six ventilated pre term infants received a 24-h [UJ3 Clglucose infusion. During the period the infants 
were intubated, tracheal aspirates were obtained and surfactant phosphatidylcholine (PC) was isolated. 
Enrichment of palmitic acid in surfactant PC was measured. Kinetic parameters were calculated using 
enrichment versus time curves from plasma glucose and surfactant PC palmitate. FSR=fractional 
synthesis rate. 
In this study, surfactant PC half-life was 4.7±1.0 (3.6 to 6.0) d, which indicates that in 
human preterm infants endogenous surfactant remains in the lung for a long time. To 
minimize the potential influence of ongoing incorporation of labeled palmitic acid produced via 
lipogenesis in the liver, we calculated half-life from the final monoexponential part of the 
enrichment versus time curve. To confirm that there is no major influence of ongoing incorpo-
ration from labeled palmitic acid during the time frame of half-life calculation, we measured 
enrichment of palmitic acid in plasma triglycerides and phospholipids in three patients who 
were clinically comparable to the study patients. The enrichment of palmitic acid in plasma 
triglycerides and phospholipids was maximal at t = 25 ± 0 h (O.22 ± 0.01 APE) and 35 ± 5 h 
(0.16 ± 0.01 APE), respectively, and decreased afterwards. The enrichment of plasma free 
palmitic acid was measured in one patient and was very low during the entire study period 
(maximal at t ~ 24 h, 0.05 APE, and at t~ 70 h, 0.01 APE). At the time of maximal enrich-
ment of surfactant PC palmitic acid (t = 70 h, 0.12 ± 0.047 APE) the enrichment of triglycer-
ides was 0.020±0.01 APE and that of phospholipids was 0.02±0.002 APE. During the 
period of half-life calculation (starting from approximately 100 h), the enrichment of surfac-
tant PC palmitate was 0.09 ± 0.03 APE. The 13C-enrichment of palmitic acid in triglycerides 
and phospholipids was much lower (0.01 ±0.01 and O.020±O.01 APE, respectively). This 
indicates that the long half-life for surfactant PC palmitate is not due to the presence of a 
high enrichment of plasma palmitic acid but a reflection of surfactant PC metabolism in the 
lungs. 
The long half-life of 4.7 d of surfactant PC in our study is compatible with findings in ani-
mal studies. In term newborn sheep, after tracheal instillation of PC labeled with [3H1palmitic 
acid the half-life of PC in the alveolar wash was approximately 11.6 d.21 In term newborn 
rabbits, who received a bolus of albumin-bound eH]paimitic acid intravenously, the specific 
activity of alveolar PC [3H]palmitate had a half-life ranging from >2 to 5.7 d.9,22In one study 
using surfactant labeled with [14C]DPPC in newborn rabbits, the half-life was approximately 
25 h,23 which is shorter than in most other studies, possibly explained by the short duration 
of this study (only 16 h). Support of a long half-life of surfactant in human preterm infants is 
provided by a study by Hallman et al. who reported that PC concentrations in tracheal 
aspirates after surfactant administration in pre term infants with RDS did not decrease during 
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the first week of Iife.5 In preterm infants with RDS treated with surfactant containing 
phosphatidylglycero!. the half-life of phosphatidyiglycerol in tracheal aspirates was ca[culated 
by Hallman et al. to be 20 to 36 h.4 This might be different, however, from the half-life of 
PC, as it is known that not all surfactant components have the same turnover rates. 
[n the present study all infants received exogenous surfactant, which readily mixes with 
the endogenous pool. Whether exogenous surfactant influences endogenous surfactant 
metabolism and whether the half-life of exogenous surfactant is similar remains to be studied. 
In our study the rate of PC palmitate synthesis from glucose was low (FSR=2.7%/d), 
which could partially explain why preterm infants with RDS who do not receive exogenous 
surfactant improve only after a few days. Thus the only way to rapidly augment the surfac-
tant pool in newborn infants with RDS is by exogenous surfactant administration. The pool 
size of endogenous PC in pre term infants with RDS is very low and estimated to be approxi-
mately 5 mg/kg.4,24 Therefore, we assumed the total lung surfactant PC pool size to be the 
estimated endogenous pool size (5 mg/kg) together with the administered dose of exogenous 
surfactant, 87 mg/kg PC after one dose or 174 mg/kg PC after two doses. With this assump-
tion, we calculated the production rate of PC palmitate from glucose to be 2.2 ± 1.1 (0.99 to 
3.95) mg/kg/d. This corresponds to a PC production rate from glucose of approximately 4.2 
mg/kg/d (absolute production rate = FSR x pool size). It is possible, however, that part of the 
exogenous surfactant is not completely retained within the lungs, which would result in an 
overestimation of pool size and surfactant PC synthesis. In newborn rabbits and in preterm 
monkeys surfactant production from palmitic acid and choline was estimated to be 8.4 and 
12.5 mg/kg/d, respectively, when measured with labeled choline and palmitic acid.9,25 The 
absolute production rate in our study was slightly lower than that in the animal studies 
mentioned above, possibly because we calculated production from glucose only. The [ow 
production rate indicates that only after several days a considerable amount of surfactant is 
present in the alveolus. This observation is in agreement with the study of Hallman, which 
showed that after 4 to 5 d the concentration of PC in the alveolus reaches values comparable 
to preterm infants without RDS.5 
In the type II pneumocyte, glucose is a primary source for fatty acid synthesis of surfac-
tant PC.26-28 In the type II cell other substrates are used for surfactant PC palmitate synthesis 
as well, such as fatty acids derived from Iipolysis,27 lactate, pyruvate, and ketone bodies.26 
We measured endogenous PC palmitate synthesis from glucose only. We have recently 
demonstrated that lipogenesis from glucose occurs in preterm infants fed sole[y glucose 
intravenously on the first day of Iife.29 Therefore, with our approach carbon-13 incorporation 
into surfactant PC occurs via lipogenesis in type II cells directly or via lipogeneSis in the liver 
and subsequent uptake of labeled palmitic acid by type II cells. 
In summary, this study shows that in preterm infants with RDS, after prenatal corticoste-
roid therapy and postnatal surfactant administration, the surfactant PC palmitate production 
from glucose is a slow process. The long half~life of 4.7 d indicates also a very slow turnover 
of the total surfactant PC palmitate pool. The novel and safe method described in this report 
could be applied to address many important issues concerning surfactant metabolism in 
preterm infants, children, and adults. 
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Summary 
Little is known about endogenous surfactant metabolism in infants, because radioactive 
isotopes used for this purpose in animals cannot be used in humans. We developed a method 
to measure the endogenous surfactant kinetics in vivo in humans by using stable isotope 
labeled fatty acids. 
We infused albumin-bound [U-13C]palmitic acid (PA) alld [U_13C]linoleic acid (LLA) for 24 h 
in eight critically ill infants (mean ± SO; weight; 3.7 ± 1.3 kg, age; 51.3 ± 61.6 d) who 
required mechanical ventilation. The 13C-enrichment of PA and LLA in surfactant phosphati-
dylcholine (PC), obtained from tracheal aspirates, was measured by gas chromatography-
combustion interface-isotope ratio mass spectrometry. 
We measured a significant incorporation of both 13C_PA and 13C-LLA into surfactant PC. 
PC·PA and PC·LLA became enriched after 8.7±4.9 (3.4 to 17.3) hand 10.0±7.2 (3.0 to 
22.4) h, respectively. The times of maximal enrichment were 49.2 ± 8.9 and 45.6 ± 19.3 h, 
respectively. The fractional synthesis rate (FSR) of PC-PA ranged from 0.4 to 3.4% per h, 
whereas the FSR of PC-LLA ranged from 0.5 to 3.8% per h. The surfactant PC-PA and PC-
LLA half·lives ranged from 16.8 to 177.7 and 23.8 to 144.4 h, respectively. 
This method provides new data on surfactant metabolism in infants requiring mechanical 
ventilation. We found that the synthesis of surfactant from plasma PA and LLA is a slow 
process and that there were marked differences in PC kinetics among infants. This variability 
could be related to differences in lung disease and could affect the clinical course of the 
respiratory failure. 
Pediatr. Res. 1999; 45: 242~246 
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INTRODUCTION 
Damage to the surfactant system has been implicated in the pathophysiology of acute lung 
injury which occur in humans in a wide variety of acute processes such as lung infection, 
sepsis, trauma, ARDS, or neonatal RDS, or occurs secondary to mechanical ventilation. All 
these processes lead to a widespread proteinaceous edema within the lungs and to a release 
of inflammatory mediators that could maintain lung inflammation. l -e 
Exogenous surfactant has been advocated as therapy in humans to overcome respiratory 
failure by restoring more uniform mechanical properties of the lungs. This approach has been 
proven to be beneficial in neonates with RDS,7 but the results in adults have been less 
encouraging. 5,8,9 There are no data in humans on endogenous surfactant synthesis and 
turnover in normal and injured lungs to support the use of exogenous surfactant after the 
neonatal period. 
We have recently published that small preterm infants with PDS have a low fractional 
synthesis of lung PC palmitate from plasma glucose. 1o Whether this low incorporation is 
caused by the precursor molecule used or the severity of the lung immaturity of the infants 
stUdied remains to be investigated. In the present study, we tested whether the labeling of 
plasma FFA with stable isotopes is a suitable technique for the measurement of surfactant 
synthesis in young infants. We developed a method for the measurement of endogenous 
surfactant production and turnover using a constant intravenous (Lv.) infusion of albumin-
bound (U-13CJPA and [U- 13CJLlA. We saw a significant incorporation of the tracers into 
surfactant PC, and new data on endogenous surfactant synthesis and turnover in humans 
could be obtained. 
METHODS 
Subjects and study design 
Surfactant synthesis was studied in eight infants whose clinical characteristics are reported in 
table 1. All patients were admitted to the Neonatal or Pediatric Intensive Care Units of the 
Department of Pediatrics, University of Padua, italy for respiratory failure. The inclusion 
criteria were: age < 6 months, stable hemodynamic condition during the isotope infusion, and 
respiratory failure that required endotracheal intubation for at least 48 h. Infants were 
excluded from the study when they presented with signs of liver and renal failure, seizures, or 
if they received blood products during the study. All infants had arterial and central venous 
lines placed for clinical monitoring and no infant received Lv. lipid emulsion during the isotope 
infusion. Feeding was started gradually, 3 d after the start of infusion. All medications given 
to the patients during the study were recorded. The study protocol was approved by the 
ethics committee on Human studies at the Department of Pediatrics of the University of 
Padua and was conducted according to the principles expressed in the Declaration of 
Helsinki. Written informed consent was obtained from the parents. 
Study protocol. [U-13C]PA (16:0; purity: 99%) and IU-13C]LLA (18:2n-6; purity: 97%) were 
purchased from Martek Biosciences (Columbia, MDI. Chemical and isotopic purity was 
confirmed by gas chromatography mass spectrometry. [U-13C1PA and [U- 13C]LLA were bound 
to human albumin (Merieux, Pasteur, Lyon, France) and prepared for Lv. infusion as described 
previously.l1 The albumin-bound tracers were infused at a constant rate by a high precision 
calibrated syringe pump (M22, Harvard Apparatus Co, Inc. Natick, MA) over a 24-h period. 
The rates of infusion were 1.0 ±0.26 and 1.19 ± 0.23 pmollkg/h for PA and LLA, respec-
tively. The arterial line was used for blood sampling and the venous line for tracer infusion. 
Before and during the isotope infusion, 0.6 mL of blood was drawn at 0, 3, 6, 12, 18, and 24 
h to determine the isotopic enrichment of PA and LLA enrichment in plasma FFA. The blood 
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drawn was placed in tubes containing EDTA and immediately centrifuged at 1300 x g. After 
separation plasma was stored in tubes containing pyrogallol as antioxidant at -20°C until 
analysis. 
Tracheal aspirates were obtained before the start of the isotope infusion and every 6 h 
thereafter until the patient was extubated. Twenty seconds after 0.5 mL normal saline was 
injected into the tracheal tube, suction was done beyond the tip of the endotracheal tube. 
Analytical procedure 
Tracheal aspirates. Normal saline was added to the tracheal aspirate to a total of 5 mL. This 
was centrifuged at 150 x g for 10 min, and supernatant was stored at -20°C. Lipids were 
extracted from tracheal aspirates according to Bligh and Dyer. 12 Surfactant PC was separated 
from other surfactant phospholipids by thin layer chromatography. 13 The PC was derivatized 
by adding 2 mL of 3 M dry Hel methanol,14 and the fatty acids were extracted with hexane 
and stored at -20°C until analysis. No tracheal aspirate contained visible blood. 
Plasma lipids were processed as previously described. 11 Plasma was delipidated according 
to Folch, 1!.i lipid classes separated by thin layer chromatography, and their fatty acids 
derivatized as methyl esters. The quantification of plasma FFA and of FA of surfactant PC 
were performed as previously described. 11 
Determination of enrichment 
The enrichment of individual fatty acids of surfactant PC was measured by gas chromatogra-
phy-combustion interface-isotope ratio mass spectrometry (VG Isotech, Middlewich, Chesire, 
UK). 1 0 The enrichment was expressed as APE, which represents the increase in percentage 
of 13C atoms in total carbon dioxide from the combusted compounds above baseline enrich-
ment (before isotope infusion). Enrichments were corrected for the contribution of unlabeled 
carbon atoms during derivatization. 
Isotopic enrichments of PA and LLA of plasma FFA were carried out on a Fisons MD 800 
gas chromatograph quadrupole mass spectrometer {Fisons, Milan, ItalyL using the chemical 
ionization mode with isobutane. 11 Each plasma sample was measured in duplicate. 
Calculations 
Surfactant in the type " cells and the alveolus were regarded as one pool, because animal 
studies showed that recycling is much faster than the de novo synthesis and clearance. 16,17 
Secretion time is the time of first appearance of the enrichment in surfactant PC and was 
defined as the time lag between the start of the (U·13ClPA and the [U_13CjLLA infusion and 
the appearance of the respective labeled fatty acid in surfactant PC. The time of first 
appearance of the enrichment was calculated by plotting the regression line for the linear 
increasing part of the enrichment versus time curve and extrapolating it to baseline enrich-
ment. 10,18 
Fractional synthesis rate (FSR) of PC-PA and PC-lLA is the percentage of the total surfac-
tant PC pool synthesized from the respective plasma fatty acid per h. It is calculated by 
dividing the slope of the linear increase of the enrichment of PC by the plasma steady state 
enrichment of the respective FA of the plasma FFA.1O,18 
Half-life of PC was calculated by exponential curve fitting at the final monoexponential part 
of the down-slope of the enrichment versus time curve. 
Peak time is the time of maximal enrichment of surfactant PC. 
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Table 1. Clinical charateristics of the infants studied 
Weight Energy MAP 
(kg) Age GA intake Main Intubation em F102 NO 
Patient Sex [centileJ (d) (wk) Kcallkg/d Diagnosis (d) H,O (%) ppm 
1 F 1.9150J 11 32 20 Sepsis syndrome 6{4 5 30 
2 M 5.813J 147 39 17 Pneumonia/sepsis 5{2 16 70 
3 F 51<31 149 40 17 Pneumonia/sepsis 30{1 18 50 25 
4 M 3.6150J 1 38 23 Esophageal atresia, postop 3/1 5 21 
5 F 2.5 [<31 23 37 14 Streptoccus 8 meningitis 20/5 8 30 
6 M 4.1 175J 53 40 21 RSV bronchHolitis 15/2 18 60 
7 M 4.1 175J 12 34 31 MAS / E. coli spsis 18{12 17 80 6 
8 M 3.2 {50] 14 37 29 Pneumothorax 20/12 20 35 
Mean 3.7 51.3 37.1 21.5 13.4 47.0 
SD 1.3 61.6 2.9 6.0 6.3 21.4 
GA = gestational age, MAP = mean airway pressure, NO = nitric oxide, RSV = respiratory syncthial 
virus, MAS = meconium aspiration syndrome, intubation = number of d intubation/d of intubation 
before the start of the study, ppm = parts per million. 
RESULTS 
In all infants, [U- '3CJPA and [U- '3CJLLA enrichments of plasma FFA reached steady state 
within 3 h from the start of the Lv. isotope infusion, because the slope of the enrichment 
curve over time did not deviate significantly between t=3 hand t=24 h (fig. 1). Total FFA, 
PA and LLA plasma concentrations and mol% values of 7 of the 8 infants studied were 
reported elsewhere. 11 
The percentage values of PA and LLA in tracheal aspirate PC were 64.4 ± 10.6 and 
2.0± 1.1 mol%, respectively. PC-PA and PC-LLA molar percentages were rather stable in the 
individual patients with a variability of less than 5% during the study period. 
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Figura 1. Isotopic enrichment {APE} of plasma free PA {A} and LLA (B) in eight critically 1/1 infants after 
a 24-11 constant infusion of albumin-bound fU- 'JCJPA and [U- '3CJLLA. All patients, identified by 
different symbols, reached steady state after the third 11 of the isotope infusion. 
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The time curves of the 13C-enrichment of individual fatty acids of surfactant PC in patient 7 
are shown in figures 2 and 3. Other fatty acids, besides PA and LLA, became enriched in 
surfactant PC. The nonessential fatty acids derived from the desaturation and/or chain 
elongation of labeled PA, namely 16:1n-7, 18:0 and 18:1n-9 are shown in figure 2. The 13C_ 
enrichment of LLA and of its metabolic derivatives, namely 20:3n-6 and arachidonic acid 
(20:4n-6) are shown in figure 3. 
Kinetic data calculated for each individual patients are shown in table 2; FSR, secretion 
time, peak time, and half-life were calculated using both PA and LLA. Surfactant PC-PA and 
PC-LLA half-lives were calculated in five patients (patients 3, 5-8) because patients 1 and 4 
were extubated within 72 h of the beginning of the study and patient 2 died 80 h after the 
beginning of the study. The FSR for PA and LLA ranged from 0.8 to 3.4 and 0.5 to 3.8% per 
h, respectively, which correspond to mean values of 34 and 50% per d, respectively. We 
could not find any correlation between PA and LLA mol% values in tracheal aspirate PC (data 
not shown). Mean secretion time and time to peak for PA versus LLA were similar (8.7±4.9 
versus 10.0 ± 7.2 hand 49.2 ± 8.9 versus 45.6 ± 19.3 h, respectively). Half-lives of PC-PA 
and PC-LLA showed large differences in the individual patients (range: 16.8 to 177.7 h). In 
patient 5, half-lives of PC-PA and of PC-LLA were 177.7 versus 43.6 h, respectively. In 
patient 6, we found the reverse, and values were 33.2 versus 144.4 h, respectively. 
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DISCUSSION 
In this study we measured the endogenous surfactant production and turnover in vivo in 
human infants by using stable isotope labeled fatty acids. We infused {U- '3CJPA and {U-
13CJLLA in infants with respiratory failure and measured the 13C-enrichment of selected fatty 
acids in surfactant PC. 
Surfactant synthesis has been studied in vivo in animals by using several metabolic precur-
sors of the surfactant PC molecule such as glycerol,19 glucose,20 choline,21 and more 
frequently, palmitic acid. 17,22 After Lv. administration, these precursor molecules have 
different volumes of distribution and are subject to a different oxidative and nonoxidative 
metabolism before taken up by the type II cells in the lungs. 
We have recently infused IU-' 3C]glucose in preterm infants with RDS and measured the 
isotopic enrichment of PA in surfactant PC.lO By infUSing labeled glucose as a tracer, we 
measured the PC-PA synthesized de novo from glucose via lipogenesis and incorporated into 
surfactant PC by the type II cells. After Lv. [U-13CJglucose, the site of PA synthesis can be 
the type II cell with direct incorporation of PA into PC-PA or the liver with the subsequent 
production of very low density lipoproteins containing labeled PA. Plasma lipids are taken up 
by the type II cells for PC synthesis.23 Under these experimental conditions, total surfactant 
PC synthesis could not be calculated, because PA from sources other than lipogenesis from 
glucose contribute to the synthesis of PC-PA. 
Table 2. Surfactant phosphatldylcholine kinetics_after infusion of labeled PA and llA 
F8R of PA ST of PA Peak of Half-life F8R of lLA ST of llA Peak of Half-life 
Patient (%/h) (hi PA (hi of PA (hI (%/hl Ihl lLA Ihl of lLA (hI 
1 3.4 11.2 NA NA 3.8 9.3 NA NA 
2 0.8 4.2 NA NA NA NA NA NA 
3 2.1 17.3 48 16.8 2.6 22.4 66 23.8 
4 0.4 4.7 NA NA 0.5 9.1 NA NA 
5 0.6 3.4 48 178 1.7 3.0 48 43.6 
6 1.3 13.2 54 33.2 NA 2.5 18 144 
7 2.1 8.4 36 33.8 2.1 16.4 36 37.3 
8 0.7 7.4 60 77.9 2.0 7.3 60 47.5 
FSR = fractional synthesis rate, ST = secretion time, peak = Hme of maximal enrichment, PA and 
LLA = palmitic acid and linoleic acid in surfactant PC, respectively. 
In the present study, by infusing labeled PA, we measured the surfactant PC synthesized by 
the type II cells using plasma PA as metabolic precursor, but we could not calculate the 
surfactant PC-PA from de novo synthesis from glucose in the type II cells. Our patients also 
received an infusion of LLA, which is an essential fatty acid and cannot be endogenously 
synthesized. We used LLA to estimate the total PC surfactant production. The incorporation 
of labeled PA and LLA in surfactant PC, namely secretion time, began 9 h after the start of 
the isotope infusion. This does not suggest a different processing of PA versus LLA during 
the de novo synthesis of surfactant PC, which is consistent with in vitro studies.24 The 
secretion time corresponds to the time required by the alveolar type II cells to take up the 
fatty acids from plasma lipids and to process and excrete them as PC into the alveolar space 
in addition to the time required by surfactant PC to reach the tracheal tree. Slightly shorter 
times have been reported in 10~d-old lambs that received [3H1palmitate as a bolus. 17 
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We reported longer secretion times (19.4 ± 2.3 h) in preterm infants with RDS treated with 
exogenous surfactant who received an Lv. infusion of [U-13CJglucose as precursor for 
surfactant PC palmitate. 1o Whether this difference is determined by the type of precursor 
used (fatty acids versus glucose), the different patient characteristics, (critically ill infants 
versus small preterm infants with RDS), or dilution of the labeled PC that could have occurred 
via recycling in the type II cells after exogenous surfactant in the pre term infants with RDS is 
currently being studied. The time of maximal isotopic enrichment of the fatty acids in 
surfactant PC was approximately 2 d for both PA and LlA; these figures are comparable with 
the animal data in newborn lambs and rabbits. 17,22,25 
Although the patients studied constitute a very heterogeneous group, the incorporation 
rate of PA in surfactant PC was consistently lower than the respective incorporation rate of 
LLA in surfactant PC. The mean incorporation rate of PA in surfactant PC was 34.2 ± 24.8% 
per d of the PC PA pool size, which is approximately one half of the incorporation of LLA 
(50.8 ± 26,0% per d). Therefore, the infants in the study synthesized one third of their 
surfactant PC-PA pool from plasma PA and one half of their surfactant PC-LLA pool from 
plasma LLA each d. lower FSR for PA than for LLA could be explained by the de novo 
synthesis of palmitate from other substrates than from fatty acids. In the case of LLA, this 
process cannot occur in animals because LLA is an essential fatty acid and there is no 
endogenous synthesis of LLA. In animals, Surfactant PC palmitate, derived from plasma fatty 
acids, represents only approximately 50% of the total PA incorporated in surfactant PC, 
whereas the other 50% is derived from glucose,2o,26 lactate, ketone bodies, and gluta-
mate. 27,28 Despite that llA represents only 2 to 3% of the total fatty acids of surfactant PC, 
its incorporation rate could be a more reliable measure of the rate of surfactant PC synthesis 
than that of PA. Therefore, according to this estimate, approximately 50% of the surfactant 
PC pool was synthesized on average by our group of patients in 1 d, which is in agreement 
with data in rabbits. 17,26 
The half-life of surfactant PC ranged between 1 and 7.4 d, with infants with the most 
severe respiratory failure having the shortest PA half-lives (patient 3, 6 and 7). The limited 
number of infants studied does not allow us to draw any firm conclusion, but the wide range 
suggests a different behavior of surfactant kinetics in our patients. In term newborn rabbits 
that received a bolus of {3HJPA Lv., the half-lives of surfactant PC yielded comparable results 
ranging between 2 and 5.7 d_ 17 Furthermore, the half-lives of PC-PA and of PC-LLA exhibited 
rather different values in the individual patients. In patient 5, the half-lives of PA and LLA 
were 178 and 43.6 h, respectively; in patient 6, we found the reverse and values were 33.2 
and 144 h, respectively. We do not have an explanation for these finding because most of 
the animal work has been focused on the metabolism of disaturated PC and little attention 
has been paid to the metabolism of polyunsaturated fatty acids. Long half-lives of PC-PA 
could result from a reduced surfactant PC catabolism and/or could be associated to an 
"active" recycling. The latter process is known to exhibit a strong preference for saturated 
fatty acids.29 Also, longer half-lives of PC-LLA could represent an inhibition of remodeling of 
unsaturated PC to saturated PC.24 A larger proportion of surfactant PC-PA, synthesized via de 
novo lipogenesis from glucose, could also contribute to shorter half-lives during periods of 
increased surfactant synthesis. We have recently observed increased incorporation of 
palmitate from glucose in preterm baboons who have been treated prenatally with corticos-
teroids in comparison with baboons who did not receive steroids.3o 
In summary, this report describes a method for the measurement of surfactant synthesis 
and turnover in vivo in humans. These preliminary results in critically ill infants are consistent 
with data obtained from animal experiments and suggest that surfactant synthesis is a slow 
process. The use of stable isotope labeled fatty acids such as LLA and PA and of labeled 
glucose will expand the understanding of surfactant metabolism in humans. This will improve 
the rational use of exogenous surfactant in infants with lung injury.8,9 
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Summary 
We studied the synthesis of surfactant and the effect of prenatal betamethasone treatment in 
vivo in very preterm baboons. Ten pregnant baboons were randomized to receive either 
betamethasone (Beta) or saline (Control) 48 and 24 h before preterm delivery. The newborn 
baboons were intubated, treated with surfactant, and ventilated for 6 d. They received a 24-h 
infusion with the stable isotope [U_13CJglucose as precursor for the synthesis of palmitic acid 
in surfactant phosphat idyl choline (PC). 
Palmitic acid in surfactant PC became enriched 27 ± 2 h after the start of the isotope infu-
sion and was maximally enriched at 100 ± 4 h. The fractional synthesis rate of PC-palmitate 
in the Beta group (1.5 ±0.2% per d) was increased by 129% above Control (0.7 ±0.1 % per 
d), (p<0.02, Mann-Whitney U-tesU. The absolute synthesis rate of PC in the Beta group 
(1.6 ± D.3 [.mol/kg/d) was increased by 128% above Controls (D.7 ±D.2 ~mol/kg/d) 
(p<O.D2). 
These data show that the synthesis of endogenous surfactant from plasma glucose as 
precursor is a slow process. It is shown for the first time in vivo, that prenatal glucocortico-
steroids stimulate the synthesis of surfactant PC in the very premature baboon. 
Am. J. Respir. Crit. Care Med. /999; 160: 1481 ~ 1485 
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INTRODUCTION 
Little is known about surfactant metabolism after preterm delivery of humans or animals. In 
term and pre term monkeys and lambs with surfactant deficiency, the pool sizes of surfactant 
in the alveolus increase slowly postnatally.' ,2 Recovery from respiratory distress syndrome 
(RDS) in monkeys is associated with larger increases in lung pool sizes of disaturated 
phosphatidylcholine (OS PC) than nonrecovery from RDS.3 In the preterm human, the accu-
mulation of alveolar surfactant is slow, as shown by a slow postnatal increase in surfactant 
phosphatidylcholine {PC} concentration in tracheal aspirates,4 and low synthesis rates of 
surfactant PC.5 
The improved pulmonary function of previously unstressed preterm animals after treatment 
with prenatal glucocorticoids results primarily from structural changes of the lungs that 
include increased lung gas volume, decreased perilobular connective tissue, decreased 
alveolar wall thickness,6 and induction of antioxidant enzyme activities.1 Improved pulmonary 
function can also result from increased amounts of surfactant. In vitro, glucocorticoids 
increase the activity of a number of enzymes of the surfactant synthetic pathway and 
increase surfactant phospholipid and protein synthesis, and lamellar body appearance in 
human fetal lung explants.8-10 However, in most in vivo studies with preterm rabbits, preterm 
lambs, and very preterm baboons, treatment with betamethasone 48 h before delivery does 
not increase surfactant pool sizes of the alveolar lavage and total lung. 2,11,12 We reported 
large increases in surfactant PC pools after birth in both the lung tissue and alveolar pools of 
preterm ventilated baboons during the first days of life, and pool sizes were not significantly 
increased by prenatal glucocorticoids,2 As pool size depends on both synthesis and clearance 
of surfactant, the measurement of the pool size is not equivalent to the measurement of the 
production rate. Therefore, it is currently unclear whether prenatal glucocorticoids increase 
surfactant production after pre term delivery. 
We studied postnatal endogenous surfactant metabolism in the very premature baboon and 
tested the hypothesis that prenatal corticosteroids influence the synthesis of endogenous 
surfactant in vivo. These studies are comparable to our recent report of endogenous surfac-
tant metabolism in preterm human infants5 because we used the same stable non-radioactive 
isotope, {U_13C}glucose, as a precursor for the synthesis of palmitic acid in surfactant PC. 
METHODS 
Animal Treatment and Postnatal Care 
Animal care, fetal treatments, deliveries, and the postnatal studies were performed at the 
Southwest Foundation for Biomedical Research (San Antonio, TX) as reported previously.2 All 
procedures were reviewed and conformed with AAALAC guidelines. PregnanCies were dated 
on the basis of cycle dates and growth parameters determined by prenatal ultrasounds 
performed at estimated fetal gestational ages of 70 and 100 d. At 123±2 d gestation (term 
is 185 d) the pregnant baboons were randomly assigned to receive 6 mg of betamethasone 
(Celestone Soluspan@; Schering Pharmaceuticals, Kenifworth, NJ) or saline by intramuscular 
injection 48 and 24 h before delivery. At delivery, the pregnant baboons were sedated with 
ketamine (10 mg/kg, 1M), intubated and anesthetized with 1.5% halothane. The preterm 
fetuses were delivered by cesarean section at 125 ± 2 d gestation and intubated. The 
newborns received surfactant (100 mg/kg) by tracheal instillation (Survanta@; donated by 
Ross Products, Columbus, OH). At birth, animals received parenteral fluids containing 
glucose, amino acids, multivitamins and appropriate electrolytes intravenously; they were not 
fed, and did not receive lipids. 
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To study the endogenous surfactant PC-palmitate production, all newborn baboons received a 
constant intravenous infusion of the stable isotope [U_13C]glucose for 24 h, starting immedi-
ately after birth (t ~OJ, at a rate of 0.17 mg/kg/min. Arterial blood (0.5 mil was drawn at 0, 
12, 18, and 24 h, for determination of plasma glucose enrichment. Tracheal aspirates were 
obtained every 12 h during the study period of 6 d. After instillation of 0.5 ml saline into the 
endotracheal tube, aspiration was performed with a 5F catheter, and the aspirate was frozen. 
At 144 h (6 d), the animals were killed with pentobarbital. Alveolar wash was performed in 
situ by filling the lungs with 0.9% NaCI at 4°C and recovering the fluid by syringe.2 The 
lavage procedure was repeated five times. The lungs were removed, weighed, and homoge-
nized and aliquots were frozen. 
Analytical Procedures 
The tracheal aspirates, alveolar washes, lung homogenates, and plasma glucose samples 
were processed as described previously.5 In brief, blood was collected and directly centri-
fuged to separate plasma and cells. Plasma was deli pi dated with chloroform and methanol. 13 
The water fraction was passed over anion- and cation-exchange resin. The glucose in the 
eluate was derivatized to an aldonitril pentacetate derivative. 14 
After thawing, the tracheal aspirate and alveolar wash were vortexed and centrifuged at 
450 x g for 10 min at 4°C, and the pellet was discarded. From the tracheal aspirate, alveolar 
wash, and lung homogenate, lipids were extracted. 15 PC was isolated from the lipid extract 
by thin layer chromatography.16 The PC was trans methylated to form fatty acid methyl 
esters. 17 The saturated (Sat) PC pool size was measured in the alveolar wash and lung 
homogenate by treatment of the lipid fractions with osmium tetroxide. IS Saturated PC was 
isolated by column chromatography using alumna, and quantified by phosphorus assay. 19 
Determination of enrichment 
The 13C-enrichment of plasma glucose and of palmitate in surfactant PC was measured by 
gas chromatography-combustion interface-isotope ratio mass spectrometry (GC-CI-IRMS) (VG 
Isotech, Middlewich, Cheshire, UK) as previously described. 5 For glucose, 1pl was injected on 
a 25 m x 0.25 mm, 0.11 pm HT-5 capillary column (Scientific Glass Engineering, Victoria, 
Australia), with a split ratio of 30:1. The oven temperature was isothermal at 220°C. For PC-
palmitate analysis, 1pl was injected on a 30 m Omega wax column (Supelco, Zwijndrecht, 
The Netherlands). The injection and oven temperature were 45°C for 2 min and raised at 
15°C/min to 175°C, held for 15 min at 175°C, and subsequently increased by 2°C/min to 
240°C. The enrichment was expressed in atom per cent excess (APE), which represents the 
increase in the percentage of carbon-13 atoms in total carbon dioxide from the combusted 
compounds above baseline enrichment (before isotope infusion). Enrichments were corrected 
for the contribution of unlabeled carbon atoms added during derivatization. 
Calculations 
Calculations were performed as described previously.5 for palmitic acid only as this is by far 
the most abundant fatty acid in PC. Tissue-bound and alveolar surfactant were regarded as 
one pool because studies in newborn rabbits showed that recycling is -16 times faster than 
the de novo synthesis and clearance.2o 
The first appearance of enrichment was defined as the time delay between the start of the 
[U-13CJglucose infusion and the detection of enriched palmitic acid in surfactant PC. The first 
appearance of enrichment was calculated by plotting the regression line for the linear 
increase of the enrichment versus time curve, and extrapolating it to baseline enrichment. 
The fractional synthesis rate {FSRJ of palmitic acid was expressed as the percentage of the 
total surfactant PC palmitate pool synthesized from glucose per day. It was calculated by 
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dividing the slope of the linear increase of enrichment of PC palmitate by the steady state 
enrichment of plasma glucose. 5,2t 
The absolute synthesis rate (ASR) of surfactant PC from glucose only, was calculated by 
multiplying the FSR by the total lung Sat PC pool size. The value for the total lung Sat PC 
pool was the Sat PC pool size measured at birth in seven similar baboons (~38 Jtmol/kg Sat 
PC) plus the amount of Sat PC in the exogenous surfactant given to the animals at birth (-68 
Ilmol/kg Sat PC).' 
Data Analysis 
Data are presented as mean ± standard error. The non-parametric Mann-Whitney U-test was 
applied to compare groups. A value of p<O.05 was accepted as significant. 
RESULTS 
The six control baboons and the four baboons exposed prenatally to betamethasone (Beta 
group), had similar birth weights: 394±65 and 340±27 g, respectively. The two groups had 
similar P02 and pco2 values while on similar ventilatory settings as reported previously.2 
The 13C-enrichment of plasma glucose reached similar steady states in all baboons during 
the period of isotope infusion (3.29±0.38 in Controls and 3.29±O.16 APE in the Beta 
group). The mean curves for 13C-enrichment of palmitic acid in surfactant PC recovered from 
tracheal aspirates for both groups are shown in figure 1 . 
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The first appearance of enrichment was similar at 27.6 ± 2.4 h for Controls and 26.0 ± 4.5 h 
for the Beta group (table 1). The 13C-enrichment of PC-palmitate increased linearly in both 
groups and the enrichment was significantly higher in the Beta group as compared with the 
Control group during the interval from 48 to 96 h (p<O.05). The FSR was significantly 
increased in the Beta group (1.5 ±0.2% per d) compared with Controls (0.7 ±O.1 % per d, 
p<0.02, table 1) as shown by the increased slopes of the enrichment versus time curves of 
PC-palmitate in the Beta group compared to the slopes in the Control group (fig. 2). 
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The ASR of Sat PC from glucose was higher in the Beta group (1.6 ± 0.3 ~mol/kg/d) com-
pared to the Control group (0.7±0.1 ,.mol/kg/d, p<0.02). On d 6, the total lung Sat PC pool 
size (alveolar wash plus lung tissue) was similar for the Control and Beta groups (table 1). 
The time of maximal enrichment tended to be earlier in the Beta group (90 ± 8 h) than in the 
Control group (107±3 h, p=O.08). The enrichments at 6 d in tracheal aspirates, alveolar 
washes, and lung homogenates were similar for the individual animals, and the mean values 
for the Control and Beta groups were also similar (tracheal aspirates, 0.052 ± 0.030; alveolar 
washes, 0.050 ±0.023; and lung homogenates, 0.056 ± 0.026 APE). This implies that the 
enrichment of surfactant PC palmitate measured from tracheal aspirates is a good reflection 
of surfactant PC in the alveoli and tissue and is in agreement with a fast recycling of surfac-
tant phospholipids. 2o 
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Table 1. Kinetics of surfactant PC palmitate in relation to prenatal betamethasone 
First appearance Maximal Absolute Lung Sat PC 
of enrichment enrichment FSR synthesis rate pool on d 6 
(h) (h) (%/d) (pmollkg/d) (pmol/kg) 
Control group 27.6±2.4 107±3 0.7 ± 0.1 0.7 ±0.1 186 ±32 
Beta group 26.0±4.5 90±8 1.5 ± 0.2 1.6±0.3 199±13 
p-value NS 0.08 0.02 0.02 NS 
Ten pregnant baboons were randomized to prenatal betamethasone or saline. After very preterm 
delivery, baboons received a 24-h /VJ3C]glucose and 13C-enrichment of palmitic acid in surfactant 
phosphatidylc/Joline (PC) was measured for 6 d. Kinetic parameters were calculated using enrichment 
versus time curves from plasma glucose and surfactant PC-palmitate. Saturated PC pool size was 
measured after killing on d 6. Statistical analysis to compare groups was performed with the Mann-
Whitney V-test. 
DISCUSSION 
An understanding of surfactant metabolism is necessary to optimize treatment of the very 
premature human infant with surfactant deficiency and possibly other diseases with de-
creased surfactant function. We infused the stable isotope [U_ 13C]glucose in very premature 
baboons for 24 h and measured the 13C-incorporation into palmitic acid in PC in the alveolar 
compartment. The 13C-labeled PC increased slowly, reached the maximal value more than 4 d 
after the start of the isotope infusion, and remained high at d 6. These data show that the 
endogenous synthesis and secretion of PC is a slow process and that endogenously synthe-
sized surfactant remains in the lung for a long time in the preterm primate. Five days after 
birth, the baboons also received an intravenous bolus of radioactive palmitate labeled with 
[3Hl and the specific activity in surfactant PC was measured at killing 24 h later, as de-
scribed.2 The percentage of surfactant PC secreted to the alveoli was only ~7.5% in 24 h. 
This slow rate of secretion is compatible with the kinetics calculated from the stable isotope 
data. A slow metabolism of surfactant has been described in nonprimate animals. In studies 
with newborn rabbits and lambs, maximal alveolar enrichments were found 35 to 60 h after a 
single injection of radiolabeled palmitic acid.2o,22,23 In term newborn sheep and term newborn 
rabbits, half-lives of eH}palmitate in surfactant PC were ~11.6 d and 2 to 4.5 d, respec-
tively.20,24.25 
In comparison with human preterm infants, the first appearance of enrichment in the al-
veolar compartment was significantly later in the baboons (~27 h versus ..... 19 h).5 The time of 
maximal enrichment in steroid-treated baboons (~90 h) was comparable to the time of 
maximal enrichment in steroid-treated human preterm infants ( ..... 70 h). In the present study, 
the absolute production of Sat PC from glucose in the Beta group of ~1.6 ~lmol/kg/d, was 
lower than ~4.3 ~Imol/kg/d in preterm human infants treated with prenatal corticosteroids and 
exogenous surfactant. 5 These comparisons suggest a slower surfactant synthesis from 
glucose in the preterm baboon as compared with the human preterm infant, but do not show 
the contributions of other precursors. These baboons were more immature than the preterm 
hUman infants, which may explain the lower synthesis rates. The effects of gestational age or 
degree of lung immaturity have not been evaluated by these techniques in either preterm 
humans or baboons. We also found that prenatal corticosteroids significantly stimulated the 
incorporation of palmitate derived from glucose into PC: the FSR in the Beta group was 
increased by ~129% relative to Controls and the absolute production rate was increased in 
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the Beta group by ~128% relative to Controls (table 1). The PC~palmitate tended to be 
maximally enriched earlier in the Beta group (~90 h) than in the Controls (~107 h, p<O.08, 
table 1, figure 1)' which is also compatible with stimulated carbon~ 13 incorporation from 
plasma glucose into PC-palmitate by betamethasone. 
In vitro studies support the idea that glucocorticoids enhance surfactant synthesis.S-lO 
Glucose incorporation into surfactant PC in perfused rat lungs is increased by betameth-
asone.26 However, data on pool size measurements as an indication of surfactant synthesis in 
vivo are conflicting. In some studies with newborn rabbits, preterm monkeys, and lambs 
chronically catheterized in utero, corticosteroid treatment 2 to 3 d before delivery increased 
surfactant PC pool sizes in alveolar lavage and lung tissue significantly after birth.27-3o In 
contrast, other studies in large animals show no prenatal steroid-induced increase of the 
alveolar9,31-34 or total lung Sat PC pool size after birth.9.31-33 Ballard et al. and Ikegami et al. 
did not find an increase in total lung Sat PC pool size at birth lambs when glucocorticoids 
were administered 2 to 4 d before preterm delivery.l1,31 However, when steroids were 
administered one week before delivery, the total lung Sat PC pool sizes at birth increased 
significantly.l1.31 In the present study, we did not measure surfactant PC pool sizes at birth. 
We demonstrated that the process of synthesis and secretion are slow and that the produc-
tion rate of Sat PC from glucose in preterm newborns is low compared to the total Sat PC 
pool on d 6. Therefore, the pool size will not increase significantly until several days after 
exposure to betamethasone. This low synthesis rate relative to the pool size may explain why 
most studies find long delays between prenatal glucocorticoid treatment and increased 
surfactant PC pools.l1,31 
The dosage and exposure time to steroids, the species (48 h exposure in a rat is relatively 
long compared to lambs or baboons), and the experimental conditions that could cause 
secondary stress to the fetus also may contribute to discrepancies in the various reports of 
glucocorticoids on surfactant metabolism. 
In the present study, there was no effect of prenatal betamethasone treatment on Sat PC 
pool size in total lung at d 6 (table 1). Probably physiological changes after birth and thera-
peutic interventions such as ventilation have larger effects on surfactant metabolism than do 
prenatal glucocorticoids. Such effects are consistent with the findings by Seidner et al., who 
showed that the lung tissue Sat PC pool size was larger in the very preterm baboon after 6 d 
of ventilation (125 d gestation plus 6 d ventilation) than in either the near term baboon (175 
d gestation) or the adult baboon.2 A theoretical explanation for the fact that we did not find 
increased pool sizes on d 6 could be that prenatal betamethasone stimulates both synthesis 
and clearance of surfactant as shown by Fiascione et al. in preterm rabbits.35 However, In 
the present study the clearance of exogenous labeled surfactant was not increased.2 
In the type II pneumocyte, glucose is a primary precursor for fatty acids used for the syn-
thesis of surfactant PC. This is especially true in a state of relative fatty acid deficiency, as in 
the present study. 36,37 The baboons did not receive any lipids during the entire study period, 
and the fat stores in these very premature baboons are minimal. Sanders at al. showed that 
the conversion of glucose to palmitic acid is a fast process.3S Other substrates for surfactant 
PC are present as well, such as intracellular glycogen, fatty acids, lactate, pyruvate, and 
ketone bodies. The overall kinetics for surfactant PC presented here, and the increased 
synthesis rates after glucocorticoids, are measured from glucose only and may not represent 
total surfactant synthesis. The synthesis rates are valid from this precursor, but probably 
underestimations; a more direct precursor of PC-palmitate such as palmitic acid may yield 
more accurate estimations of absolute synthesis rates but ignores the importance of lipo-
genesis in the type II cell. It is, in the present study, unclear whether prenatal glucocorticos-
teroids stimulate the use of other precursors and how they influence glucose enrichment in 
the type II cell. 
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In vitro, steroids increase glycogenolysis in the type II cell, which is associated with synthesis 
of surfactant PC; whether this occurs in the living primate has not been studied. If prenatal 
steroids increased glycogenolysis in the type II cell during the period of labeled glucose 
incorporation into surfactant PC palmitate, than the glucose as a precursor would be diluted, 
resulting in a lower enrichment of surfactant PC palmitate after steroids. We found, however, 
increased 13C·enrichment of surfactant PC palmitate. It is unlikely that glycogen depletion had 
already occurred before birth, as in a few baboons no glycogen depletion was found by 
electron microscopy after 6 d of venti/ation. 2 Glucose can be used to describe surfactant 
metabolism, to evaluate differences between groups, and to study effects of interventions 
and clinical conditions. In addition, glucose can be used safely and easily in critically ill 
preterm human infants. 
In conclusion, the data show that endogenous surfactant synthesis and turnover are slow 
processes. The endogenous synthesis of surfactant PC from glucose is stimulated within 48 h 
by prenatal betamethasone after delivery of the very premature baboon. 
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Summary 
Most in vitro studies show that (prenatal) corticosteroids stimulate the synthesis of surfactant 
phosphatidylcholine (PC) but studies in animals are controversial. 
Whether prenatal corticosteroids stimulate the surfactant PC synthesis in humans has not 
been studied. We studied the endogenous surfactant PC synthesis in relation to prenatal 
corticosteroid treatment in 27 preterm infants with respiratory distress syndrome. Infants 
received a 24-h infusion with the stable isotope [U-' 3C]glucose starting -5 h after birth. The 
13C-incorporation into palmitic acid in surfactant PC from serial tracheal aspirates and in 
plasma triglycerides and phospholipids was measured by isotope-ratio mass spectrometry. 
Premature infants had received either zero {n = 11 J, one (n = 4), or two doses (n = 12) of 
prenatal betamethasone (12 mg intramuscularly). The fractional synthesis rate (FSR) of 
surfactant PC from glucose was 1.7 ±0.3%/d without corticosteroid treatment, 2.9 ± 1.4%/d 
with one dose and 5.8 ± 1.3%/d after two doses of prenatal corticosteroids. Using multiple 
regression analysis, the FSR of surfactant PC increased with 40% (confidence interval: 7 to 
82%/d, p<O.02J per dose of corticosteroids and doubled after two doses corticosteroids. 
The 13C-enrichment of plasma triglycerides and phospholipids was not increased by cortico-
steroids. 
These data show that prenatal corticosteroid treatment stimulates surfactant synthesis in 
the preterm infant. 
Am. J. Respir. Grit. Gare Med. in press 
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INTRODUCTIDN 
After very premature delivery, many infants develop respiratory distress syndrome (RDS) 
caused by primary surfactant deficiency among other factors. Prenatal corticosteroid admini-
stration to women at risk for premature delivery reduces the incidence and severity of RDS as 
well as mortality in preterm infants.1 Prenatal corticosteroids improve pulmonary function in 
preterm animals with RDS by stimulating structural development,2 induction of antioxidant 
enzymes,3 and decreasing vascular permeability.4 Improved pulmonary function can also 
result from increased amounts of surfactant in the alveolar space. In many in vitro studies 
corticosteroids increase the activity of the enzymes for the synthesis of surfactant Iipids5-7 
and increase surfactant protein synthesis. 6,8-10 In in vitro experiments with lung slices and 
isolated type" cells, corticosteroids increase the incorporation of radiolabeled precursors into 
surfactant PC, reflecting increased PC synthesis.5,7,11-13 Despite these strong indications for 
corticosteroid stimulation, most studies in animals do not show increased surfactant PC pool 
sizes or increased precursor incorporation after prenatal corticosteroid treatment, 2,4,14-20 
some studies reported increased pool sizes2o-22 and one study found decreased alveolar 
surfactant pool sizes after a single dose of prenatal betamethasone.23 
The amount or concentration of surfactant in the alveolar space does not adequately re-
flect surfactant synthesis because they depend on the amount secreted to and cleared from 
the alveolus. In a randomized study in preterm baboons it was recently found that surfactant 
PC synthesis from glucose was stimulated by two doses of prenatal corticosteroids. 24 
Whether prenatal corticosteroids stimulate the surfactant PC synthesis in preterm infants 
with primary surfactant deficiency has not been studied. We recently reported data on 
surfactant metabolism in six preterm infants using a novel and safe technique. 25 The present 
clinical study is the first implementation of our recently developed method. With this tech-
nique, using stable isotopes, the hypothesis was tested whether prenatal corticosteroids 
stimulate surfactant synthesis in critically ill preterm infants with RDS. 
METHODS 
Subjects and study design 
Consecutive infants requiring mechanical ventilation were studied starting directly after birth. 
Inclusion criteria were: gestational age < 32 wk, intubation for RDS as defined clinically and 
by chest radiograph,26 and written parental informed consent. Exclusion criteria were: 
congenital infection, maternal diabetes, and chromosomal abnormality. Patients received a 
constant Lv. infusion of the stable isotope [U_13C]glucose (Campro Scientific, Veenendaal, 
The Netherlands) for 24 h at 0.17 mg/kg/min. The start of the study (t ~ 0) was defined by 
the start of the isotope infusion. This was 5.3 ±O.5 h after birth. The total glucose intake 
was 5.7 mg/kg/min including nonlabeled glucose, the infants did not receive any lipids the 
first 48 h of the study. Before and during the glucose infusion, 1 ml arterial blood was drawn 
every 6 h for the determination of 13C-enrichment of plasma glucose and of palmitic acid in 
plasma triglycerides, phospholipids, and in the free fatty acid fraction. 
Exogenous surfactant (Survanta®; Abbott Laboratories, North Chicago, IL) was adminis-
tered endotracheally at t=O, at a dose of 100 mg/kg phospholipids, if the mean airway 
pressure exceeded 7.5 em of water, or if the inspiratory oxygen fraction was higher than 
0.40. Infants received a second dose 6 h later if the criteria were still met. The attending 
neonatologist administered a third dose if appropriate within 20 h from the second dose. 
Tracheal aspirates were obtained every 6 h during the time that the infant was intubated. The 
tracheal suctioning procedure was performed during routine patient care and did not deviate 
from the normal clinical protocol.25 Tracheal aspirates were immediately placed at -20QC, 
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until further processing. No tracheal suction was done within 6 h after surfactant administra-
tion. Total parenteral nutrition including lipids was started at t =48 h. Infants were grouped 
according to the number of doses of prenatal corticosteroids that their mother received (one 
dose is 12 mg dexamethasone intramuscularly). When delivery at admission was expected 
immediately, corticosteroids were not given (= Group 0). When delivery was not expected 
immediately, the first dose corticosteroids was given (= Group 1). A second dose corticos-
teroids was given 24 h after the first dose if delivery had not occurred (= Group 2). The 
study was approved by the local medical ethics committee. 
Table 1. Patients' characteristics 
Birth weight Gestational age RDS grade Doses of Days of 
(g) (wk) (I-IV) surfactant ventilation 
Group 0 [111 1035 (640-2030) 29.4 (25.9-32.0) 3.5 (1-4) 2.0 (1-3) 5.5 (1.0-51) 
Group 1 141 878 (590-1800) 26.6 (25.6-31.3) 3.0 (2-3) 2.0 (1-3) 8.5 (5.0-17) 
Group 2 [12] 905 (715-1270) 27.9 (26.6-30.3) 2.5 (0-4) 1.5 (0-2) 6.8 (1.0-39) 
o vs 2, p-varue 0.5 0.3 0.1 0.02 0.8 
Analytical procedures 
Surfactant PC palmitate isolation. The tracheal aspirates were processed as described 
before.25 In short, cells were removed by centrifugation, internal standard was added, organic 
extraction was used to isolate surfactant Iipids,27 and surfactant PC was isolated by TLC.28 
The PC was derivatized,29 and the fatty acid methyl esters were stored at -20QC. Tracheal 
aspirates containing visible blood were not analyzed. 
Surfactant PC concentration. The fatty acid methyl esters were analyzed by gas-
chromatography (GCI and the amount calculated using the internal standard.3o The concen-
tration of surfactant PC in the epithelial lining fluid (ELF) was calculated by correction for 
dilution of the ELF during endotracheal suction with normal saline: dilution factor 
[urea1serum![urea]tracheal aspirate' 31 
Blood samples. Collected blood was directly centrifuged to separate cells and plasma. By 
organic extraction plasma was divided in a water fraction containing glucose and an organic 
solvent fraction containing Iipids.32 The glucose was isolated using anion and cation ex-
change resin. 25 The glucose was derivatized to an aldonitril pentacetate derivative. 33 From 
the plasma lipid fraction, triglycerides, phospholipids, and free fatty acids were isolated by 
TLC using Kieselgel plates (Merck, Darmstadt, Germany). The solvent system contained 
heptane/diisopropylether/acetic acid 60/40/3, v/v/v). The triglycerides, phospholipids, and 
free fatty acids were derivatized/9 and the fatty acid methyl esters were stored at -20°C. 
Determination of enrichment. The '3C-enrichment of palmitic acid in surfactant PC, triglyc-
erides, phospholipids, free fatty acids, and of plasma glucose was measured by gas chroma-
tography-combustion interface-isotope-ratio mass spectrometry (GC-CHRMS) {VG Isoteeh, 
Middlewieh, Cheshire, UK).25,29 The enrichment is expressed in atom per cent excess (APE), 
which represents the increase in percentage of carbon-13 atoms in total carbon dioxide from 
the combusted compounds above baseline enrichment (before isotope infusion). Enrichments 
were corrected for the contribution of unlabeled carbon atoms added during derivatization. 
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Calculations 
As palmitic acid is by far the most abundant fatty acid in surfactant PC, calculations were 
performed for this fatty acid only.25 
The first appearance of enrichment was defined as the time delay between the start of the 
[U_1 3C]glucose infusion and the detection of 13C-enriched palmitic acid in surfactant PC. The 
first appearance of enrichment was calculated by plotting the regression line for the linear 
increase of the enrichment versus time curve, and extrapolating it to baseline enrich-
ment. 26,34 
The fractional synthesis rate (FSR) of surfactant PC is the percentage of the total surfac-
tant PC pool synthesized from glucose per day. The FSR was calculated by dividing the slope 
of the linear increase of enrichment of PC palmitate by the steady state 13C-enrichment of 
plasma glucose.25,34 
The half-life of surfactant PC was calculated by exponential curve fitting of the downslope 
of the enrichment versus time curve.25 
Data analysis 
Data are presented as mean ± SEM or as median (range). Comparisons between the largest 
groups of 0 (n = 11) and 2 (n = 12) doses of prenatal steroids were made using the Mann-
Whitney U-test. To adjust for potential confounding factors in the evaluation of the number of 
doses of steroids regarding enrichment, multiple regression analysis was used. In this analysis 
the FSR had to be transformed logarithmically in order to obtain normally distributed data. 
RESULTS 
Twenty-seven infants were included, 11 in Group 0 (no prenatal corticosteroids), four in 
Group 1 (one dose), 12 in Group 2 (two doses of prenatal corticosteroids) (table 1). The 
patient groups were comparable regarding gestational age, birth weight, and the fraction of 
infants which were adequate or small for gestational age. The RDS grade and number of days 
of ventilation were similar between groups (table 1). The 13C-enrichment of plasma glucose 
reached steady state in all infants between t = 6 and 24 h and was similar in all groups 
(Group 0: 2.65±0.15; Group 1: 2.28±0.09; Group 2: 2.43±0.14 APE). Infants in Group 2 
required a significantly lower number of doses of surfactant compared to Group 0 (1.5 [0 to 
2] and 2.0 [1 to 31, respectively, p=0.02). In total 468 tracheal aspirates were analyzed. 
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The 13C-enrichment of palmitic acid in surfactant PC in the three groups is shown in figure 1. 
The increased 13C-enrichment in the corticosteroid treated groups compared to Group 0 is 
evident. The kinetic parameters were calculated from these curves and shown in table 2. The 
first appearance of 13C-enrichment and half-life of surfactant PC were similar in the three 
groups. There was a trend towards earlier maximal enrichment in Group 2 compared to Group 
o (59.4±4.0 and 76.9±7.B h, p~O.071. The FSR of palmitic acid in surfactant PC from 
glucose increased significantly by the administration of prenatal corticosteroids (fig. 2). By 
univariate analysis between Group 0 and Group 2, the surfactant synthesis significantly 
increased by corticosteroids (1.7 ±0.3 versus 5.9 ± 1.3%/d{ p =0.0002). 
Exogenous surfactant dilutes the labeled surfactant PC derived from endogenous synthe-
sis. Therefore, we corrected for the number of doses of surfactant administered using 
multiple regression analysis. This analysis also allowed to correct for the effect of gestational 
age. The mean FSR increased linearly on a logarithmic scale, with an increase of 40% (95% 
confidence interval: 7 to 82%, p<O.02) per dose of corticosteroids administered prenatally. 
This is an increase of 96% after two doses prenatal corticosteroids. 
The liver can use the infused [U- 13C]glucose for lipogenesis which results in labeled plasma 
Iipids. 26 The type II pneumocyte can use palmitic acid from plasma triglycerides, phospholip-
ids, and free fatty acids for surfactant PC synthesis. So, an increased labeling of surfactant 
PC after prenatal corticosteroids could in theory result from increased 13C-enrichment of 
plasma lipids from synthesis by the liver after corticosteroids with subsequent uptake by lung. 
To study this possibility, we measured the 13C-enrichment of palmitic acid in plasma trig Iyc-
erides, phospholipids, and in the free fatty acid fraction. The palmitic acid in triglycerides and 
phospholipids became enriched within 6 h after the start of the [U_13C]glucose infusion (fig. 
3A and 38). The enrichment of free palmitic acid was too low (much lower than that of 
surfactant PC palmitate) to be measured accurately and was therefore only performed in 
several patients (data not shown). There was no statistically significant difference between 
the groups regarding 13C-enrichment of palmitic acid in plasma triglycerides and phospholip-
ids. These data show that the increased enrichment of surfactant PC palmitate after prenatal 
steroids is due to increased endogenous synthesis of surfactant PC, and is not a reflection of 
plasma lipid enrichment. 
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Table 2. Kinetics of surfactant phosphatidylcholine 
First appearance Time of maximal Half-life FSR Concentration of 
of enrichment (h) enrichment (h) (h) % per d PC (mglml ELF) 
Group 0 [11] 18.7±2.8 76.9 ± 7.8 [7[ 98.8±8.3 [5) 1.70.3 2.4 [0.4-14.3) [5) 
Group 2 [4] 21.3±2.2 76.8±7.6 [4) 105 ± 10.9 [3) 2.91.4 2.911.7-4.2) (2) 
Group 2 [12] 17.4±3.0 59.4 ± 4.0 [8) 86.0±9.9 [9) 5.91.3 8.1 (0.9-37.5) (9) 
o vs 2, p-value 0.26 0.07 0.34 0.0002 0.19 
Twenty-seven pre term infants received either zero, one, or two doses of prenatal corticosteroids. The 
fractional synthesis rate (FSR) and time of first appearance of enrichment were measured in all infants. 
Time of maximal enrichment, half-life, and the PC concentration were measured in the number of 
infants mentioned between brackets In}. 
The surfactant PC concentration at birth (before surfactant administration) was 2.4 (0.4 to 
14.3) in Group 0, 2.9 (1.7 to 4.2) in Group 1, and 8.1 (0.9 to 37.5) mgimL ELF in Group 2. 
Although the concentration tended to be higher in Group 2, this was not significant, probably 
due to the small number of infants. The concentration of surfactant PC was measured in only 
16 of the 27 patients because some infants received exogenous surfactant as therapy 
already before informed consent was obtained for this study. 
DISCUSSION 
This study describes for the first time in humans the relation between the exposure to 
prenatal corticosteroids and de novo surfactant PC synthesis. Preterm infants received [U-
13C}glucose as a precursor for the synthesis of palmitic acid in surfactant PC. We found a 
significantly increased surfactant PC synthesis from gfucose with a linear increase of 40% 
per dose of prenatal corticosteroids (fig. 2). This implies that administration of two doses of 
corticosteroids to the mother at risk of pre term labor as is generally accepted35 doubles the 
production of surfactant PC from glucose in the preterm infant. This finding shows that 
stimulated general lung maturation is accompanied by increased surfactant PC production. 
These findings are in line with many in vitro studies that show induction of enzymes for 
surfactant synthesis and increased precursor incorporation after prenatal corticosteroids. 11 ,12 
Glucose incorporation into surfactant PC in organotypic cultures of type II cells is increased 
by betamethasone. 12 In a study by Kessler et al. in premature baboons, a 72-h treatment 
with prenatal dexamethasone did not increase radioactive palmitate incorporation in lung 
lipids, but shifted the incorporation to disaturated PC in lung lavage fluid 3 h after birth.2o We 
recently found that in very preterm baboons which received exogenous surfactant and were 
ventilated for 6 d, surfactant PC synthesis from glucose approximately doubled after two 
doses prenatal corticosteroids, which is comparable to the findings in the present study.24 
Data on surfactant pool sizes in animal studies as an indication of surfactant synthesis in 
vivo are conflicting; some studies find increased pool sizes20·22 but most studies do not find 
an increased surfactant pool in the lung after corticosteroids.2,4,14-19 The concentration 
surfactant PC in the ELF tended to increase after two doses of corticosteroids at birth (table 
2). The concentration of PC was measured in only 16 from the 27 patients because some 
infants received exogenous surfactant already before informed consent was obtained. In a 
study by Kari et al. in human preterm infants, prenatal dexamethasone had no significant 
effect on the surfactant concentration in ElF.36 Ballard ~t al. and Ikegami et al. did not find 
62 
Prenatal steroids and surfactant metabolism in infants 
an increased total lung saturated PC pool size at birth in preterm lambs when corticosteroids 
were administered 2 to 4 d before preterm delivery. However, when corticosteroids were 
administered one week before delivery, the total lung saturated PC pool at birth had increased 
significantly.16,21 The discrepancies between increased surfactant synthesis and not signifi-
cantly elevated surfactant pools or concentrations in our and other studies can be explained 
by the [ow synthesis rate relative to the pool size. 
This hypothesis is supported by the other kinetic parameters (table 2). The long delay 
between the start of the stable isotope infusion and the first enrichment in surfactant PC 
palmitate show that the synthesis of palmitate, intracellular processing, and secretion of 
surfactant to the alveolar space is a slow process. The delay between the start of the isotope 
infusion and the time of maximal enrichment was long in all groups. The time to reach 
maximal enrichment and half-life of surfactant PC tended to be shorter in Group 2 which is 
compatible with stimulated surfactant metabolism. The long half-lives of '3C-enrichment show 
that endogenous synthesized surfactant remains in the lungs for many days and is diluted 
slowly by newly synthesized unlabeled surfactant. The half-lives for phosphatidylglycerol 
(-105 h) and sphingomyelin (-97 h) in preterm infants treated with Survanta(!l were compara-
ble to our data.37 The half-live of phosphatidylglycerol was ..... 30 h in preterm infants treated 
with human amniotic extracted surfactant.3S In the newborn rabbit, the half-life of surfactant 
PC was ..... 57 h when labeled with palmitic acid and -136 h when labeled with choline.39 
Increased clearance of labeled surfactant from the lung shortens half-life and more recycling 
of components of surfactant prolongs half-life. These variables were not measured and can 
playa role in other studies as well. The type of surfactant studied and the label used also 
influence half-lives measurements.37,39 
In the present study, we measured the synthesis of palmitic acid of surfactant PC from the 
precursor glucose only. The type /I cell has, besides glucose, several other sources for the 
synthesis of surfactant PC, like palmitic acid, intracellular glycogen, lactate, and ketone 
bodies.40 Glucose is, however, an important substrate for the fatty acids of surfactant PC.41-
43 certainly in relative fatty acid deficiency like in these infants as intravenous feeding with 
lipids started 48 h after the start of the isotope infusion. The type /I cell can use palmitic acid 
from the plasma free fatty acid fraction, from plasma triglycerides, and probably phospholip-
ids for the synthesis of surfactant PC.42 
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Figure 3. The 13C-enrichment of plasma triglycerides fA} and of plasma phospholipids fBJ. After a 24-h 
IU- 13Clglucose infUsion. The 13C-enrichment was measured in palmitic acid in these plasma lipids. The 
13C-enrichment of plasma triglycerides and phospholipids did not increase by prenatal corticosteroids. 
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The lung fibroblast accumulates triglycerides and transfers these lipids to the type II pneumo-
cyte, and this process is stimulated in vitro in rat lung by glucocorticoids. 44 An increased 13C_ 
enrichment of surfactant PC could therefore be a reflection of increased 13C-enrichment of 
plasma lipids due to stimulated lipogenesis in the liver after prenatal steroids. 
We measured the 13C-enrichment of palmitic acid in plasma free fatty acids, triglycerides 
and phospholipids in all groups. As shown in figures 3A and 38 the 13C-enrichment of 
triglycerides and phospholipids did not change after prenatal steroids and can not lead to 
increased 13C_ incorporation in surfactant in the corticosteroid treated groups. The 13C_ 
enrichment of palmitic acid in the free fatty acid fraction was too low to be measured 
accurately (much lower than that of surfactant PC), and was therefore only measured in 
some patients (data not shown). 
Thus, the increased incorporation of 13C from glucose into surfactant PC found in Groups 1 
and 2 does not reflect the enrichment of plasma lipids, but reflects increased surfactant 
phospholipid synthesis from glucose. The increased FSR of surfactant PC reflects the 
principle that prenatal corticosteroids increase surfactant phospholipid production in the 
preterm infant, but it is unclear what the total absolute increase is as the contribution of the 
other precursors is unknown. 
The total surfactant pool and the pools of the metabolic intermediates are unknown, but 
influenced by the treatment with large amounts of exogenous surfactant. We corrected by 
multiple regression analysis for the potential confounding effects of the number of doses of 
exogenous surfactant. As a result of the way of inclusion of the patients, the different groups 
could have been subject to different durations of prenatal stress. The impact of the prenatal 
stress is, however, not known, and is a limitation of the study. It is, however, ethically not 
possible to perform this study in preterm infants in a randomized fashion, as administration of 
prenatal corticosteroids is an established therapy to improve the outcome in the premature 
infants. 
In summary, this study shows for the first time that treatment with prenatal corticoster-
oids increases surfactant PC production from the important precursor glucose in the pre term 
infant with severe RDS. The data show that endogenous surfactant metabolism is a slow 
process and that stimulation of synthesis by steroids increases alveolar pool sizes probably 
only after many days. Therefore, the increased surfactant synthesis after the generally 
ad vi zed corticosteroids treatment,35 probably plays only a minor role in the reduced incidence 
of RDS and improved outcome. The accelerated development of the surfactant system is part 
of the enhanced integrated development of the lung. 
ACKNOWLEDGEMENTS 
We thank Daphne J. M. T. Janssen, Department of Pediatrics, Sophia Childrens' Hospital 
Rotterdam, The Netherlands for excellent technical assistance and the nursing staff, residents 
and neonatologists for their help and support with this study. 
REFERENCES 
1. Crowley PA. Antenatal corticosteroid therapy: a meta·analysis of the randomized trials, 1972 to 1994. Am 
J Obstet Gyneco/1995; 173: 322-35. 
2. Beck JC, Mitzner W, Johnson JW, et al. Betamethasone and the rhesus fetus: effect on lung morphometry 
and connective tissue. Pediatr Res 1981; 15: 235-40. 
3. Walther FJ, Jobe AH, Ikegami M. Repetitive prenatal glUcocorticoid therapy reduces oxidative stress in the 
lungs of preterm lambs. J Appl Physio/1998; 85: 273-8. 
4. Ikegami M, Berry D, Elkady T, et al. Corticosteroids and surfactant change lung function and protein leaks 
in the lungs of ventilated premature rabbits. J Clin Invest 1987; 79: 1371'8, 
64 
Prenatal steroids and surfactant metabolism in infants 
5. Rooney SA, Gobran LI, Marino PA, Maniscalco WM, Gross I. Effects of betamethasone on phospholipid 
content, composition and biosynthesis in the fetal rabbit lung. Blochim Bicphys Acta 1979; 572: 64-76. 
6. Ballard Pl. Hormonal regulation of pulmonary surfactant. Endocr Rev 1989; 10: 165·81. 
7. Post M, Barsoumian A, Smith BT. The cellular mechanism of glucocorticoid acceleration of fetal lung 
maturation. Fibroblast-pneumonocyte factor stimulates choline-phosphate cyUdylyltransferase activity. J 
BiolChem 1986; 261: 2179-84. 
8. Ballard Pl, Ertsey R, Gonzales lW, Gonzales J. Transcriptional regulation of human pulmonary surfactant 
proteins SP-8 and SP-G by g[ucocorticoids. Am J Respir Cell Mol Blo/1996; 14: 599·607. 
9. Liley HG, White RT, Warr RG, et a/. Regulation of messenger RNAs for the hydrophobic surfactant proteins 
in human lung. J Clln Invest 1989; 83: 1191·7. 
10. Mariendieck W, Crouch E. Modulation of surfactant protein 0 expression by glucocorticoids in fetal rat 
lung. Am J Resplr Celf Mol 8io/1994; 10: 419-29. 
11. Gonzales lW, Baffard Pl, Ertsey R, Williams MG. Glucocorticoids and thyroid hormones stimulate 
biochemical and morphological differentiation of human fetal lung in organ culture. J Clin Endocr/nol Metab 
1986; 62: 678-91. 
12. Sanders Rl, Engle MJ, Douglas WHo Effect of doxamethasone upon surfactant phosphatidylcholine and 
phosphatidylglycerol synthesis in organotypic cultures of type /I celfs. Biochim Biophys Acta 1981; 664: 
380-8. 
13, Tsao FH, Gutcher GR, Zachman RD. Effect of hydrocortisone on the metabolism of phosphatidylcholine in 
maternal and fetal rabbit lungs and livers, PediatrRes 1979; 13: 997-1001. 
14. Chen CM, Ikegami M, Ueda T, Polk DH, Jobe AH, Exogenous surfactant function in very preterm lambs 
with and without fetal corticosteroid treatment, J Appl Physio/1995; 78: 955-60, 
15. Ikegami M, Polk DH, Jobe AH, et al. Postnatal lung function in lambs after fetal hormone treatment. Effects 
of gestational age, Am J Respir erit Care Med 1995; 152: 1256-61, 
16, Ikegami M, Polk DH, Jobe AH, et al. Effect of interval from fetal corticosteriod treatment to delivery on 
postnatal lung function of preterm lambs. J Appl Physio/1996; 80: 591-7, 
17. Ikegami M, Polk D, Jobe A, Minimum interval from fetal betamethasone treatment to postnatal lung 
responses in preterm lambs, Am J Obstet Gynecol1996; 174: 1408-13, 
18. Polk DH, Ikegami M, Jobe AH, et al. Postnatal lung function in preterm lambs: effects of a single exposure 
to betamethasone and thyroid hormones. Am J Obstet Gyneco/1995; 172: 872-81, 
19. Seidner S, Rider E, Jobe A, Yamada T, Ikegami M, Effects of antenatal thyrotropin-releasing hormone, 
antenatal corticosteroids, and postnatal ventilation on surfactant mobilization in premature rabbits. Am J 
Obstet Gyneco/1992; 166: 1551-9. 
20. Kessler Dl, Truog WE, Murphy JH, et aI, Experimental hyallne membrane disease in the premature monkey: 
effects of antenatal dexamethasone, Am Rev Respir Dis 1982; 126: 62-9. 
21, Ballard Pl, Ning Y, Polk D, Ikegami M, Jobe AH. Glucocorticoid regulation of surfactant components in 
immature lambs, Am J Respir Crit Care Med 1997; 273: l1048-l1057. 
22, Platzker AC, Kitterman JA, Mescher EJ, Clements JA, Tooley WH, Surfactant in the lung and tracheal fluid 
of the fetal lamb and acceleration of its appearance by dexamethasone. Pediatrics 1975; 56: 554-61. 
23. Sun B, Jobe A, Rider E, Ikegami M. Single dose versus two doses of betamethasone for lung maturation in 
preterm rabbits. Pedlatr Res 1993; 33: 256-60, 
24_ Bunt JEH, Carnielli VP, Seidner SR, et aI, Metabolism of endogenous surfactant in premature baboons and 
effect of prenatal steroids. Am J respir Crit Care Med 1 999; 160: 1481-1485. 
25. Bunt JEH, Zimmermann lJI, Wattimena JlD, et al. Endogenous surfactant turnover in preterm infants 
measured with stable isotopes. Am J Respir Crit Care Med 1998; 157: 810-814. 
26. Giedion A, Haefliger H, Dangel p, Acute pulmonary X-ray changes in hyaline membrane disease treated 
with artificial ventifation and positive end-expiratory pressure IrEP). Pediatr Radio/1973; 1: 145-52, 
27, Bligh EG, Dyer WJ, A rapid method of total lipid extraction and purification, Can J Biochem Physio/1959; 
37: 911-917. 
28. Touchstone JC, Chen JC, Beaver KM, Improved separation of phospholipids in thin layer chromatography, 
Lipids 1979; 15: 61-62. 
29. Carnie iii VP, Sulkers EJ, Moretti G, et aI, Conversion of octanoic acid into long-chain saturated fatty acids 
in premature infants fed a formula containing medium-chain trlglycerides. Metabolism 1994; 43: 1287-92, 
30, IJsselstijn H, Zimmermann LJI, Bunt JEH, de Jongste JC, Tibboel D, Prospective evaluation of surfactant 
composition in bronchoalveolar lavage fluid of infants with congenital diaphragmatic hernia and of age-
matched controls. Crit Care Med 1998; 26: 573-580, 
31. Halfman M. Merritt TA, Akino T, Bry K. Surfactant protein A, phosphatidylcholine, and surfactant inhibitors 
in epithelial lining fluid, Correlation with surface activity, severity of respiratory distress syndrome, and 
outcome in small premature infants. Am Rev Respir Dis 1991; 144: 1376-84. 
32, Folch J, lees M, Stanley HS. A simple method for the isolation and purification of total lipids from animal 
tissues. J B;ol Chem 1957; 226: 497-509, 
65 
Chapter 6 
33. Pfaffenberger CD, Szafranek J. Horning MG, Horning EC. Gas chromatographic determination of polyols 
and aldoses in human urine as polyacetates and aldononitrile polyacetates. Anal Biochem 1975; 63: 501-
12. 
34. Ballmer PE, McNurlan MA, Milne E, et al. Measurement of albumin synthesis in humans: a new approach 
employing stable isotopes. Am J Physiol1990; 259: E797·803. 
35. Anonymous. Effect of corticosteroids for fetal maturaHon on perinatal outcomes, NIH Consensus 
Statetment. FASEB J 1994; 12: 1-24. 
36. Kari MA, Akino T, Hallman M. Prenatal dexamethasone and exogenous surfactant therapy: surface activity 
and surfactant components in airway specimens. Pediatr Res 1995; 38: 676-84. 
37. Griese M. Dietrich P, Reinhardt D. Pharmacokinetics of bovine surfactant in neonatal respiratory distress 
syndrome. Am J Respir Crit Care Med 1995; 152: 1050-4. 
38. Hallman M, Merritt T A, Pohjavuori M, Gluck L. Effect of surfactant substitution on lung effluent phospho-
lipids in respiratory distress syndrome: evaluation of surfactant phospholipid turnover, pool size, and the 
relationship to severity of respiratory failure. Pediatr Res 1986; 20: 1228-35. 
39. Jobe AH, Kirkpatrick E, Gluck L. Lecithin appearance and apparent biologic half-life in term newborn rabbit 
lung. Pediatr Res 1978; 12: 669·675. 
40. Patterson CE, Rhoades RA. Substrate utilization in the perinatal lung. Am J Physlo/1989; 257: L318-30. 
41. Batenburg JJ, Longmore WJ, van Golde LM. The synthesis of phosphatidylcholine by adult rat lung alveolar 
type II epithelial cells in primary culture. Biochim Blophys Acta 1978; 529: 160-70. 
42. Rooney SA. Fatty acid biosynthesis in developing fetal lung. Am J Physio/l989; 257: l195-201. 
43. Maniscalco WM, Finkelstein IN, Parkhurst AB. De novo fatty acid synthesis by freshly isolated alveolar 
type 11 epithelial cells. Biochim Biophys Acta 1983; 751: 462-9. 
44. Nunez JS, Torday JS. The developing rat lung fibroblast and alveolar type II cell actively recruit surfactant 
phospholipid substrate. J Nutr 1995; 125: 1639S-1644S. 
66 
Chapter 7 
Treatment with Exogenous Surfactant Stimulates 
Endogenous Surfactant Synthesis in Premature Infants with 
Respiratory Distress Syndrome 
Jan Erik H. Bunt', Virgilio P. Carnielli2, Daphne J. M. T. Janssen' 
J.L. Darcos Wattimena3 , Wim C. Hop', Pieter J. J. Sauer" 
Luc J. I. Zimmermann' 
IOepartment of Pediatrics/Neonatology, Sophia Children's Hospital/University 
Hospital/Erasmus University Rotterdam, The Netherlands. 2Pediatrics/Neonatology, 
University Hospital Padova, Italy. 3Department of Internal Medicine II, University 
Hospital/Erasmus University Rotterdam, The Netherlands. 4Department of Epidemiology and 
Biostatistics, Erasmus University Rotterdam, The Netherlands, 5Department of Pediatrics, 
Beatrix Children's Hospital/University Hospital, Groningen, The Netherlands 
Summary 
Treatment of preterm infants with respiratory distress syndrome (ROS) with exogenous 
surfactant has greatly improved clinical outcome. Some infants require multiple doses and it 
has not been studied whether these large amounts of exogenous surfactant disturb endoge-
nous surfactant metabolism in humans. We studied endogenous surfactant metabolism in 
relation to different amounts of exogenous surfactant, administered as rescue therapy for 
RDS. 
Preterm infants were intubated and mechanically ventilated for respiratory insufficiency. 
They received a 24-h infusion with the stable isotope [U_ 13C]glucose starting 5.3±O.5 h after 
birth. The 13C-incorporation into palmitic acid in surfactant phosphatidylcholine (PC) isolated 
from serial tracheal aspirates was measured. Infants received either zero (n = 5)' one (n = 4), 
two (n = 15), or three (n = 3) doses of Survanta® (1 00 mg/kg) when clinically indicated. Using 
multiple regression analysis, the absolute synthesis rate (ASR) of surfactant PC from plasma 
glucose increased with 1.3 ± 0.4 mg/kg/d per dose of Survanta@ (p = 0.007) (mean ± sem). 
The ASR of surfactant PC from glucose was increased by prenatal corticosteroid treatment 
with 1.3±0.4 mg/kg/d per dose corticosteroid (p=0.004), and by the presence of a patent 
ductus arteriosus with 2.1 ±O.7 mg/kg/d (p=O.Ol). 
These data are reassuring and show that multiple doses of exogenous surfactant for RDS 
in preterm infants are tolerated well by the developing lung and stimulate endogenous 
surfactant synthesis. 
Crit. Care Med. in press 
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INTRODUCTION 
Pulmonary surfactant deficiency at birth is the main cause of neonatal respiratory distress 
syndrome (RDS). Administration of exogenous surfactant rapidly augments the alveolar 
surfactant pool size and acutely decreases the degree of respiratory failure and increases the 
survival rate in neonates with RDS.1 However, some infants do not respond or respond only 
temporarily to surfactant therapy, and require retreatment with surfactant. A sustained 
clinical improvement is probably depending on a sufficient endogenous surfactant production, 
among other factors. 
Feedback' inhibition of endogenous surfactant production could occur as one treatment 
dose of 100 mg phospholipids/kg contains 10 to 20 times the amount of phosphatidylcholine 
(PC) present in the alveoli in preterm infants with RDS, 2,3 and 5 to 10 times the amount of 
alveolar PC in the adult rabbit.4 In vitro studies showed that the addition of surfactant or 
lavage fluid inhibited the incorporation5 of labeled precursors into disaturated PC and de-
creased secretion6 of surfactant lipids by type II cells, and Miles et al. hypothesized the 
presence of a negative feedback mechanism in vitro.7 In another in vitro study, however, the 
incorporation of [3H]choline was stimulated and the incorporation of eH]acetate was not 
affected by administration of phospholipids.s Oetomo et al. showed in adult rabbits in vivo an 
increased synthesis and secretion of PC after treatment with exogenous natural rabbit 
surfactant.9 After instillation of Survanta® only the secretion was stimulated, but not precur-
sor incorporation.9 Others reported no change in surfactant metabolism in vivo by surfactant 
treatment. 10, 11 
Whether surfactant administration in human preterm infants influences endogenous surfac-
tant metabolism has not been studied. After exogenous surfactant administration, the 
concentrations of PC remains elevated for many days.12,13 However, it is not possible to 
distinguish between the exogenous and endogenous surfactant in those studies, so the 
contribution of newly synthesized surfactant CQuld not be estimated. Furthermore the 
surfactant synthesis is not reflected adequately by the measurement of pool sizes or concen-
trations alone. 
We tested the hypothesis that the administration of exogenous surfactant influences en-
dogenous surfactant synthesis in preterm infants. The stable isotope [U-13C)glucose was used 
as a precursor for palmitic acid in surfactant PC to measure endogenous synthesis after 
various doses of exogenous surfactant used as rescue therapy for RDS. 
METHODS 
Subjects 
All infants were admitted to the neonatal intensive care unit of the Sophia Children's Hospi-
tal. Inclusion criteria were: primary intubation and mechanical ventilation directly after birth, 
gestational age < 32 wk, and written parental informed consent. Exclusion criteria were: 
congenital infection, maternal diabetes, and chromosomal abnormality. The study was 
approved by the Medical Ethics Review Board of the University Hospital/Erasmus University 
Rotterdam. Patients received a constant infusion of the stable isotope [U-13C)glucose {Campro 
Scientific, Veenendaal, The Netherlands} for 24 h at 0.17 mg/kg/min. The start of the isotope 
infusion defined t = 0 (5.3 ±0.5 h after birth). The total glucose intake was 5.7 mg/kg/min. 
The infants did not receive any lipids during the first 48 h of the study. Before and during the 
glucose infusion, 1 ml arterial blood was drawn every 6 h for the determination of 13C_ 
enrichment of plasma glucose. RDS was defined clinically and by chest radiograph. 14 
Exogenous surfactant (Survanta®, Abbott Laboratories, North Chicago, IL, USA) was adminis-
tered endotracheally at t=O, at a dose of 100 mg/kg phospholipids, if the mean airway 
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pressure exceeded 7.5 cm of water, or if the inspiratory oxygen fraction was higher than 
0.40. Infants received a second dose 6 h later if the criteria were still met. A third dose was 
administered within 20 h from the second dose if respiratory failure persisted. 
Tracheal aspirates were obtained every 6 h during the time that the infant was intubated. 
The tracheal suctioning was performed during routine patient care and did not deviate from 
the normal clinical protocol. Tracheal aspirates were immediately placed at -20°C, until 
further processing. No tracheal suction was done within 6 h after surfactant administration. 
Total parenteral nutrition including lipids was started at t = 48 h. A patent ductus arteriosus 
(PDA) was considered significant for this study when clinical suspicion was confirmed by 
echo and when treatment with indomethacine was necessary. Infants were grouped accord-
ing to the number of doses of exogenous surfactant received (Group 0 received no surfac-
tant; Group 1 received one dose; Group 2, two doses; Group 3, three doses). 
Analytical procedure 
Surfactant PC palmitate isolation. The tracheal aspirates were processed as described 
before. 15 In short, cells were removed by centrifugation, organic extraction was used to 
isolate surfactant Iipids,16 and surfactant PC was recovered by thin layer chromatography.17 
The PC was derivatized,18 and the fatty acid methyl esters were stored at -20°C. Tracheal 
aspirates containing visible blood were not analyzed. 
Blood samples. Collected blood was directly centrifLiged to separate cells and plasma. 
Plasma was delipidated with chloroform and methanol. 19 The glucose was isolated using 
anion and cation exchange resin,15 and derivatized to an aldonitril pentacetate derivative.2o 
Determination of enrichment. The 13C-enrichment of palmitic acid in surfactant PC and of 
plasma glucose was measured by gas chromatography-combustion interface-isotope ratio 
mass spectrometry (GC-CI-IRMS) (VG Isotech, Middlewich, Cheshire, UK)_15,18 The enrich-
ment is expressed in atom per cent excess (APE), and represents the increase in the percent-
age of carbon-13 atoms in total carbon dioxide from the combusted compounds above 
baseline enrichment (before infusion). Enrichments were corrected for the contribution of 
unlabeled carbon atoms added during derivatization. 
Calculations 
As palmitic acid is by far the most abundant fatty acid in surfactant PC, calculations were 
performed for this fatty acid only.15 The tissue-bound and alveolar surfactant was regarded 
as one pool as the recycling is ..... 16 times faster than de novo synthesis and clearance.4,10.21 
In preterm baboons that received [U_ 13C]glucose, the 13C-enrichment of PC-palmitate in 
alveolar lavage, tracheal aspirate and lung tissue was similar on d 6 after birth.22 This shows 
that alveolar and lung tissue surfactant (:=: total surfactant pool) can be considered as one 
metabolic pool for the calculations. 
The first appearance of enrichment was calculated by plotting the regression line for the 
linear increase of the enrichment versus time curve of surfactant PC palmitate, and extrapo-
lating it to baseline enrichment. 16 
The fractional synthesis rate (FSR) of palmitic acid in surfactant PC is the percentage of 
the total PC-palmitate pool synthesized from glucose per day. The FSR was calculated by 
dividing the slope of the linear increase of enrichment of surfactant PC palmitate by the 
steady state enrichment of plasma glucose. 15 In the present study the total surfactant pool 
sizes were different due to different amounts of exogenous surfactant administered. To 
correct for this we calculated the absolute synthesis rate (ASR) of surfactant PC. 
The ASR was calculated by multiplying the FSR with the total lung surfactant PC pool. We 
did not measure the total surfactant PC pool in these infants but estimated the total PC pool. 
For the preterm infants without RDS, the total pool size was considered to be equal to the 
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total lung pool (alveolar wash plus lung tissue) found in 140 d preterm baboons without RDS 
as this is the closest model of the human; this pool size was 39 mg PC/kg body weight. 23 For 
the infants with RDS, this pool size was halved (19 mg PC/kg) as many studies have shown 
that the surfactant concentration3 and amounts in total lung found in postmortem studies in 
ROS24 is approximately half the amount in premature infants without ROS. For the infants 
that received exogenous surfactant for ROS, the pool size was considered to be the sum of 
endogenous surfactant (19 mg/kg) and the amount from exogenous surfactant (one dose of 
Survanta" ~87 mg PC/kg). 
The half-life of surfactant PC was calculated by exponential curve fitting of the downslope 
of the enrichment versus time curve. 15 
Data analysis 
Data are presented as mean ± sem or as median (range). In evaluating the effects of surfac-
tant administration on the ASR, while adjusting for the effects of prenatal corticosteroids, 
multiple regression analysis was used. Using this method also other potential confounders 
were taken into account. A value of p<0.05 (two-sided) was regarded as significant. 
RESULTS 
Twenty-seven infants were included, five in Group 0 (no surfactant treatment), four in Group 
1 (one dose of surfactant), 15 in Group 2 (two doses of surfactant), and 3 in Group 3 (3 
doses of surfactant) (table 1). The patient groups were comparable regarding gestational age 
and birth weight. All infants in Group 0 had received a full course of prenatal dexamethasone 
(two doses between 7 d and 24 h before birth). In Group 0, one infant had ROS grade two 
and one infant had grade one, three infants had mild respiratory insufficiency with apnea's 
without pulmonary pathology on chest radiograph (table 1). In Group 2 and 3, most infants 
had severe ROS. 
The '3C-enrichment of plasma glucose _ was in steady state in all infants between t = 6 and 
24 h and was similar in all groups (Group 0: 2.22±0.08; Group 1: 2.36±0.12; Group 2: 
2.55 ± 0.13; Group 3: 2.71 ±0,48 APE). 
In total 468 tracheal aspirates were analyzed. The '3C-enrichment of surfactant PC palmi-
tate in the four groups is shown in figure 1. The more exogenous surfactant was adminis-
tered the lower the enrichment of PC palmitate was, due to massive dilution of label by the 
unlabeled surfactant. 
Table 1. Patient characteristics 
Group 0 Group 1 Group 2 Group 3 
Birth weight (g) 8451715·1270} 848 1690·2030} 1080 1590·1800} 9201640·1610) 
Gestational age (wk) 27.7 126.0,28.4) 27.4126.0·32.0) 28.0 125.6·31.4) 29.7 (27.4·31.0) 
Doses prenatal steroids 2.012·2) 1.010·2) 1.0 10·2) 010·0) 
RDS grade lOA) 0.010·2) 2.5 11·3) 3.012·4) 4.0 13.0A.0) 
Patent ductus arteriosus 2 1 10 3 
Duration of ventilation 7.0 12·39) 2.011.0·12) 6.011.5·31) 2213.0·31) 
Patient characteristics according to the number of doses of surfactant. RDS=resplratory distress 
syndrome. Data in median {range}. 
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The time of first appearance of enrichment (table 2) was found to increase significantly 
(p<O.01) with increasing doses of exogenous surfactant (increase: 4.6 ± 1.6 h per dose). This 
is probably due to dilution of label by exogenous surfactant. The time of maximal enrichment 
and the half-life could not be measured in all infants because some infants were already 
extubated. For the evaluable subjects, the time of maximal enrichment and the half-life 
tended to increase (both p<O.1 O) when more surfactant was administered (table 2). 
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Figure 1. 13C-enrichment of pal-
mitic acid in surfactant phos-
phatidylcholine after a /U-
13C]glucose infusion. Infants in 
Group 0 received no exogenous 
surfactant, in Group lone dose, 
in Group 2 two doses, and in 
Group 3 three doses of surfactant. 
The FSR decreased significantly (p<O.001) with increasing doses of exogenous surfactant 
(table 2). The FSR is directly calculated from the linear increase in figure 1 (see Methods) and 
therefore can not be used to directly compare synthesis rates of surfactant PC between the 
groups due to dilution by exogenous surfactant. By calculating the absolute synthesis rates, 
groups with different pool sizes can be compared (ASR = FSR times pool size). Allowing for 
the effects of prenatal corticosteroids using multiple regression analysis, the mean ASR was 
found to increase significantly in a linear fashion with increasing amounts of surfactant (figure 
2 and table 3). This analysis also showed that the ASR increased significantly with the 
presence of PDA and decreased with advancing gestational age (table 3). 
DISCUSSION 
Although the administration of surfactant has become routine treatment of neonatal RDS, 
there is little information whether large amounts of exogenous surfactant influence endoge-
nous surfactant metabolism, and whether feedback mechanisms operate. In vitro and animal 
studies give conflicting results regarding this issue and studies in humans have not been 
performed. The present study reports the effects of surfactant therapy on endogenous 
surfactant metabolism. Surfactant synthesis was measured by using glucose labeled with the 
stable isotope 13C as a precursor for surfactant PC-palmitate, and was related to the number 
of doses of exogenous surfactant. 
The endogenous surfactant PC synthesis from glucose increased by -1.3 mg/kg/d per dose 
of exogenous surfactant. This implies that exogenous surfactant stimulates endogenous 
surfactant PC production and that the presence of a negative feedback mechanism is 
unlikely. Although the increase of -1.3 mg/kg/d per dose surfactant is small compared to the 
surfactant pool sizes after treatment with exogenous surfactant, the importance of this 
finding is that endogenous surfactant synthesis is not suppressed by surfactant treatment. 
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Table 2. Kinetics of surfactant PC in relation to doses of exogenous surfactant 
Group 0 Group 1 Group 2 Group 3 
FSR (%/d) B.9 ± 2.4 3.3± 1.4 2.5±0.3 1.7±0.6 
ASR Img/kg/d) 2.7±0.8 3.5± 1.4 4.8±0.7 4.8± 1.8 
First appearance of 11.2±3.3 15.7±3.9 21.8±2.1 22.8±3.4 
enrichment (h) 
Time of maximal 53±3.8131 65 III 73±4.91131 72±17 121 
enrichment(h) 
Half·life Ih) 70±15 131 98111 99±6.5110] 99±26 12] 
Group 0 = no surfactant, Group 1 = one dose, etc. The fractional synthesis rate (FSR), absolute 
production rate (ASR), and time of first appearance of enrichment were measured in all infants. The 
time of maximal enrichment and the half-life were measured in the number of infants indicated between 
brackets [n1. Per dose surfactant, the ASR increased with 1.3±0.4 mg PClkg/d {p = 0.007), the time of 
first enrichment increased with 4.6± 1.6 per dose surfactant {p<0.01J, the time of maximal enrich-
ment and the half-life tended to increase {both p<0.1J. 
These findings are in agreement with increased precursor incorporation after incubation with 
surfactant components in isolated type II cel/s8 and in primary cultures of type II cells.25 In 
healthy adult rabbits in vivo, administration of surfactant to the left lung only resulted in 
increased incorporation of radiolabeled plasma palmitic acid in the left but not in the right 
lung.9 In preterm ventilated lambs, surfactant treatment did promote [3H]palmitic acid 
incorporation into surfactant PC, after correction for increased pool size due to exogenous 
surfactant. to A negative effect of exogenous surfactant has been reported in in vitro studies. 
These studies used surfactant preparations containing surfactant protein A {SP-A),5-7 and 
Dobbs et al. showed a specific inhibition of surfactant secretion by SP_A.6 In the present 
study Survanta® which does not contain SP-A was used. This could explain the discrepancy 
between our study and the studies showing inhibition of endogenous surfactant synthesis. 
Other components of Survanta® could have a stimulating effect on endogenous synthesis, 
like phosphatidylglyceroi {4% of phospholipids}. Phosphatidylglycerol has been shown to 
stimulate surfactant synthesis in vitro by stimulating the rate limiting enzyme CDP-
phospho choline cytidylyltransferase.25,26 By the administration of Survanta large amounts of 
palmitic acid are delivered to the lung, as a degradation product and as free palmitate (7 % of 
total lipids). Palmitic acid has been shown to stimulate enzymes involved in surfactant 
synthesis and to increase the surfactant PC synthesis in rat lung explants.27 
Table 3. Absolute synthesis rate of PC 
Variable 
Exogenous surfactant 
Prenatal corticosteroids 
Gestational age 
PDA 
Effect on ASR (mg PC/kg/d) 
+ 1.3 ±Oo4 per dose 
+ 1.3 ± 004 per dose 
-004±O.2 per week 
+ 2.1 ±O.7 yes versus no 
P-value 
0.007 
0.004 
0.03 
0.01 
Multiple regression analysis of the effects of parameters on absolute synthesis rate {ASR} of surfactant 
PC palmitate from glucose. Regression coefficients±standard error. PDA =patent ductus arteriosus. 
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Others, however, found no increased surfactant PC synthesis by palmitic acid in vitro. 25,28 
The increased surfactant PC synthesis from glucose in the present study could be induced by 
the recycling of certain components of exogenous surfactant which could stimulate the 
surfactant metabolic pathway. An alternative explanation for increased surfactant synthesis 
could be that pulmonary improvement after surfactant therapy is accompanied by increased 
lung surfactant synthesis. 
The time of first appearance and time of maximal enrichment were longer in the groups 
that received surfactant compared to Group O. They were both longer probably due to dilution 
by exogenous unlabeled surfactant. The half-lives calculated tended to be shorter in Group 0, 
but the number of measurements were rather small. The half-lives are comparable to those as 
reported before. 15 
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Figure 2. Absolute synthesis 
rate {ASR} of surfactant PC 
from plasma glucose according 
to the number of doses of 
surfactant. Infants in Group 0 
received no exogenous sur-
factant, in Group 1 one dose, in 
Group 2 two doses, and in 
Group 3 three doses of 
surfactant. The number of sub-
ject between brackets [n/. 
Mean±SEM 
The ASR of surfactant PC was increased by prenatal corticosteroids with 1.3 mg/kg/d per 
dose corticosteroids (table 3). This implies that after two doses of corticosteroids, the ASR 
increased with 2.6 mg/kg/d which is three times higher than in preterm baboons who 
received two doses of prenatal corticosteroids.22 In preterm infants with RDS the FSR 
increased with ..... 100% after two doses of prenatal betamethasone,29 in that report, however, 
the ASR had not been calculated. Although the ASR increased in the present study, it is 
unlikely that this increase plays a major role in decreasing the incidence and severity of RDS 
at birth. Probably other effects of prenatal corticosteroids like stimulated structural develop-
ment, induced antioxidant enzymes, and decreased vascular permeability play a more 
important role as some of these factors occur within 15 h after corticosteroid treatment in 
preterm lambs.3o 
When recovery from RDS occurs several days after birth, pulmonary vascular resistance 
falls, which can lead to the clinical appearance of a significant PDA. The use of exogenous 
surfactant could accelerate pulmonary improvement accompanied by earlier occurrence of 
PDA.31 This could explain why surfactant synthesis increased in the presence of PDA. It 
could be that the PDA leading to pulmonary congestion and decreased pulmonary function 
stimulates surfactant synthesis as a compensation mechanism. A compensation mechanism 
in a situation of surfactant dysfunction could be suggested as meconium inhibits surfactant 
function in vitro32 but stimulates surfactant secretion in isolated rat alveolar type" cells.33 
However, in preterm infants with RDS and with or without PDA, the percentage disaturated 
PC, lecithin/sphingomyelin ratio, percentage phosphoinositol and phosphatidylglycero! in 
tracheal aspirates were similar. 34 
We found that the surfactant synthesis rate decreases with advancing gestation (table 3). 
Although this decrease is small (0.4 mg/kg/d per week GAl, it is in contrast to current belief 
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that surfactant synthesis increases with maturation. The gestational age of the infants 
studied was, however, maximally 32 weeks, while the concentration and lecithin I sphingo-
myelin ratio in amniotic fluid has been found to increase later than 32 weeks.35 It could be 
that surfactant synthesis is relatively constant up to approximately 32 weeks, and increases 
afterwards. Other reasons for decreased ASR with gestation could be that smaller infants use 
relatively more glucose for PC-palmitate synthesis. The contribution of substrates used for 
surfactant phospholipid synthesis changes during development due to changes in substrate 
availability.36 Fatty acids synthesized de novo from glucose account for 30 to 60% and 20 to 
40% of total lipids synthesized by the type II cell in adult and newborn rats, respectively.37-39 
Another explanation could be that older infants have already produced larger surfactant PC 
pools before birth, resulting in more dilution of labeled surfactant during the first days of life. 
As intubation and ventilation were inclusion criteria, we included a selected group of older 
patients requiring ventilation. An alternative is therefore, that older infants had relatively more 
severe pulmonary pathology than the younger infants resulting in lower surfactant synthesis 
rates. 
The ASR was calculated using estimated surfactant total pool sizes but the surfactant pool 
size in Group 0 could be smaller or larger. A larger pool size in Group 0 would increase the 
ASR and at a certain pool level the ASR would not be lower than in the surfactant treated 
groups. In order to study the strength of our conclusions, we calculated the maximal pool size 
of surfactant PC for Group 0 that would still show that exogenous surfactant increases 
endogenous production, this was a value of 57 mg/kg. The maximal pool size of surfactant 
PC for Group 0 associated with the finding that exogenous surfactant does not suppress 
endogenous production was .... 250 mg/kg (Group 0 versus Groups 1, 2, and 3 together). 
These calculated surfactant PC pool sizes are probably not so high in vivo as total lung 
surfactant pool PC sizes are 40 to 50 mglkg in preterm baboons,23 preterm lambs,40 and 
preterm rabbits.41 Therefore, our conclusions hold even though the surfactant PC pool size in 
Group 0 could be higher. 
In the surfactant treated infants, the ASR would be lower than calculated by us when 
exogenous surfactant would leave the lung resulting in smaller surfactant pool sizes. It is, 
however, not likely that the pool size decreased significantly after surfactant treatment. In 3-
day-old rabbits, total lung surfactant pool sizes remained absolutely constant for 3 dafter 
increasing the pool three- to five-fold by exogenous surfactant.42 Seidner et al. found in 
preterm ventilated baboons which received 100 mglkg Survanta at birth, that total lung Sat 
PC pool sizes were higher on d 6 of life than the sum of the endogenous pool and the amount 
administered.23 This could suggests that in the preterm infant the total surfactant pool size 
remains constant or increases after surfactant treatment during the first days of life. Glatz et 
al. measured a loss of only .... 25% of a treatment dose of exogenous surfactant in newborn 
lambs and rabbits in 48 h. 13 Others showed that a fixed percentage of multiple doses 
exogenous surfactant is lost from the lung in 3-day-old rabbits. 43 If the ASR is calculated in 
the present study under the premise that the total PC pool size decreased with 25 % due to 
loss of exogenous surfactant, than the ASR increased linearly per dose surfactant (1.0 
mg/kg/d per dose, p < 0.01 I. 
To study endogenous surfactant metabolism, we used the stable isotope [U_ 13C]glucose as 
precursor. Other substrates available for the synthesis of surfactant PC palmitate include 
palmitic acid from plasma lipids, intracellular glycogen, lactate, and ketone bodies.44 These 
substrates have been used as radioisotopes in animals and in vitro, and recently surfactant 
metabolism in older infants was studied using [U-13Clpalmitate.45 Glucose is, however, an 
important substrate for the fatty acids of surfactant PC,37,46,47 certainly when lipids are not 
available, and has been reported to account for 20 to 40% of the de novo synthesized fatty 
acids in the type II cell in newborn rats. 37-39 In order to achieve low levels of plasma lipids 
during the measurement of the synthesis of surfactant PC palmitate, the preterm infants 
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received Lv. lipid feeding 48 h after the start of the isotope infusion. However, the calculation 
of the total synthesis rates by us are underestimations as the contribution of other precursors 
to the surfactant phospholipids is unknown. 
In summary, treatment of the preterm infant with RDS using exogenous surfactant as 
rescue therapy stimulates endogenous surfactant synthesis from the important precursor 
glucose. It is reassuring that the presence of a negative feedback mechanism of endogenous 
surfactant metabolism is unlikely. The data show that the absolute production of surfactant 
PC is moderately increased after prenatal corticosteroids. These data show that the combined 
use of prenatal steroids and postnatal surfactant have additive effects on endogenous 
surfactant metabolism. The presence of a PDA was correlated with increased endogenous 
surfactant synthesis, but it is unclear which mechanism could explain this finding. 
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Summary 
Surfactant composition and turnover were studied in human preterm infants « 32 weeks 
gestation, n=28). Infants received either 0, 1, 2, or 3 doses of Survanta" (-85% palmitic 
acid, PAl. During the period of intubation, tracheal aspirates were collected and the surfac~ 
tant PC was analyzed by gas chromatography. 
Exogenous surfactant increased the PA immediately to -82%. Subsequent endogenous 
surfactant PC synthesis (-62% PAl diluted the alveolar surfactant. This dilution resulted in a 
decrease in PA percentage with a half-life of 18.2, 78.2, and 95.0 h after 1, 2, or 3 doses, 
respectively. Infants received intravenous lipids (-53% linoleic acid, LA). Linoleic acid (con-
sidered as a label as it is an essential fatty acid) became incorporated in surfactant PC after a 
delay of -3 d. Without intravenous lipids there was no increase of LA in surfactant PC. Exo-
genous surfactant increased the alveolar surfactant PC concentration for 2 dafter 1 dose of 
surfactant but for more than a week after 2 doses. 
The slow dilution of exogenous surfactant by endogenous surfactant and the delayed in-
corporation of plasma lipids into endogenous PC suggest a slow synthesis of surfactant PC. 
The surfactant deficiency in premature infants with severe respiratory distress syndrome is 
reversed for more than a week with 2 doses of surfactant. The composition of intravenous 
feeding in the neonatal period influences surfactant composition and potentially function. 
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INTRODUCTION 
Respiratory distress syndrome (RDS) remains a major cause of morbidity and mortality in the 
premature infant, although surfactant substitution therapy has greatly improved outcome. 
Several issues regarding surfactant therapy remain unclear such as optimal dosing, timing, 
composition of surfactant, mode of administration, and effect on endogenous surfactant pro-
duction. 1-4 Some infants do not respond or require retreatment with multiple doses. 5 These 
different clinical responses in individual patients might be related to differences between in-
fants in the synthesis and clearance of surfactant, and might be important variables in the 
recovery from RDS. To better understand the pathophysiology of RDS and to optimise treat-
ment a thorough understanding of surfactant metabolism is essential. Although some studies 
have focussed on surfactant metabolism, there is still very little known about surfactant syn-
thesis and clearance in preterm infants. Surfactant is a mixture of lipids ( ..... 90%) and specific 
proteins ( ..... 10%). The main surface tension lowering component is dipalmitoylphosphatidyl-
choline (DPPC, containing 2 palmitic acids). 
Surfactant synthesis and clearance have been described in animals using substrates la-
beled with radioactive isotopes6,7 but this approach is not acceptable in preterm infants. 
Hallman et al. reported that the concentration of surfactant phosphatidylcholine (PC) in tra-
cheal aspirates increases slowly over several days in infants with RDS and reaches values as 
found in infants without RDS after ..... 5 d. B Recently, a new method with stable isotopes for 
studying surfactant metabolism in humans has become available.9 In the preterm infant, the 
synthesis rate of surfactant PC from glucose is very low. 9 Only few studies have assessed 
the effect of exogenous surfactant therapy in RDS on PC concentrations in premature infants. 
Treatment with 1 dose of human amniotic fluid surfactant containing surfactant protein A 
increased the PC and surfactant protein A concentrations for more than a week.s The surfac-
tants used today, however, are derived from organic lipid extraction usually with specific lip-
ids added, but lack surfactant protein A. The different composition could result in different 
clearance rates.1O Ashton et at. found increases of the DPPC:palmitoyl-oleoyl-PC ratio 
(DPPC:POPC ratio) in tracheal aspirates after administration of artificial surfactant with a sub-
sequent decrease over several days.11 The half-lives of phosphatidylglycerol and sphingomye-
lin from the airways after tracheal instillation of surfactant have been estimated but the half-
life of the PC has not been measured. 10,12 
We studied general surfactant PC metabolism in preterm infants. Infants received exoge-
nous surfactant which was regarded as "Iabeled" because it contains 85% palmitic acid (PA) 
in PC while endogenous surfactant contains 62% PA in PC. The time to reach initial ("base-
line") PA percentage in PC after exogenous surfactant administration is a reflection of en-
dogenous surfactant PC synthesis. Infants received intravenous (i.v.) lipids containing 53% 
linoleic acid (LA). The LA was regarded as a label as it is an essential fatty acid which can 
not be synthesised by the human body. The delay between the start of i. v. LA administration 
and the incorporation of LA in surfactant PC was used as a measure of surfactant PC synthe-
sis. Surfactant clearance was studied from the decrease in surfactant concentration in the 
epithelial lining fluid. 
METHODS 
Subjects 
The studies were approved by the medical ethics committee of the Erasmus University Rot-
terdam/University Hospital Rotterdam. Patients were included if they were < 32 weeks of 
gestation and intubated at birth for respiratory insufficiency, without congenital infection, and 
after written parental informed consent. RDS was defined clinically and radiographically, and 
78 
Fatty acid composition of surfactant phosphatydylcholine 
graded. 13 Patients received exogenous surfactant (Survanta®, Abbott laboratories, North Chi-
cago, IL, USA) endotracheally at a dose of 100 mg/kg phospholipids, if the mean airway 
pressure exceeded 7.5 em of water, or if the inspiratory oxygen fraction was higher than 
0.40. Infants received a second dose 6 h later if the criteria were still met. A third dose was 
administered within 20 h from the second dose if respiratory failure persisted. Infants were 
grouped according to the number of doses of exogenous surfactant received (Group 0 re-
ceived no surfactant; Group 1 received one dose; Group 2, two doses; Group 3, three doses). 
For Group 0 the study started at 5 h after birth, and the administration of the first dose of 
surfactant ("'5 h after birth) defined the start of the study for Group 1, 2, and 3. Survanta® 
contains a higher percentage of DPPC ("'85% PAJ than natural human surfactant. The fatty 
acid composition of PC in Survanta® was measured to be: C14:0:2.1 ±0.2 (myristic acid, 
MA); C16:0 (PA): 84.7±1.1; C16:1ro7:1.4±0.1; C16:1ro9:0.8±0.1; C18:0:3.0±0.0; 
C18:1ro7:0.4±0.1; C18:1ro9:6.24±0.9; 18:2ro6 (linoleic acid, LA):0.5±0.1 weight percent. 
Tracheal aspirates were obtained before surfactant therapy and then every 6 h as long as 
the infant was intubated. No tracheal suctioning was done within 6 h after surfactant admini-
stration. The tracheal suctioning procedure was performed during routine patient care and did 
not deviate from the normal clinical protocol. Twenty seconds after 0.5 ml normal saline was 
instilled into the tracheal tube, suction was performed beyond the tip of the endotracheal 
tube, the suction catheter was then flushed with normal saline. Tracheal aspirates were im-
mediately placed at _200C.14 As energy source, only glucose Lv. was administered initially, 
and 48 h after the start of the study, parenteral feeding was started. The parenteral feeding 
consisted of lipids (lntralipid® 20% Pharmacia & Upjohn, Woerden, The Netherlands, 2.9 
g/kg/d containing ..... 53% LA, .... 11 % PA, and .... 0.1 % MAl and amino acids (PrimE'me® 10% 
CUntec, Montargis, France, 2.4 g/kg/d). The first day of parenteral feeding half of these 
amounts were given. 
Baboon studies 
In our neonatology unit, all preterm infants receive total parenteral nutrition including lipids. 
Because we did not deviate from the normal clinical protocol for this study, we did not in-
clude a group of preterm infants without Lv. lipids. Instead, we used the very premature ba-
boon as a model for RDS.15 Preterm baboons (125 ± 2 d) were delivered, intubated, and re-
ceived 1 dose of Survanta® (100 mg/kg) immediately after birth. Blood was collected at t=O, 
t =0.75, t = 1, and t = 6 d. Tracheal aspirates were collected every 12 h until killing on d 6. 
The baboons did not receive any lipids during the study. The clinical data of the baboons have 
been described by Seidner et al. 15 
Table 1. Patients' characteristics 
Group (n=) Gestation (wk) Birth weight (g) RDS grade Days ventilation 
0 (5) 27.8±1.t 909±214 O.4±O.9· 16.7 (2-63) 
1 (5) 29.0±2.9 10S3±541 2.0±1.4 4.6 (2·12) 
2 (14) 2S.3±2.1 109S±352 3.2±O.7 11.3(1-51) 
3 (4) 28.1±2.1 1003±422 3.8±O.5 23.S (S·3S) 
Patients were attributed to a group based on the number doses of surfactant required. Mean±SD, day 
of ventilation: mean (range). *Patients without RDS were classified as grade D. 
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Analytical procedure 
Tracheal aspirates. After thawing, normal saline was added up to a total volume of 2.6 ml, 
and from this sample urea was determined using a highfy sensitive urease-based kit. The aspi-
rate was vortexed and centrifuged at 450 x g for 10 min at 4°C, and the supernatant was 
recovered. 14,16 A known amount of internal standard (PC-(C17hl was added, and the lipids 
were extracted. 17 PC was isolated from the lipid fraction by thin layer chromatography (TLC) 
using Kieselgel 60 TLC plates (Merck Darmstadt, Germany) and a Camag Linomat IV (Merck 
Darmstadt, Germany). The solvent system contained chloroform, methanol, 2-propanol, KCI 
25%, and triethylamine (10/3/S.3/2/6, v/v/vlvlv).'8 The PC was derivatized,'9 and the fatty 
methyl esters extracted with hexane and stored at -20°C. Tracheal aspirates containing visi-
ble blood were not analyzed (15 samples). 
Blood samples. After collection the blood from the baboons was directly centrifuged to 
separate cells and plasma. The lipids from plasma were extracted according to Folch. 2o Tri-
glycerides (TG) and phospholipids (PL) were isolated by TLC. The solvent system contained 
heptane, diisopropylether, acetic acid (60/40/3, vlvlv). The triglycerides and phospholipids 
were derivatized,19 the fatty acid methyl esters were stored at -20°C. 
Determination of composition and concentration 
Fatty acid composition of surfactant PC, plasma TG and plasma PL, and amount of surfactant 
PC were analyzed by gas-chromatography (GCI (5890 series II, Hewlett-Packard, Amstel-
veen, The Netherlands)19,21 with a variability of reinjection of the same sample of less than 
2%. When one sample was diluted a 100 times, the maximal coefficient of variation was 4% 
between the undiluted and diluted sample. This variability is low and less than the biologic 
variability. The concentration of surfactant PC in the epithelial lining fluid (ELF) was calculated 
by correcting for dilution of the ELF during endotracheal suction: dilution factor = 
[ureaJserum/[ureaJasPirate supernatant. 8 
Data analysis 
Data are presented as mean ± standard error of the mean (sem), unless stated otherwise. The 
urea was measured after addition of saline to the aspirate (see analytical procedure) and 
therefore could be very low and variable. The dilution factors were: Group 0: 98.9 ± 10.8 (12-
653) mean ± sem (range); Group 1: 93.0 ± 7.S (2S·27S); Group 2: 119 ± S.S (7-906); Group 
3: 138 ± 12 (8-557), There was no correlation between the urea dilution factor and the PC 
concentration in ELF (data not shown), and therefore, the sampling procedure probably had 
no influence on the PC concentrations in the tracheal aspirates. The one-way-ANOVA test 
was applied to compare groups. A value of p<0.05 (two tailed) was accepted as significant. 
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Figure 1. The number of 
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RESULTS 
The patient characteristics are presented in the table and the number of patients intubated 
during the study in figure 1. From 28 patients 498 tracheal aspirates were analyzed. Five in-
fants did not require surfactant (= Group 0) of whom 3 infants had mild respiratory insuffi-
ciency with apneas without pulmonary pathology on chest radiograph, and no cardiac dis-
ease, pulmonary infection, sepsis, or any other major disease. One infant in Group 0 had RDS 
grade 1 and one infant had grade 2. Five infants required 1 dose (Group 1 L 14 infants re-
quired 2 doses (Group 2), and 4 infants required 3 doses of surfactant (Group 3). Gestational 
age and birth weight were similar in all groups (table). The severity of RDS was significantly 
less in Group 0 compared to Group 2 and 3 (p<O.01). The number of patients included per 
group on each day is shown in figure 1. 
Group 0 had higher concentrations of surfactant PC in ELF at birth than Groups 1, 2, and 3 
together (19.8±5.1 versus 2.2±O.6 mg/ml ELF, respectively, p<O.OOOOl) (fig. 2). The PC 
concentration in Group 0 decreased significantly (p<O.05) on d 3 and 4, and increased af-
terwards. In Groups 1, 2, and 3 the surfactant PC concentrations were similar before surfac-
tant administration. In Groups 1 and 2, treatment with surfactant increased the PC concen-
tration to values as measured in Group O. After the admjnistration of one dose of surfactant, 
the PC concentration decreased already by d 2 to reach low values by d 3, while in group 2 
the PC concentration did not decrease for more than 11 d (fig. 2). 
In Group 3 the PC concentrations increased much higher than in Groups 0, 1, and 2 but re-
turned to low levels (-4 mg/ml) by d 6 (see legends of figure 2). The effect of 4 times per d 
endotracheal suctioning has probably little effect on total surfactant pool size as we meas-
ured the total surfactant PC removed during 10 d with suctioning every 6 h to be only ..... 3 mg. 
At birth, infants in Group 0 had a significantly higher percentage of palmitic acid (PA) in PC 
when compared to Groups 1, 2, and 3 combined (62.2± 1.1 versus 55.8 ± 1.5, p~O.05) (fig. 
3). There was no difference between males and females in any group. The percentage of PA 
in PC in Group 0 remained constant from birth up to d 8 (fig. 3). In the groups receiving ex-
ogenous surfactant ( ..... 85% PA in PC), the percentage of PA in PC increased to values ex-
ceeding 82% (fig. 3). The percentage of PA in PC in the tracheal aspirates decreased due to 
endogenous surfactant synthesis with a lower percentage of PA and disappearance of exoge-
nous surfactant. During the first 3 d after surfactant administration in Group 1, the PA per-
centage decreased to baseline with a half-life of ..... 18 h, but then increased again to a slightly 
higher constant level (fig. 3). 
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Figure 2. Surfactant phos-
phatidylcholine concentra-
tions [PC} in epithelial lining 
fluid. The [PC] in Group 0 
decreased significantly on d 
2 to 4 (p<O.05), and the 
decrease in Group 2 on d 2 
to 4 was not significant. 
Because the [PC} in Group 
o +----.---~--~~--~--~r_--_, 3 increased to very high 
o 2 4 6 
Days 
8 10 12 values, the curve of Group 3 is not depicted for clarity 
of the figure. In Group 3, 
the [PC} before surfactant 
was 1.6±O.9 mglml ELF, and increased after 3 doses surfactant to 41.0±2B.5 mglml on d 1.5, and 
decreased to 4.5 mglml on d 6 and remained constant afterwards. Results were pooled at 12 h inter-
vals. When error bars are not visible, they are small and within the size of the data symbols. 
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in Groups 11 21 and 31 than in Group 0 after exogenous surfactant until d 6. When error bars are not 
visiblel they are smal/and within the size of the data symbols. 
The decrease of the percentage of PA in PC in Group 2 had a half-life of 78.2 h. For the half-
life calculation, the average percentage of Group 0 was considered as the new baseline (62% 
PA in surfactant PC) for Group 1 and 2. The PA percentage in Group 3 decreased to a base-
line of .... 70% PA in surfactant PC with a half-life of .... 95 h. 
The percentages of the main fatty acids (except PA} in PC in Group 2 are shown in fjgure 
4. The LA (18:2ro6) percentage (and all other fatty acids) in surfactant PC decreased due to 
surfactant administration with a high percentage of PA and subsequently increased due to the 
disappearance of exogenous surfactant and the endogenous PC synthesis. 
The increase of LA in PC could coincide with -and thereby obscure- specific incorporation 
of plasma LA into surfactant PC. As both LA and myristic acid (C14:0, MA) percentages in 
PC are influenced equally by exogenous surfactant, we revealed the specific the increase in 
LA by calculating the ratio of the percentages of LA to MA; the LA:MA ratio (fig. 5). We 
choose MA as the comparator for LA as both fatty acids are esterified at the sn-2 position of 
PC. Moreover, MA is very low in Intralipid® and is present in endogenous surfactant. Three 
days after the start of the i. v. feeding with lipids, the LA:MA ratio in PC in Group 0 and Group 
2 started to increase above baseline value (fig. 5). The data for Group 1 and 3 are not shown, 
but the same trend was present in these groups as well. The LA:MA ratio of surfactant PC, 
and plasma TG and PL in the baboons which did not receive intravenous lipids remained con-
stant (fig. 6). 
12 Figure 4. Percentage of the minor fatty acids in surfactant 
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DISCUSSION 
This study describes in critically ill preterm infants the concentration of surfactant PC and the 
percentages of the different fatty acids in PC after surfactant administration and Lv. lipids 
during the first 11 d of life. Changes in surfactant PC concentration and composition with 
time give information on surfactant synthesis and clearance. Our data show that the endoge-
nous synthesis and secretion of surfactant is a slow process. This is shown by a slow dilution 
of exogenous surfactant by endogenous surfactant (fig. 3) and a slow incorporation of LA 
from plasma into surfactant PC (fig. 5). 
This study suggests that two doses but not one dose of exogenous surfactant are suffi-
cient to increase surfactant concentration for long periods. Furthermore, the data are in line 
with previous studies in which infants who develop RDS have biochemical evidence of lung 
immaturity. 8, 12,22-24 
In the present study, infants that did not require surfactant therapy (Group 0) had -8 times 
higher PC concentrations in the ELF at birth and a significantly higher PA percentage in PC as 
compared to infants that required surfactant therapy. Others have found 422 and 7 times8 
higher concentrations of PC in tracheal aspirates in infants without RDS than in infants with 
RDS at birth; After one and two doses of surfactant, the concentration of PC reached values 
as in Group O. The decreased PC concentration of Group 0 on d 3 and 4 could reflect insuffi-
cient surfactant production. The following increased PC concentration could be explained by 
stimulation of synthesis by the introduction of intravenous feeding. The provided fatty acids 
could stimulate PC synthesis with LA incorporation into PC with subsequent acyl remodel-
ling. 25•26 However, the PC concentration in the tracheal aspirate is only an indirect reflection 
of the synthesis. In Group 1, the PC concentration decreased by d 2 to reach low values by d 
3. This is in concord with the observation that one dose of surfactant accomplishes a tran-
sient decrease in ventilatory requirement. 27 In Group 2, the concentration did not decrease at 
all atter surfactant treatment for 11 d (fig. 1 J. This slow catabolism of exogenous surfactant 
in our study is in agreement with findings in animal studies. In 3-d-old rabbits that received a 
trace amount of labeled PC, the clearance was -16%/d.28 In term newborn sheep, after tra-
cheal instillation of PC labeled with eH]PA, the half-life of PC was .... 11 d. 29 In term newborn 
rabbits who received [3H1PA i.v., alveolar [3H]PC had a half-life of >2 to 5.7 d.30,31 Others 
have found indications of a slow clearance of exogenous surfactant in human preterm infants. 
After treatment with one dose human amniotic fluid surfactant which contained SP-A, the PC 
concentration in tracheal aspirates did not decrease for 1 week.8 
4 
-¥- Group 0 ---*- Group 2 ......... 
o 2 4 6 8 10 12 
Days 
Figura 5. Ratio of linoleic acid (LA) to myristic acid (MA) in surfactant phosphatidylcholine PC. The 
horizontal dashed line indicates the baseline value of the LA.'MA ratio. The oblique dashed line is the 
slope of the increasing ratio. On d 5 in both groups, the LA.'MA ratio started to increase above baseline 
and indicates a specific incorporation from plasma LA into surfactant PC. 
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Treatment with two doses synthetic surfactant increased the ratio of DPPC:POPC for 4 d, 
illustrating slow clearance of exogenous DPPC.l1 In another study in preterm infants that re-
ceived one or two doses Survanta@, Sat PC concentrations were increased up to -A d.22 
The time necessary for plasma lipids to be taken up by the type II cell, incorporated into 
surfactant PC, intracellularly processed and secreted to the alveoli was estimated from the 
interval between initiation with Lv. lipids containing 53% LA and a specific increase of the LA 
percentage in surfactant PC. LA is an essential fatty acid and can not be synthesised de novo 
by the type II cell and the liver. Therefore, the LA was derived from exogenous sources and 
thus can be used as a label. This specific increase was expressed as a LA:MA ratio in order 
to minimize effects of surfactant therapy (see Results). In Group 0 and 2 the LA:MA ratio 
increased above baseline value 3 d after the start of the lipid infusion (fig. 5). This interval is 
long which could mean that surfactant synthesis and accumulation is slow, and plasma fatty 
acids are incorporated slowly in surfactant PC in preterm infants. In newborn rabbits and 
sheep there was a slow incorporation of radiolabeled plasma PA into PC and a maximal spe-
cific activity only after ~32 and ..... 42 h, respectively. 32,33 When term infants with a postnatal 
age of ..... 50 d received LA labeled with the stable isotope 13C intravenously, the 13C-label was 
first seen in LA in surfactant PC after ..... 10 h.34 This is faster than the 3 d in the present 
study, probably because in older infants precursor incorporation and surfactant synthesis are 
enhanced, as is the case in animal studies.32,33 Because we could not include a group of in-
fants without Intralipid®, we used the preterm baboon that did not receive i.v. lipids as a 
model for the preterm infant without i.v. feeding. The fact that the LA:MA ratio in plasma TG 
and PL, and in surfactant PC did not increase (fig. 6) strongly suggests that the increased 
LA:MA ratio in the preterm infants is related to i.v. lipid administration. These data show that 
the composition of the feeding influences surfactant composition and potentially function. 
The delay of specific incorporation of LA from parenteral lipids could also be related to up-
take by the liver before delivery to the lungs as lipoproteins. Whether and to which extend 
liver metabolism plays a role in the delay of plasma LA incorporation into surfactant PC is 
unclear, and therefore the delays calculated by us are probably maximal values. It is, how-
ever, unlikely that a significant part of the delay of ..... 3 d is due to incorporation of fatty acids 
from Intralipid® into lipoproteins in the liver, as this is a much faster process and lipid metabo-
lism in the premature is in extreme flux. 35 
At birth, the PA percentage in PC was significantly higher in Group 0 than in Groups 1, 2, 
and 3, illustrating a more mature surfactant composition in infants that did not require surfac¥ 
tant therapy. The PA percentage in PC increased significantly after surfactant therapy ( ..... 85% 
PA in Survanta® PC). An indication of endogenous surfactant synthesis and secretion can be 
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appreciated from the dilution of exogenous surfactant by endogenous surfactant with ..... 62 % 
PA in PC. In the present study, the dilution is expressed as a half-life of percentage of PA 
towards a new baseline. The fact that the percentage in all groups remained higher than in 
Group 0 indicates significant recycling of exogenous surfactant and a slow de novo surfac-
tant synthesis. The long half-lives of the PA percentage in surfactant PC Groups 2 and 3 are 
comparable with the half-life of -113 h of PA in surfactant PC in preterm infants that re-
ceived [U_ 13C]glucose intravenously.9 The half-life was longer in Group 3>2>1 (95,78, and 
18 h, respectively), probably because of the larger pool size of surfactant PC when more 
doses surfactant were administered. Our data are in agreement with studies in preterm lambs 
that received radio labeled surfactant. The specific activity in these preterm lambs decreased 
slowly, indicating that dilution from unlabeled endogenous secretion was low.36 Half-lives of 
other surfactant phospholipid components after exogenous surfactant have been measured in 
human pre term infants. Half-lives for phosphatidylglyceroi were -30 h with human amniotic 
fluid surfactant,12 ..... 43 h with Alveofact®1 10 and "'4.4 d with Survanta®.10 Half-life of sphin-
gomyelin was calculated to be "'4 d. 10 The half-life of the major phospholipid PC has not been 
measured before. 
Some animal studies suggest that the surfactant pool size remains stable because endoge-
nous synthesis can compensate for surfactant clearance. Seidner et al. found in ventilated 
preterm baboons which received 100 mg/kg Survanta® at birth, that total lung surfactant PC 
pool sizes were higher at killing on d 6 of life than the sum of the endogenous pool and the 
amount administered. 15 In newborn rabbits that received surfactant treatment and were time-
killed until d 3 of life, the total lung surfactant PC pool did not change for 3 d.37 It is a limita-
tion of the current study that we can not measure total surfactant pool size at multiple time 
points in these infants, and therefore can not calculate absolute values of surfactant synthe-
sis and clearance. 
We measured concentration and composition of surfactant in aspirates after deep endotra-
cheal suctionlng because it gave us the opportunity to do frequent sampling. Recently the 
surfactant phospholipids from tracheal aspirates and bronchoalveolar lavage were shown to 
have the same composition of the phospholipids and PC fatty acids.38 We measured the dif-
ferent fatty acids in PC, but the measurement of the complete spectrum of individual mo-
lecular species of PC by HPLC as described by Postle et al., can provide more detailed infor-
mation about PC metabolism and the acyl remodelling of PC to DPPC.25,26,39 Although Groups 
1 and 3 are small, the data are in line with the conclusions from Group 0 and 2. Differences 
between the groups should, however, be regarded with some caution. Despite the mixed di-
agnoses in Group 0, the results apply to preterm infants that did not require exogenous sur-
factant at birth. Indeed, surfactant concentrations at birth were higher than in the other 
groups. 
In conclusion, the composition of intravenous feeding in the neonatal period influences sur-
factant composition and possibly function. 40,41 The delayed incorporation of plasma lipids into 
endogenous surfactant PC and the slow dilution of exogenous surfactant by endogenous sur-
factant indicate that premature infants with RDS synthesise surfactant PC at a low rate. Sur-
factant deficiency is reversed adequately for more than one week by administration of 2 
doses of surfactant. 
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INTERPRETATION AND IMPLICATIONS OF THE STUDIES 
A major problem after premature delivery is the deficiency of adequate amounts of surfactant 
leading to respiratory distress syndrome (RDS). The surfactant synthetic pathway matures 
during gestation and alveolar surfactant concentrations in the alveoli start to increase after 20 
to 24 weeks. The alveolar surfactant pool at birth in infants with RDS is 5 t010 mg PC/kg 
and increases afterwards. 1 From animal studies it is known that the synthesis of surfactant is 
slow and in humans the concentration of surfactant in the alveoli increases slowly after birth. 
In the studies performed in infants in the past, surfactant analysis of sequential tracheal aspi-
rates was the only available method for the evaluation of surfactant production in humans.2+4 
Although this method provides information on quality and concentration of surfactant, it does 
not give information on endogenous surfactant synthesis and catabolism. 
We developed a method employing the safe nonradiating stable isotopes to study surfac-
tant metabolism (chapter 3). We measured in preterm infants with RDS that the endogenous 
labeling of surfactant PC palmitate from plasma glucose started after"", 18 h and that the la-
beled surfactant disappeared from the alveoli with a half-life of > 100 h.5 This slow labeling 
reflects a low synthesis rate of endogenous surfactant (fractional synthesis rate, FSR, from 
glucose ...... 2.7%/kg/d). This finding is agreement with studies performed in animals using ra-
dioactive precursors and with studies on surfactant concentrations in preterm lnfants.3,6-9 In 
older critically ill infants, the synthesis rate of surfactant PC was much higher when studied 
with the intravascular precursors [U- '3C]palmitic acid (~34%/kg/d) and [U- '3Cmnoleic acid 
(~50%/kg/dJ than in the study in premature infants with [U-' 3C]glucose as precursor (chapter 
4).10 Thus it could be that free fatty acids are a more important precursor for the fatty acids 
of surfactant PC than de novo fatty acid synthesis from glucose. However, one has to con-
sider that, when comparing the studies between the preterm infants and the older infants 
that the two studies were significantly different. Presence or absence of RDS, differences in 
the diet, the labeled precursor, the measured surfactant component, the age, the surfactant 
pool size have impact on study results. In piglets, it was recently shown that plasma free 
fatty acids are the primary source of the fatty acids surfactant PC as compared to de novo 
fatty acid synthesis from acetate. 11 
The observation that in preterm infants endogenous surfactant remains in the alveoli for 
long times (half-life ~100 h) is in contrast to studies in preterm infants with exogenous sur-
factant where half-lives are shorter ( ..... 36 h).12It could be that the use a plasma precursor ([U-
13C]glucose) to label endogenous surfactant prolongs the half-life of endogenous surfactant by 
ongoing synthesis (chapter 3). This is, however, not certain as we also found in critically ill 
infants that the half-life of endogenous labeled surfactant (with plasma [U- '3C]palmitic and 
linoleic acid) was only ",40 h (chapter 4).10 Furthermore, Griese et al. found similar half-lives 
of surfactant components (phosphatidylglyceroi and sphyngomyelin) of ~ 100 h.4 It would, 
therefore, be interesting to study in the same individual the disappearance of an exogenous 
label and an endogenous label simultaneously. 
Prenatal corticosteroids are nowadays routinely used to reduce the risk of RDS.13 It is cur-
rently unclear whether the beneficial effects of prenatal corticosteroids are related to the sur-
factant system. In vitro studies show increased activities of the enzymes involved in surfac-
tant synthesis. In some animal studies increased labeled precursor incorporation and in-
creased surfactant pool sizes have been observed after prenatal corticosteroids. However, 
many studies in animal studies show no effect on surfactant pool size. In preterm infants, 
prenatal corticosteroids did not increase surfactant concentration in the epithelial lining 
fluid. 14 In a randomized study in baboons (chapter 5) and in a nonrandomized study in pre-
term infants (chapter 6) prenatal corticosteroids increased the surfactant PC synthesis from 
plasma glucose (FSR of PC doubles after 2 doses). An increased labeling of palmitic acid in 
surfactant PC after prenatal corticosteroids could in theory result from increased 13C_ 
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enrichment of plasma lipids from synthesis by the liver after corticosteroids with subsequent 
uptake by lung. We found no difference in labeling of plasma triglycerides and phospholipids 
between treated and control groups in the preterm infants. Thus the increased enrichment of 
surfactant PC palmitate after prenatal steroids was probably due to increased endogenous 
synthesis of surfactant PC, and is not a reflection of plasma lipid enrichment. In the free fatty 
acid fraction, the enrichment was so low that the fatty acids could not be a precursor for the 
higher enriched surfactant PC fatty acids. This suggestion is in contrast to the findings of 
Martini et al. in piglets who showed that free fatty acids are more important than de novo 
fatty acid synthesis. t 1 Probably, in the premature infant with little fatty acid supply during the 
first three days after birth as in our studies, de novo fatty acid synthesis in the type II cell is 
more important than lipid uptake from plasma. When fatty acids are available as in the older 
children (chapter 4) and in the piglets,11 lipid uptake may become more important. 
This increased synthesis from glucose after prenatal corticosteroids is rather small and will 
probably lead to small increases in surfactant pool size. In addition to improved lung develop-
ment after prenatal corticosteroids as shown by others, 15, 16 the increased surfactant synthe-
sis could playa role in the prevention of RDS. A smaller increase in surfactant pool size is 
necessary to prevent the development of ROS than to treat ROS. The study in preterm infants 
was not randomized as randomization in this patient population is not possible anymore as 
prenatal corticosteroids are routine treatment. 
Exogenous surfactant administered at birth for RDS is distributed homogeneously through-
out the lung, mixes with the endogenous surfactant pool, and reduces surface tension di-
rectly. The amounts of exogenous surfactant administered are large compared to the endoge-
nous surfactant pool (10 to 20 times). As many feedback mechanisms operate in the human 
to regulate metabolism, others studied the influence of exogenous surfactant on endogenous 
surfactant synthesis in vitro and in animals. In vitro studies mainly described inhibition of pre-
cursor incorporation after surfactant administration. In rabbits the precursor incorporation was 
increased after surfactant administration. 17 Such studies have not been performed in humans. 
We found that exogenous surfactant stimulated the endogenous surfactant synthesis signifi-
cantly, which is in agreement with the studies in rabbits (chapter 7). Although the increases 
found by us appear to be low ("",1.3 mg/kg/d PC from glucose), it is reassuring that endoge-
nous synthesis is not suppressed and that the presence of a negative feedback mechanism is 
unlikely. 
LIMITATIONS OF THE STUDIES 
The studies in the infants on the effects of prenatal corticosteroids and exogenous surfactant 
were not randomized as it is ethically not possible to randomize these patients for prenatal 
corticostertoids and exogenous surfactant. Furthermore, this kind of experiments is very ex-
pensive and intensive; it is difficult to study large series. Correction for some variables was 
performed by using strict inclusion criteria and multiple regression analysis. 
We used tracheal aspirates to collect alveolar surfactant PC. In most animal studies, bron-
choalveolar lavage is used, but this method cannot be used for frequent sampling in the 
studied population. All tracheal aspirates were handled similarly in all studies. Therefore, any 
inaccuracy would have occurred in all patient groups probably to the same extent. The tra-
cheal aspirates were centrifuged (10 min at 450 x g) at a greater speed than in most studies 
{normally 10 min at 150 x gJ. This high speed was chosen to pellet any degraded cells due to 
freezing and thawing after collection of the aspirate. Loss of surfactant by this procedure 
does not influence the measurement of 13C-enrichment in surfactant PC palmitate. The 13C_ 
enrichment is measured by mass spectrometry; by direct measurement of the 13C/'2C ratio in 
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palmitic acid of surfactant PC. This ratio is not influenced by sampling size or loss during 
preparation. 
We concentrated on the palmitic acid metabolism of surfactant PC. The PC molecule com-
prises different fatty acids, choline, glycerol and phosphate. In vitro studies showed a differ-
ent metabolism for the different components which could be the case in our studies as well. 
We found for example different synthesis rates (FSR) of surfactant PC from plasma palmitic 
acid and plasma linoleic acid. This should be considered with the interpretation of the results. 
It is, however, unknown to which extent the metabolism of the different components of PC 
differ in infants. For proper functioning of surfactant, other phospholipids and surfactant pro-
teins are necessary as well. The metabolisms of the components are probably different and 
therefore, the metabolism of PC palmitate does not necessarily represent overall surfactant 
metabolism. There is probably no overall surfactant metabolism. 
We measured the incorporation of the 13C molecules derived from labeled plasma glucose 
and palmitic acid. The palmitic acid in the type \I cell is also synthesized from other sub-
strates like glycogen, intracellular palmitate, ketone bodies, glycerol, and lactate. The synthe-
sis measured by us is therefore not the total surfactant PC synthesis but an underestimation. 
In fact, calculation of the fractional synthesis rate is only possible from the enrichment of the 
direct precursor. The direct precursor in the type \I cell for palmitic acid synthesis is acetyl-
CoA. The enrichment of acetylCoA cannot be measured, and therefore the calculations were 
performed from plasma precursors enrichments in all groups in the same way. 
When labeled surfactant PC is newly synthesized, it is diluted by the unlabeled surfactant 
pool. The 13C-enrichment of PC in tracheal aspirates is thus dependent on the size of the total 
surfactant PC pool size. The comparison of labeling of surfactant is thus only correct when 
total surfactant PC pool sizes are similar. We corrected for differences in pool size by multiple 
regression analysis for doses of surfactant (chapter 6) and by multiplying the FSR with the 
amount of surfactant administered (chapter 7). 
It is not entirely clear how to interpret the calculated half-life of 13C-enriched surfactant 
PC. Synthesis of unlabeled surfactant after stopping isotope infusion decreases the enrich-
ment of alveolar surfactant. Loss of labeled surfactant from the lung decreases the labeled 
surfactant pool size which leads to more rapid dilution of the label by unlabeled endogenous 
surfactant. In the patients that received exogenous surfactant, the decrease of enrichment is 
also related to the decrease in pool size after unlabeled surfactant administration. As all proc-
esses occur simultaneously, a short half-life could have two explanations: a rapid loss of ex-
ogenous surfactant, the negative scenario, or a rapid synthesis of newly unlabeled surfactant, 
the positive scenario. 
Studies using labeled components to study surfactant metabolism can give very different 
results, which can be related to the labeled substrate used, the route of administration, the 
surfactant pool studied (e.g. alveolar or lung tissue), and the developmental stage of the sub-
ject. These different experimental conditions make direct comparisons between studies diffi-
cult and should always be considered carefully. 
DIRECTIONS FOR FUTURE RESEARCH 
The study of the metabolism of the specific surfactant proteins would be an enormous con-
tribution to the overall understanding of surfactant metabolism. The proteins are essential for 
normal lung function in terms of alveolar gas exchange, but also for the natural defence 
against inhaled micro-organisms. Studies require significant amounts of labeled exogenous 
aminoacids, for example leucine. 
The metabolism of PC has been studied by us using labeled glucose and fatty acids. The 
data give valuable information but methodological problems remain. The use of a more direct 
92 
General Discussion 
precursor could be used to reflect more directly surfactant metabolism. An example could be 
the use of labeled choline, as this component is not synthesized in large amounts by the body 
and is merely derived from feeding. Therefore, after equilibration with alveolar and lung tis-
sue, the plasma enrichment of choline could be comparable with enrichment in the type II 
cell. 
As choline is an essential substance for PC synthesis, and parenteral feeding of the pre-
term infants does not contain choline, there could possibly be a relative choline deficiency, 
hampering surfactant synthesis in the critical period of RDS. The effect of choline supplemen-
tation on surfactant synthesis in the preterm infant would be interesting to study. 
It would be interesting to study the relative contribution of de novo fatty acid synthesis of 
palmitic acid in PC from glucose or the contribution from plasma palmitic acid by infusion of 
labeled glucose and palmitic acid simultaneously in one individual. 
It is not entirely clear how to interpret the calculated half-life of surfactant PC. The de-
crease of enrichment is related to newly synthesised unlabeled PC, and the catabolism and 
clearance from the lung. Synthesis of unlabeled surfactant after stopping isotope infusion 
decreases the enrichment of alveolar surfactant. Loss of labeled surfactant from the lung de-
creases the labeled surfactant pool size, which leads to more rapid dilution of the label by 
unlabeled endogenous surfactant. To study this, it would be necessary to administer an intra-
venous labeled precursor and a labeled exogenous surfactant in the same patient. 
Dexamethasone administered in the immediate postnatal period to preterm infants with 
RDS reduces the severity of lung disease and the incidence of bronchopulmonary dysplasia. 18 
It is not known whether this beneficial effect is related to the stimulation of lung maturation 
including surfactant synthesis. It would be interesting to study whether the development of 
BPD and the beneficial effects of postnatal dexamethasone are related to surfactant metabo-
lism. 
There are indications of a disturbed surfactant metabolism in several other neonatal lung 
diseases for which currently exogenous surfactant is not routinely used. Such diseases in-
clude congenital surfactant protein B deficiency,19-22 congenital diaphragmatic hernia,23 me-
conium aspiration syndrome,24-28 sepsis with pneumonia or ARDS, severe respiratory insuffi-
ciency requiring extra corporal membrane oxygenation.29,3o It would be a challenge to study 
surfactant metabolism in these diseases in infants with the use of the methods that have 
been discussed in the current thesis. 
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Chapter 1 introduces the function, composition, and metabolism of pulmonary surfactant and 
some questions regarding surfactant metabolism. 
The studies in this thesis were performed to: 
1 . develop and use a novel method to study surfactant metabolism in preterm and older 
infants. 
2. study endogenous surfactant synthesis in relation to prenatal glucocorticosteroids. 
3. study the influence of surfactant therapy on endogenous surfactant metabolism. 
4. study surfactant composition and concentration after surfactant therapy. 
Chapter 2 reviews the literature on surfactant metabolism with emphasis on preterm infants. 
Primary surfactant deficiency is a major cause of respiratory distress syndrome (RDS) in the 
preterm infant. Surfactant is a mixture of lipids (90%) and specific proteins (10%). Phospha-
tidylcholine (PC) accounts for ..... 70% of the surfactant lipids. Surfactant is synthesized and 
stored as lamellar bodies in the alveolar type II pneumocyte. Surfactant is secreted to the al-
veolar space and prevents alveolar collapse by reducing the surface tension at the air-liquid 
interface. Surfactant is cleared from the alveoli mainly by reuptake by the type II cell and is 
recycled to a large extend, or can be cleared from the lungs. During fetal lung development 
the synthetic pathways of surfactant phospholipids mature leading to increased surfactant 
pool sizes and improved composition. The endogenous de novo synthesis and secretion of 
surfactant PC seem to be slow processes. Therefore, the lungs of the premature infant seem 
not to be able to adapt rapidly to extra-uterine life which requires a considerable alveolar sur-
factant pool and therefore exogenous surfactant administration is necessary to rapidly aug-
ment surfactant pools in RDS. After surfactant administration the concentration of alveolar 
surfactant remains elevated for many days. Some in vitro and animal studies suggest the 
presence of a negative feedback mechanism of exogenous surfactant to regulate endogenous 
surfactant synthesis. However, data from preterm infants show that multiple doses of exoge-
nous surfactant do not suppress endogenous surfactant synthesis. 
Corticosteroids increase the activity of the enzymes for surfactant synthesis in vitro. Data 
on surfactant pool sizes after corticosteroids from animals studies are conflicting. In preterm 
infants surfactant synthesis is stimulated by prenatal corticosteroids, but synthesis rates are 
low in general, which allows alveolar pool sizes to increase only several days after stimulation 
by corticosteroids. 
Chapter 3 describes a study in preterm infants with respiratory insufficiency who received at 
birth a 24-h infusion with the stable isotope {U-13C]glucose as a precursor for palmitic acid of 
surfactant PC. During the entire period of intubation, tracheal aspirates were collected to ob· 
tain serial time points to measure the incorporation of the stable isotope 13C into PC palmi-
tate. PC palmitate became enriched after'" 19 h and reached maximum enrichment'" 70 h after 
the start of the isotope infusion. The fractional synthesis rate (FSR) was calculated to be 
",2.7%/d, which is the percentage of the total surfactant PC pool synthesized from glucose 
per day. The labeled PC-palmitate disappeared with a half-life of ",,113 h. 
In conclusion, these data show that endogenous surfactant synthesis and clearance are 
slow processes. This method is used further in next chapters to study surfactant metabolism. 
Chapter 4 describes endogenous surfactant metabolism in infants requiring mechanical venti-
lation for a variety of diseases. Surfactant deficiency has been implicated in the pathophysio-
logy of adult respiratory distress syndrome. We used the intravenous tracers [U- '3C]palmitic 
acid and {U-13C]linoleic acid. Infants received a 24·h constant infusion with both tracers si-
multaneously. Surfactant PC became labeled with 13C-palmitic acid and '3C·linoleic acid after 
",10 h. The time of maximal enrichment was -47 h for both tracers. The FSR of surfactant PC 
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from palmitic acid ranged from 0.4 to 3.4%/h and the FSR from linoleic acid ranged from 0.5 
to 3.8%/h. The half-lives of palmitate' labeled PC ranged from 17 to 178 h and the half-lives 
from linoleic acid labeled PC ranged from 24 to 144 h. 
There was a large variability in metabolic parameters of surfactant between patients 
probably reflecting the diversity in diseases of the subjects studied. 
Chapter 5 describes surfactant metabolism in very premature baboons and reports on the ef-
fects of prenatal corticosteroids on surfactant synthesis. Pregnant baboons were randomized 
to receive either betamethasone (beta) or placebo (control). After preterm delivery at 67% of 
term gestation, baboons were intubated and received surfactant for RDS. [U- 13Clglucose was 
used as a tracer to study surfactant PC metabolism. Palmitic acid in surfactant PC became 
enriched after ~27 h and was maximally enriched at ",100 h. The fractional synthesis rate of 
PC-palmitate in the beta group ('V1.5%/d) was increased by 129% above control (-0.7%/ d). 
The total lung pool sizes of PC were not increased in the beta group as compared to the con-
trol group on day 6. We hypothesize that factors after birth like ventilation stimulate surfac-
tant synthesis and overpower the effects of prenatal steroids. 
These data show that the synthesis of endogenous surfactant PC from plasma glucose is a 
slow process and that prenatal corticosteroids stimulate the synthesis of surfactant PC in the 
very premature baboon. 
Chapter 6 shows the effect of prenatal corticosteroid treatment on endogenous surfactant 
synthesis in preterm infants. Pregnant women at risk of pre term delivery had received either 
zero (n=ll), one (n=4), or two doses (n=12) of prenatal betamethasone (12 mg intramus-
cularly). After birth, 27 infants received [U_13CJglucose as a precursor for palmitate in surfac-
tant PC, plasma phospholipids, and triglycerides. The FSR of surfactant PC from glucose was 
~1.7%/d without prenatal corticosteroid treatment, ~2.9%/d with one dose and .... 5.8%/d af-
ter two doses of prenatal corticosteroids. The PC concentration in the epithelial lining fluid 
tended to be higher in the corticosteroid-treated groups. The enrichment of palmitic acid of 
plasma triglycerides and phospholipids from glucose was not increased by corticosteroids. 
In conclusion, the increased enrichment of surfactant PC palmitate is not a reflection of in-
creased liver lipogenesis. These data show that treatment with prenatal corticosteroids 
stimulates surfactant synthesis in the preterm infant. However, the increased synthesis is 
probably too slow to increase the surfactant pool size rapidly. 
Chapter 7 deals with the impact of exogenous surfactant on endogenous surfactant synthesis 
in preterm infants. Some in vitro and animal studies suggest that exogenous surfactant regu-
lates endogenous surfactant synthesis by a feedback mechanism. Preterm ventilated infants 
received a 24-h infusion with the stable isotope [U-13CJglucose starting ~5 h after birth. The 
13C-incorporation into palmitic acid of surfactant phosphatidylcholine (PC) isolated from serial 
tracheal aspirates was measured. Infants received either zero (n:=; 5), one (n = 4), two (n= 15), 
or three (n = 3) doses of Survanta® (100 mg/kg) when clinically indicated. The absolute syn-
thesis rate (ASR) of surfactant PC from plasma glucose increased with ~ 1.4 mg PC/kg/dose 
of Survanta® (p = 0.007). Using multiple regression analysis prenatal corticosteroid treatment 
increased the ASR from plasma glucose with ~1.4 mg PC/kg/dose (p=O.Ol). The presence of 
a patent ductus arteriosus was associated with an increase of the ASR from plasma glucose 
with -2.1 mg PC/kg {p<0.05). The ASR decreased with -0.4 mg PC/kg/week advancing ges-
tational age {p~0.03). 
These data are reassuring and show that in preterm infants, that multiple doses of exoge-
nous surfactant for RDS do not down regulate but even stimulate endogenous surfactant syn-
thesis. 
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Chapter 8 presents a study on the concentration and composition of surfactant obtained from 
serial tracheal aspirates from preterm infants and preterm baboons both with respiratory dis~ 
tress. Infants requiring surfactant (one, two, or three doses) had significantly lower surfactant 
PC concentrations than infants that did not require surfactant (2.2±0.6 versus 19.8±5.1 
mg/ml ELF, respectively, p <0.00001). The percentage PA in PC increased after exogenous 
surfactant (containing ...... 85 % palmitic acid in PC), and then decreased with a half~life of 18, 
78, and 95 h after one, two, and three doses of surfactant, respectively. This decrease in 
palmitic acid percentage in tracheal aspirates was due to dilution by endogenous surfactant 
containing a lower percentage of palmitic acid. Three days after the start of parenteral feeding 
containing ...... 53% linoleic acid, there was a specific increase in linoleic acid percentage in sur~ 
factant PC in the preterm infants. Preterm baboons that did not receive any lipids were used 
as control group for the infants who all received intravenous lipids. In the baboons, the lino~ 
leic acid percentage did not increase in the plasma triglycerides and phospholipids, nor in sur~ 
factant PC. 
It is concluded that the composition of parenteral feeding influences surfactant PC compo~ 
sit ion and possibly function. The delayed incorporation of plasma lipids into endogenous sur~ 
factant PC and the slow dilution of exogenous surfactant by endogenous surfactant suggest a 
slow synthesis of surfactant PC. 
Samenvatting 
Hoofdstuk 1, Introduktie. Surfactant wordt in de longen gemaakt en uitgescheiden naar de 
longblaasjes (:=:alveoliJ die met lucht zijn gevuld. Het surfactant in de longblaasjes is nodig om 
de longblaasjes te ontplooien bij de inademing en open te houden bij de uitademing. Surfac-
tant kan deze functie vervullen doordat het de oppervlaktespanning tussen het water en de 
lucht in de longblaasjes verlaagt. Bij te weinig surfactant in de longblaasjes zullen de long-
blaasjes samenvallen en daardoor de opname van zuurstof en de afgifte van kooldioxide ern~ 
stig belemmeren. Tekort aan werkzaam surfactant direkt bij de geboorte is de belangrijkste 
reden van het Respiratoir Distress Syndroom (RDS), ook wei hyaliene membraan ziekte (HMZ) 
genoemd, bij te vroeg geboren kinderen. 
Het onderzoek beschreven in dit proefschrift heeft de volgende vraagstellingen: 
1. kan een methode ontwikkeld worden am de produktie en afbraak (metabolisme) van sur~ 
factant te bestuderen bij te vroeg geboren en oudere kinderen. 
2. hebben corticostero'lden die voor de geboorte van het kind (:=: prenataal) werden toege~ 
diend invloed op de produktie van surfactant na de geboorte. 
3. wordt de eigen (= endogene) produktie van surfactant bernvloed als aan het kind surfac~ 
tant via de beademingsbuis direkt in de longen wordt toegediend. 
4. hoe verlopen de concentratie en samenstelling van surfactant in de longblaasjes nadat sur~ 
factant aan het kind is toegediend. Zegt dit iets over het metabolisme van surfactant. 
Hoofstuk 2 is een overzicht van de literatuur over het metabolisme van surfactant met name 
bij te vroeg geboren kinderen. Met de aanmaak, afbraak en hergebruik wordt het metabolisme 
van surfactant bedoeld. Surfactant bestaat voornamelijk uit vetten (90%), voornamelijk 
(± 70%) fosfat idyl choline (FC) en eiwitten (5 tot 10%). Het wordt gemaakt en opgeslagen als 
lamellaire structuren, in de type II cellen in de longen. Nadat het surfactant is uitgescheiden 
naar de longblaasjes verspreid het zich als een zeer dunne laag over het totale longoppervlak. 
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Na een aantal ademhalingscycli wordt surfactant afgebroken en grotendeels door de type II 
cell weer opgenomen en hergebruikt; een klein deel wordt afgevoerd. 
Tijdens de foetale ontwikkeling van het kind ontwikkelt het enzymsysteem dat betrokken is 
bij de aanmaak van surfactant, waardoor de hoeveelheid toeneemt en de samenstelling van 
het surfactant in de longblaasjes verbetert. Daardoor zijn de longen van het voldragen kind bij 
de geboorte goed geschikt voor lucht·ademhaling. De aanmaak van surfactant fosfatidylcho· 
line en de uitscheiding naar de longblaasjes zijn waarschijnlijk langzame processen. De long en 
van het te vroeg geboren kind lijken daardoor niet in staat te zijn zich snel aan te passen aan 
het leven buiten de baarmoeder; want voor gasuitwisseling is een voldoende hoeveelheid sur· 
factant noodzakelijk. Daarom is het bij sommige te vroeg geboren kinderen nodig na de ge· 
boorte surfactant aan de longen toe te dienen (exogeen surfactant). Nadat exogeen surfactant 
is toegediend, blijft de concentratie in de longblaasjes verhoogd gedurende meerdere dagen. In 
enkele studies met ge'(soleerde type /I cellen en dieren wordt de eigen aanmaak van surfactant 
geremd door exogeen surfactant toe te dienen. In een studie bij te vroeg geboren kinderen lijkt 
er geen negatief terugkoppelingsmechanisme te bestaan. 
In ge'(soleerde type /I cellen en weefselkweken blijkt dat glucocarticostero'iden de aktiviteit 
van enzymen die no dig zijn voar de aanmaak van surfactant verhogen. In studies met dieren 
blijkt echter niet altijd dat de hoeveelheid surfactant ook toeneemt na behandeling met gluco· 
corticostero,(den. In te vroeg geboren kinderen lijkt echter wei de aanmaak van surfactant ge-
stimuleerd te worden. Echter, de aanmaak blijft toch een langzaam preces, waardoor het 
enkele dagen duurt voordat de hoeveelheid surfactant significant is toegenomen. 
Hoofdstuk 3 beschrijft een studie in te vroeg geboren kinderen met hyaline membra an ziekte. 
Het metabolisme van surfactant werd bestudeerd door stabiele isotopen in de vorm van een 
24·uurs infuus met [U·13C]glucose toe te dienen en vervolgens de inbouw van het 13C·isotoop 
in surfactant te vervolgen. Het 13C isotoop in de glucose wordt door de longen gebuikt am de 
Vetzuren van surfactant fosfatidylcholine te maken. Als dlt 13C wordt aangetoond in surfac-
tant is het surfactant "verrijkt". Eenvoudig gesteld geldt dat hoe meer 13C in surfactant FC 
gemeten wordt, des te hoger de aanmaak van surfactant FC is. 
Surfactant kan uit slijm vanuit de longblaasjes worden ge'isoleerd. Dit slijm wordt routine· 
matig bij aile beademde kinderen om de paar uur uit de beademingsbuis gezogen am deze 
doorganklijk te houden. Het materiaal verkregen door uitzuigen wordt een trachea-aspiraat 
genoemd. Bij de kinderen in de studies van dit proefschrift werden niet meer trachea-aspiraten 
afgenomen dan voor de norma Ie patientezorg nodig was. De snelheid van inbouw en ver-
dwijning van 13C is een maat voor de surfactant-aanmaak en verdwijning van surfactant. Het 
infuus met [U·13C1glucose werd ongeveer 5 uur na de geboorte gestart en na 24 uur gestopt. 
Zolang het kind beademd werd, kon slijm uit de longen worden verkregen waaruit surfactant 
fosfatidylcholine werd ge'lsoleerd. Het belangrijkste vetzuur in fosfatidylcholine, palmitinezuur 
(C16:0L werd verrijkt met 13C ongeveer 19 uur na start van het infuus. 
De verrijking was maximaal na ongeveer 70 uur. De fractionele synthese snelheid was 
ongeveer 2,7% per dag. Dit betekent dat 2,7% van de totale hoeveelheid surfactant fosfati-
dylcholine per dag uit glucose wordt aangemaakt. Het surfactant fosfatidylcholine verdween 
uit de longblaasjes met een half·waardetijd van ongeveer 113 uur. 
Dit betekent dat endogeen surfactant langzaam wordt aangemaakt en langzaam uit de 
longblaasjes verdwijnt. Deze nieuwe en veilige methode is gebruikt om het metabolisme van 
surfactant te bestuderen zoals beschreven in de volgend hoofdstukken. 
Hoofdstuk 4. T ekort aan surfactant is niet aileen beschreven bij te vroeg geboren kinderen, 
maar ook bij bij oudere kinderen met respiratoir falen. Daarom werd in deze groep kinderen 
het metabolisme van surfactant bestudeerd. De tracers [U·13CJpalmitinezuur en [U-
13C]linolzuur werden tegelijkertijd via een infuus gegeven gedurende 24 uur tegelijkertijd. Deze 
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vetzuren kunnen door de long direkt gebruikt worden voor de opbouw van surfactant fosfati· 
dylcholine; daardoor wordt het fosfatidylcholine verrijkt met 13C. Na toediening van isotaap 
was het surfactant fosfatidylcholine verrijkt na ongeveer 10 uur onafhankelijk van de gemeten 
tracer (palmitinezuur of linolzuurl. Het tijdstip van maximale verrijking was voor beide tracers 
gelijk en was ongeveer 47 uur. De fractionele synthese snelheid varieerde van 0,4 tot 3,4% 
per uur vanuit palmitinezuur en 0,5 tot 3,8% per uur vanuit linolzuur. De half·waardetijd 
varieerde voor palmitinezuur-verrijkt surfactant van 17 tot 178 uur en voor linolzuur-verrijkt 
surfactant van 24 tot 144 uur. 
Conclusie: de variabiliteit van het metabolisme van surfactant is aanzienlijk en hangt mo-
gelijk samen met het ziektebeeld. 
Hoofdstuk 5 beschrijft het metabolisme van surfactant in te vroeg geboren bavianen en de 
invloed van corticosterarden op de aanmaak van surfactant. CorticosteroYden voor de ge-
boorte (= prenataal) werken als stress wat de aanmaak van surfactant zou kunnen stimule-
ren. Zwangere bavianen kregen, gerandomiseerd, of corticosteroYden tijdens de zwangerschap 
af fysiologisch zout (placebo). Bij deze bavianen werd bij 67% van de norma Ie zwanger-
schapsduur een keizersnede verrlcht waardaor te vroeg geboren bavianen verkregen werden 
voor deze studie. De bavianen werden beademd en kregen surfactant-therapie. [U_ 13C]glucose 
werd via een infuus gedurende 24 uur toegediend als bouwstof voor vetten in surfactant fos-
fatidylcholine. Surfactant fosfatidylcholine werd verrijkt na ongeveer 27 uur en was maximaal 
verrijkt na ongeveer 100 uur. De factionele synthese snelheid van fosfatidylcholine in de pla-
cebo-graep was 0,7% per dag en in de groep met corticosteraYden 1,5% per dag. De totale 
haeveelheid surfactant in de long en was na zes dagen even graot in beide groepen. 
Wij hypothetiseren dat de totale hoeveelheid surfactant FC op dag 6 niet vergroot was na 
corticostero'iden omdat andere stress-faktoren in beide graepen na de geboorte zoals 
beademing het stimulerende effekt van corticosteraYden teniet doen. Deze data tonen aan dat 
het metabolisme van surfactant in de te vroeg geboren baviaan langzaam is en dat de aan-
maak van surfactant gestimuleerd wordt door toediening van corticosteroi'den voor de ge-
boorte. 
Hoofdstuk 6 beschrijft het effekt van prenatale corticostero'iden op de aanmaak van surfac-
tant in te vroeg geboren kinderen. Kinderen kregen voor de geboorte via de moeder 0 keer 
(n = 11), 1 keer (n = 4) of 2 keer (n = 12) prenataal corticosteroi'den (12 mg betamethasone 
intramusculair aan moeder toegdiend). Na de geboorte kreeg leder kind [U_13C)glucose intra-
veneus als bouwstof voor vetzuren in surfactant fosfatidylcholine. De [U-13CJglucose kan ook 
worden gebruikt door de lever vaor het maken van fosfolipiden en triglyceriden die vervalgens 
in het bloed circuleren. 
Het surfactant FC was meer verrijkt met 13C na corticostero'iden. De fractionele synthese-
snelheid van surfactant fosfat idyl choline uit glucose was 1,7; 2,9 en 5,8% per dag na 0, 1 en 
2 doses prenatale corticostero'iden, respectievelijk. Er was een trend van verhoogde concen-
tratie van surfactant in de longblaasjes na corticostero'iden. 
De [U- '3C]glucose in het bloed wordt ook door de lever gebruikt om plasma-fosfolipiden en 
-triglyceriden van te maken. Het zou kunnen dat de lever door corticostero'iden meer plasma-
fosfolipiden en -triglyceriden lipiden gaat maken en dat dus meer 13C-verrijkte lipiden circule-
ren. oeze lipiden zouden door de long kunnen worden opgenomen uit het bloed en worden 
gebruikt voor de aanmaak van surfactant. Op die manier zou een toegenomen verrijking van 
surfactant na corticosteroYden veroorzaakt kunnen worden door toegenomen omzetting van 
glucose in lipiden door de lever met daarna opname door de long met omzetting in surfactant, 
zonder toename van aanmaak van surfactant. De verrijking van triglyceriden en fosfolipiden in 
bloed was echter gelijk in de drie groepen. oit geeft aan dat de toegenomen verrijking in sur-
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factant na corticostero'lden niet het gevolg is van toegenomen aanmaak van Iipiden in de 
lever, maar van toegenomen aanmaak van surfactant in de long. 
De conclusie is dat behandeling met corticostero'(den voor de geboorte de eigen aanmaak 
van surfactant FC stimuleert. Echter, de toename van aanmaak is waarschijnlijk klein, waar-
door een significante toename van de hoeveelheid surfactant enkele dagen duurt. Prenatale 
corticosteroYden hebben echter toch een positieve invloed op de ziekte en overleving van het 
kind als ze binnen 24 uur voor de geboorte worden toegediend. Waarschijnlijk is het positieve 
effekt van pre nata Ie corticosteroYden meer een gevolg van toegenomen structurele ontwik-
keling van de long dan een toegenomen hoeveelheid surfactant. 
Hoofdstuk 7 beschrijft het effekt van toediening van surfactant (exogeen) op de eigen aan-
maak (endogeen) van surfactant. In enkele studies met ge"lsoleerde type II cellen en dieren 
wordt de eigen aanmaak van surfactant geremd door exogeen surfactant toe te dienen, en 
wordt de aanmaak via een negatief feedback-mechanisme gereguleerd. Te vroeg geboren kin-
deren kregen een 24-uurs infuus met [U_13C]glucose. De 13C inbouw in palmitinezuur van sur-
factant fosfatidylcholine werd gemeten als maat van endogene aanmaak van surfactant fos-
fatidylcholine. Beademde kinderen kregen geen surfactant, 1 dosis, 2 doses of 3 doses sur-
factant omdat dit op klinische gond ge'lndiceerd was. De absolute produktiesnelheid van sur-
factant fosfatidylcholine vanuit plasma glucose steeg met ongeveer 1,4 mg/kg per dosis sur-
factant (p =0.01). De absolute synthesesnelheid steeg met ongeveer 1,4 mk/kg per dosis 
prenatale corticostero'lden. 
Bij kinderen is voor de geboorte een bloedvat (ductus Botalli) aanwezig tussen de slagader 
naar de longen (longslagader) en de grote lichaamsslagader (aorta). De ductus Botalli moet na 
de geboorte sluiten om problemen te voorkomen. In deze stu die bleek dat als de ductus Botalli 
niet sloot binnen enkele dagen na de geboorte en klinische problemen gaf, de aanmaak van 
surfactant hoger was. Deze bevinding was niet verwacht en kUnnen wij niet verklaren. De 
aanmaak van surfactant nam at met ongeveer 0,4 mg/kg per week met het toenemen van de 
zwangerschapsleeftijd. 
De conclusie is dat de eigen aanmaak van surfactant niet wordt onderdrukt door behan-
deling met surfactant, en juist enigszins wordt gestimuleerd. 
Hoofdstuk 8 beschrijft de vetzuursamenstelling en de concentratie van surfactant fosfat idyl-
choline bij te vroeg geboren kinderen en bavianen met respiratoir distress syndroom_ Kinderen 
kregen 0 tot 3 doses exogeen surfactant, de bavianen kregen 1 dosis. Bij kinderen die surfac-
tant nodig hadden, werden significant lagere surfactant-concentraties gevonden direct na de 
geboorte dan bij kinderen die geen surfactant nodig hadden (2,2±0,6 en 19,8±5,1, repec-
tievelijk, p<O,OOOOl). 
Het percentage palmitinezuur in surfactant fosfat idyl choline in het trachea-asp ira at steeg 
nadat exogeen surfactant (met ongeveer 85% palmitinezuur) was toegediend. Na deze 
steiging daalde het percentage palmitinezuur met een half-waarde tijd van 18, 78 en 95 uur 
na 1, 2 of 3 doses surfactant, respectievelijk. Deze daling werd veroorzaakt door verdunning 
van het exogene surfactant door endogeen surfactant met een lager percentage palmitinezuur. 
Orie dagen na de start met intraveneuze vetten met ongeveer 52% linolzuur, werd een 
specifieke steiging in het percentage linolzuur in surfactant gevonden. Bij de bavianen die 
geen intraveneuze vetten kregen bleef het percentage linozuur in het bloed constant. Daarom 
werd geen toename van linolzuur in surfactant bij de bavianen gevonden. 
De conclusie is dat intraveneuze voeding invloed he eft op de samenstelling van surfactant 
en daardoor ook mogelijk de werking bei'nvloed. De vertraagde inbouw van linolzuur uit bloed 
in surfactant en de trage verdunning van het surfactant in de longen door eigen aanmaak 
toont aan dat de endogene aanmaak van surfactant fosfatidylcholine een langzaam proces is. 
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